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Background, Aim of the work and Major Findings  
Nowadays, medical imaging techniques play a central role in clinical 
diagnoses and the follow-up after treatment, particularly in an 
oncological context. Magnetic Resonance Imaging (MRI) is a 
routinely applied diagnostic imaging tool because of its not invasive 
nature and its ability to obtain three-dimensional tomographical 
information of soft tissues. Furthermore, it can be used for visualizing 
functions of cardiac, brain, and central nervous system, as well as 
detecting tumor1-3. 
However, this technique suffers from the lack of sensitivity and 
information obtained from a simple unenhanced MR image and, 
consequently, more than 35% of all clinical MRI scans utilize Contrast 
Agents (CAs)4 to improve these aspects by selectively relaxing the 
water molecules near the complex. Commonly available MRI CAs 
come from paramagnetic compounds as gadolinium (Gd3+) chelates3,5 
and superparamagnetic iron oxide (SPIO) conjugates, a 
nanoparticulate MRI probe6,7. For Gd-based CAs, they enhance the 
signal in T1-weighted images, otherwise SPIO conjugates provide a 
strong contrast effect in T2-weighted images. T1-weighted MRI CAs 
utilize paramagnetic metal ions to enhance the contrast in an MR 
image by positively influencing the relaxation rates of water 
protons in the immediate surroundings of the tissue in which they 
localize. The ability of CAs to effectively enhance image contrast 
depends on their relaxivity (longitudinal r1; transversal r2) and 
Background, Aim of the work and Major Findings 
2 
 
the level of accumulation at the target site8. The relaxivity is 
defined as the rate of change in relaxation times of the water 
protons per mM concentration of metal ions. Larger is the 
relaxivity of a given CA, larger will be the induced relaxation 
time (T1, T2) shortening. In details, spin-lattice relaxation time T1 
and spin-spin relaxation time T2 may be shortened considerably 
in presence of paramagnetic species. While shortening of T1 
leads to increase in signal intensity, shortening of T2 produces 
broader lines with decreased intensity. The net result is a 
nonlinear relationship between signal intensity and the 
concentration of the CAs. Indeed, at low concentrations, an 
increase of the amount of the CA provides an increase in signal 
intensity due to effect on T1 until the optimal concentration is 
reached. However, a further increase in concentration reduces the 
signal because of effect on T2 producing a negative contrast 
effect. This peculiar behavior dictates their use in clinical 
practice, preferring CAs that have a relatively greater effect on 
T1 than on T2.  
In these perspectives, the possibility to have a CA that could 
work at low concentration but without giving over its signal 
intensity and, therefore, positive contrast effect is of great 
interest.  
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Among different CAs, Gd chelates based ones, owing to its enhanced 
stability and paramagnetic properties, are used in up to 30% of clinical 
MRI scans and are considered clinically approved for human use.  
However, their effectiveness remains limited owing to nephrotoxicity 
effects9, lack of tissue specificity, low relaxivity, short in vivo 
circulation time and poor specificity which restraints its application. 
Furthermore, McDonald et al.10 have recently reported results about 
progressive Gd deposition in various central nervous system after 
repeated intravenous administration of CAs, even if these signal 
intensity changes are not specific and can be seen with several other 
pathologic conditions.  
In effect, Food and Drug Administration (FDA) has alarmed the 
medical community and has recommended the health care 
professionals to limit the use of Gd-based CAs unless necessary, with 
potential negative impact on the early diagnosis of several pathologies. 
Despite the valuable role of the CAs for MRI, this case history 
confirms the need to build up a biocompatible system with higher 
relaxivity able to protect the chelate around Gd ions from 
transmetallation phenomena and control the accumulation and the 
clearance of the Gd-based CAs in a specific organ.11-15 
The effectiveness of a Gd-chelate as an MRI CA is usually assessed 
in vitro by measuring the corresponding relaxivity r1 and r2. As stated 
by Solomon–Bloembergen-Morgan (SBM) theory,16,17 high relaxivity 
can be achieved by fine and accurate control of the characteristic 
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parameters that regulate the dipolar interaction between water protons 
and Gd-based CAs:18 the number of water molecules (q) in the Inner 
Sphere (IS), i.e. those present in the coordination sites of the Gd ion, 
and their residence lifetime (τM); the rotational correlation time of the 
metal complex (τR); the diffusion correlation time (τD) of the water 
molecules in the Outer Sphere (OS), i.e. those diffusing nearby the 
metal complex.  
According to these parameters and by exploiting the versatile 
properties of nano- and bio-materials19,20, several nanostructured CAs 
with enhanced relaxivity have been investigated.21-26 
In particular, nanoparticle-based T1-weighted MRI CAs can be 
classified as 1) Gd-chelate grafted organic/inorganic 
nanoparticles22,27,28; 2) nanoparticles encapsulating Gd27,29,30; 3) Gd-
based unusual nanometer-sized architectures, such as dendrimers and 
micelles31-36. Among these classes, grafting of metal nanoparticles 
with Gd3+ chelates reach values of r1 ~ 60 mM−1s−1 at 1.5T37,38, 
although their colloidal stability and toxicity are still a challenge39-44. 
However, attempts to exploit “rigidification”45 and “confinement”8 of 
metal chelates seem to be the most effectiveness to enhance the effect 
of Gd-based CAs without the chemical modification of the chelate, 
compared to other strategies based on bio-conjugation or 
encapsulation46. 
Research focusing on polymeric hybrid nanosystems, nanoparticles, 
nanospheres and nanocapsules, for bioengineering, nanomedicine and 
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theranostic applications has undergone drastic transformations in the 
past few decades. The interest of these nanosystems particularly relies 
on the new dimensions and new potentials they offered regarding their 
enhanced interactions with micro- or macro-environments due to a 
higher available surface-volume ratio of the nanostructure. In fact, 
they are able to penetrate living tissues, and encapsulate, protect and 
deliver the drug into specific targeted sites. In addition, nanocarriers 
can also be used to stabilize CAs with poor aqueous solubility47. 
Furthermore, systems with monodisperse size under 100 nm are likely 
to improve delivery functions48 to the tissues, stability of the metal 
chelates, and also provide enhanced relaxometric properties of the Gd-
based CAs. In fact, it is also highly interesting to have monodisperse 
size of core material, which is one of the most important parameters 
for imaging49. Conventionally, for example, SPIO are produced by the 
solution-phase chemical reduction of ionic iron precursors, which 
often results in the formation of polydispersed and poorly crystalline 
iron oxide nanoparticles with inferior magnetic properties50. For 
polymeric nanoparticles encapsulating or conjugating CAs, the main 
ways to produce are solvent evaporation, salting-out, 
emulsificationsolvent diffusion process, supercritical fluids that 
replace the solvent in the precipitation techniques, polymerization, and 
nanoprecipitation51,52. Among several techniques, nanoprecipitation 
represents a very powerful approach to produce polymeric 
nanoparticles in batch processes53 even if polydispersity due to 
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aggregation effects challenges in the complete removal of the solvents, 
in particular for high polymer–solvent affinities, and low loadings of 
hydrophilic compounds54. Indeed, the inherent variability and 
complexity of conventional batch precipitation processes often make 
it problematic to produce particles with well-defined physicochemical 
and functional attributes52,53.  
To circumvent this issue to obtain high-quality MRI imaging, different 
procedures for producing size- and shape-controlled nanoparticles are 
being explored. Microfluidics has demonstrated its ability to improve 
size- and composition- control in the field of nanoparticle 
synthesis55,56. Microfluidic technologies are adapted to tightly control 
the nanoprecipitation, the mixing rate between solvent and non-
solvent phase, and clearly showed advantageous results in term of the 
final particle properties, i.e. size, polydispersity, etc., due to the 
process’s ability to accurately control process parameters and thus 
enables efficient, continuous and tunable mixing55,57-62. 
As dominantly used core materials in MRI contrast agents, SPIO have 
been prepared by continuous flow microfluidic devices63. Such 
microfluidic platforms could have the potential to profoundly improve 
development of MRI-based molecular imaging CAs. 
But, even if, in the recent years, a great effort has been made to apply 
microfluidic technologies to the production of SPIO for MRI and to 
the production of polymeric nanoparticles for other applications, the 
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exploitation of the microfluidic approaches to support the design of 
hydrogel nanostructures for MRI is still lacking.  
Recently, in our work published on Interface Focus “Impact of 
biopolymer matrices on relaxometric properties of contrast agents”64, 
we have explored the impact of crosslinked and un-crosslinked 
biopolymer matrices on relaxometric properties of CAs where the 
contribution to the enhancement of CAs is highlighted and attributed 
to the reduced mobility of water within the hydrogel. The proposed 
approach for characterizing polymer-based CAs could be applied to 
study the mechanisms involved in several combinations of different 
types of polymers and metal ions. 
The idea is that the knowledge of these complex systems could be 
scaled to nanoscale dimensions, inspiring the development of a new 
class of nanostructured MRI CAs with highly tunable relaxometric 
properties.  
Moreover, the possibility to modulate the properties of the 
nanoparticles through a microfluidic system to impact the 
relaxometric properties of the CAs without chemical modification of 
the chelates has not been tested55,65,66 and could be investigated to 
obtain a new class of MRI approaches based on rational polymer 
nanostructures.  
In these perspectives, in another work recently published by Scientific 
Reports “A Microfluidic Platform to design crosslinked Hyaluronic 
Acid Nanoparticles (cHANPs) for enhanced MRI”67, a controlled 
Background, Aim of the work and Major Findings 
8 
 
nanoprecipitation in a microfluidic flow focusing approach is used to 
synthesize intravascularly-injectable and biocompatible hydrogel 
nanoparticles as low as 35 nm in which a clinically relevant MRI-CAs, 
Gd-DTPA, is entrapped. By fine-tuning the mixing of all species, 
nanoprecipitation behaviour and crosslinking reaction are adjusted 
very precisely simultaneously, leading to relaxivity values about 12 
times larger than that of free CAs clinically available, at the common 
field of clinical MRI, 1.5 Tesla. This approach is optimized to perform 
a crosslinking reaction able to retain the Gd-CAs in the polymer 
matrix of the precipitated morphology. The proposed methodology 
has the goal to introduce microfluidic strategies to modulate the 
nanoprecipitation playing on the hydrophilic-lipophilic properties of 
the surfactants or the pH solution conditions to optimize relaxometric 
performances of the MRI CAs. 
A multidisciplinary study of the interference of the Gd-DTPA in the 
polymer conformation is reported for the first time and could add 
significant advances to the fundamental knowledge of the interaction 
between the Gd-chelates and hydrogels structures. 
The developed microfluidic strategies allow a fine tuning of the 
hydrogel structure, and it can be easily applied to different polymer 
and materials involved in nanomedicine field. Additional strengths of 
the proposed work, compared to the other investigations related to the 
formation of nanostructures, are also the achieved nanoparticles size 
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of 35 nm and the low polydispersity, as so the controlled degradation 
and release behaviors. 
Preliminary in vivo results clearly show the improvement of the MRI 
and confirm the stability of NPs ensuring no leakage of Gd-DTPA 
during the time course of the relaxation measurements. Gd-entrapped 
cHANPs could potentially provide tissue specificity and reduce 
nephrotoxicity and, at the same time, they have the capability to retain 
Gd-based contrast agents to boost the MR signal without the chemical 
modification of the chelates. Furthermore, cHANPs could ensure an 
improvement of the time window for clinical imaging acquisitions due 
to the reduction of long scan time and rapid renal clearance. 
Starting from the observation of a peculiar swelling behavior and in 
vitro relaxometric properties of the cHANPs, we have also proposed 
an explanation of how the hydrogel structural parameters can be used 
to improve the relaxometric properties of CAs. 
In our last work under revision “Hydrodenticity to enhance relaxivity 
of Gd-DTPA within crosslinked Hyaluronic Acid Nanoparticles 
(cHANPs)”, we report how the water dynamics in a hydrogel matrix 
can interfere with the relaxation properties of the Gd-based CAs 
irrespective of NPs size or way of production. For the first time, the 
new concept of Hydrodenticity is here defined to intend the peculiar 
environment within the nanostructures composed by the ternary 
system, hydrogel/water/CAs able to improve the relaxometric 
properties. Parameters related to the hydrodenticity are individuated 
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and explained, supported by the literature, and a theoretical 
explanation is fully provided by the consolidated Flory-Rhener theory. 
In this case, the microfluidics in not the main actor but the approach, 
as presented in the Chapter I, becomes a tool to prove that 
Hydrodenticity can be modulated to obtain desired crosslink density, 
mesh size, hydrophilicity and loading capability, playing on the 
biodegradable behavior and relaxometric properties of the Gd-loaded 
nanostructures. In this work, Hydrodenticity refers to the status of the 
hydrated Gd-DTPA with the coordination water subjected to osmotic 
pressure deriving from elastodynamics equilibrium of swollen gels. 
The capability to control these parameters within the nanoparticles can 
be applied to define a new class of medical devices useful to improve 
the properties of CAs for MRI.  
We firmly believe that our findings could lead to direct benefits of the 
clinical field due to the utilization and improvement of completely 
biocompatible and FDA approved products without their chemical 
modifications, the ease of the synthesis, the nature of the materials, 
and the scalability of the proposed process, as reported in the next 
Chapters. 
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I. CHAPTER I – Controlled nanoprecipitation to 
synthesize Hyaluronic Acid Nanoparticles (HANPs) in a 
microfluidic Flow Focusing system  
 
Abstract 
A new microfluidic-based process is presented to synthesize Hyaluronic Acid 
Nanoparticles for potential application in diagnosis and therapy. A controlled 
nanoprecipitation in a flow focusing configuration is used to allow a 
continuous and controlled production of nanoparticles, overcoming the limits 
of common batch processes, and guaranteeing an instantaneous formulation 
and absence of purification step. By fine-tuning the mixing of all species and 
the processing parameters, nanoprecipitation behavior is adjusted very 
precisely to obtain a monodisperse collection of Hyaluronic Acid 
Nanoparticles under 50 nm. Furthermore, the solvent and the non solvent 
flow rates can be varied to adjust nanoparticles properties, opening new 
possibilities for nanoparticle production by nanoprecipitation. 
  
Graphical Abstract I-1. Efficient, fast, uniform and controllable mixing to produce 
Hyaluronic Acid Nanoparticles (HANPs) through nanoprecipitation in a microfluidic 
system. 
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I.1 Background 
I.1.1 Biopolymeric nanoparticles for therapy and 
diagnostics  
Over the past decade, a growing interest has been dedicated on 
polymeric nanoparticles (NPs) for application in therapy and diagnosis 
to treat different types of diseases1. Compared with conventional 
drug/agents vehicles, such as liposomes or micelles, polymeric NPs 
have been shown to increase the stability of drugs and to control their 
release properties, owing to their tailored sizes, morphologies, and the 
possibility to use biodegradable polymers2,3.  
Polymeric nanoparticles are defined as particulate dispersions or solid 
particles with a size in the range of 10-200 nm4. There has been a 
considerable research interest in drug delivery using particulate 
delivery systems as carriers for small and large molecules. Particulate 
systems like nanoparticles have been used as a physical approach to 
alter and improve the pharmacokinetic and pharmacodynamic 
properties of various types of drug molecules. Several methods to 
prepare polymeric nanoparticles have been developed and classified 
according to whether the particle formation involves a polymerization 
reaction or nanoparticles form directly from a macromolecule or 
preformed polymer5,6.  
Polymers used in the preparation of nanoparticles should be 
compatible with the body in terms of adaptability (nontoxicity and 
nonantigenic) and should be biodegradable and biocompatible. 
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Natural polymers used include chitosan, gelatin, sodium alginate, 
albumin, hyaluronic acid. There are also many Synthetic polymers for 
example Polylactides (PLA), Polyglycolides (PGA), Polylactide co-
glycolides (PLGA), Polyanhydrides, Polyorthoesters, Poly glutamic 
acid, Poly malic acid, Poly(methyl methacrylate), Poly(vinyl alcohol), 
Poly(acrylic acid), Poly acrylamide, Poly(ethylene glycol), 
Poly(methacrylic acid)7. 
The properties of polymeric NPs must be optimized depending on the 
application. In order to achieve the properties of interest, the mode of 
preparation plays a key role. Thus, it is highly advantageous to choose 
techniques to obtain polymeric NPs with the desired properties for a 
particular application. The main experimental ways for generating 
polymeric NPs can be namely listed as: solvent evaporation, salting-
out, emulsification-solvent diffusion process, supercritical fluids that 
replace the solvent in the precipitation techniques, polymerization, and 
nanoprecipitation.  
Among several biopolymer-based batch processes, it has been already 
reported that nanoprecipitation represents a very promising and 
powerful approach in producing nanoparticles8 since it is a simple, 
fast, and reproducible method, and also widely used to produce NPs. 
Polymeric and pure drug NPs were first prepared through 
nanoprecipitation by Fessi and coworkers2. 
The main principle driving the process is a fast mixing of a material 
solution (polymer and/or pure drug/contrast agents in a solvent) with 
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a non-solvent of the material. Herein, ideally, the solvent should be 
miscible with the non-solvent. The structure material (i.e. polymer 
and/or drug) should be free-soluble in the solvent and insoluble in the 
non-solvent. Controlling the size of the NPs passes through the 
optimization of process parameters as well as the formulation and 
physicochemical parameters, like the chemical nature of the solvent 
and non-solvent, the respective solubility of the material in both 
phases, their concentrations, the surfactant properties of the polymer 
and/or drug. In fact, the solvent transfer is one of the main parameters 
governing the nanoprecipitation9, likely related to the miscibility 
between solvent and non-solvent which controls the speed of the mass 
transfer. The usefulness of this simple technique is limited to water-
miscible solvents, in which the diffusion rate is enough to produce 
spontaneous emulsification. Then, even though some water-miscible 
solvents provoke a certain instability when mixed in water, 
spontaneous emulsification is not observed if the coalescence rate of 
the formed droplets is sufficiently high.  
On the other hand, the literature reviewed that it is possible to tune this 
transfer with microfluidic approaches, which eventually improve the 
control on the NPs characteristics10-12.  
Microfluidics, the science and technology of manipulating nanoliter 
volumes in microscale fluidic channels, has impacted a wide range of 
fields including biological analysis, chemical synthesis and processes, 
single cell analysis, and tissue engineering13,14. 
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From 1998, a very intense research was initiated and has now 
drastically widened the application of microfluidic systems,15 but in 
the recent years, microfluidic systems were adapted to control the 
mixing rate between solvent and non-solvent phase, and clearly 
showed advantageous results in term of NPs size control, compared to 
classical batch processes16,17. The earliest example has reported the 
fine control of the mixing of two phases at nanoliters level within few 
microseconds with a flow focusing silicon-based micromixer18. This 
method was later adapted for the nanoprecipitation of PLGA 
(polylactic-co-glycolic acid) derivative NPs, providing the pioneer 
report on the controlled nanoprecipitation in microfluidic setup19. 
These works initiate a great research effort to explore the potentials of 
such novel microfluidic platforms for the elaboration of polymer and 
pure drug NPs by nanoprecipitation20.  
I.1.2 Nanoprecipitation and advantages of microfluidic 
systems  
Literature reviews16 report two theoretical explanation about the 
formation of polymeric NPs by nanoprecipitation3: a dispersion 
mechanism such as the spinodal decomposition, which is classified as 
a “mechanical mechanism”, and the well-known nucleation and 
growth mechanism. In the first case, the solvent solution is broken into 
small chunks of fluids which are dispersed into the non-solvent 
solution21,22. In the nucleation and growth mechanism23, nuclei are first 
produced when the polymer reaches a supersaturation state due to the 
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solvent diffusion into the non-solvent solution. Then, the nuclei grow 
by molecular deposition of polymer chains at their surface24,25.  
Lince et al. (2008)25 indicated that the process of particle formation in 
the nanoprecipitation method consists of three phases: nucleation, 
growth and aggregation. The rate of each step determines the particle 
size and the driving force of these phenomena is supersaturation, 
which is defined as the ratio of polymer concentration over the 
solubility of the polymer in the solvent mixture. The split between the 
nucleation and the growth phases is the crucial factor for 
monodisperse particle formation. Ideally, operating conditions should 
allow a high nucleation rate strongly dependent on supersaturation and 
low growth rate. The second theory is based on Gibbs–Marangoni 
effect, that explained rapid nanoparticle formation as a process due to 
differences in surface tension, since a liquid with a high surface 
tension (aqueous phase) pulls more strongly on the surrounding liquid 
than one with a low surface tension (organic phase solvent). These 
differences between surface tensions cause interfacial turbulence and 
thermal inequalities in the system, leading to the continuous formation 
of eddies of solvent at the interface of both liquids. Consequently, 
violent spreading is observed due to mutual miscibility between the 
solvents, the solvent flows away from regions of low surface tension 
and the polymer tends to aggregate on the oil surface and forms 
nanocapsules. According to this explanation, nanocapsule formation 
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is due to polymer aggregation in stabilized emulsion droplets, while 
apparently the nucleation and growth steps are not involved26. 
However, polydispersity due to the aggregation effects, complete 
removal of the solvents, in particular for high polymer–solvent 
affinities, and a low loading of hydrophilic compounds are still a 
challenging task26 for the nanoprecipitation technique. Indeed, the 
inherent variability and complexity of conventional batch processes 
often make it challenging to produce particles with well-defined 
physicochemical and functional attributes3,8. 
Recently, the literature has shown that it is possible to precisely tune 
this transfer with microfluidic tools, which eventually enhance the 
control on the NPs size.  
Microfluidics27 refers to a set of technologies that control the flow of 
minute amounts of liquids or gasses typically measured in nano and 
picoliters in a miniaturized system. Microfluidic devices are designed 
to manipulate fluids in microchannels with significantly reduced 
consumption of reagents and demonstrate intrinsically efficient heat 
and mass transfer due to high surface-area-to-volume ratios. In fact, 
micrometer scale of the flow channels in microfluidic systems 
increases the surface to volume ratio, and is, therefore, advantageous 
for many applications. For microfluidic system, the specific Reynolds 
number (Re = 1 ρv/η) of liquid flows in such microchannels is very 
small, typically smaller than 100. In such low Reynolds number 
regimes, turbulent mixing does not occur, and hence diffusive species 
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mixing plays an important role but is an inherently slow process. 
Consequently, the aim of microfluidic mixing schemes is to enhance 
the mixing efficiency such that a thorough mixing performance can be 
achieved within shorter mixing channels, which can reduce the 
characteristic size of microfluidic devices. Furthermore, the 
development of efficient mixing schemes is essential for increasing 
the throughput of microfluidic systems. Indeed, increasing the contact 
area between the species to be mixed is one of the most efficient means 
of enhancing the diffusive mixing effect28. Accordingly, previous 
studies presented mixing schemes by feeding the samples of interest 
through discrete via holes, cantilever plate-valves or multi-channels in 
the microfluidic device. An alternative approach is to increase the 
contact area between the mixing species by designing the 
microchannel configurations so that the species are folded multiple 
times as they flow along the mixing channel. Efficient mixing and 
rapid chemical reaction at the nanoliter to picoliter scales allow 
microfluidic devices to better control the synthesis parameters and 
thus the nanoparticle sizes and properties. The miniaturization of 
synthesis systems provides new opportunities for advanced chemical 
synthesis, and also enables a broad range of biological and medical 
applications17. Microfluidics has impacted a wide variety of fields 
including biological analysis, chemical synthesis, single cell analysis, 
and tissue engineering13.  
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The use of microfluidic devices for nanoparticle synthesis is 
advantageous in many aspects, including enhanced processing 
accuracy and efficiency; flexibility for multi-step platform design; 
rapid turnaround results for fine tuning properties of synthesized 
nanoparticles, cost savings from reduced consumption of source 
materials and reagents, and safer operation and environmental 
friendliness since the process consumes much reduced hazardous 
chemicals and reagents. Microfluidic devices can generate 
homogeneous emulsions particles in a controllable manner. 
Microfluidic systems have been used for various applications such as 
the production of single and double emulsions and nanoparticles with 
numerous advantages on size control, the economy of reagents, among 
others. A relevant question, however, is that these systems operate 
with flow rates on a scale of μL/min and often take hours to produce 
a few milliliters of solution. Thus, on one hand the systems are 
accurate to produce homogeneous particles with low consumption of 
reactants in a continuous flow, on the other hand, they have low 
productivity. Droplet generation in a microfluidic system is a well-
understood and studied phenomena, which is attracting increasing 
attention owing to a variety of potential applications in biology, 
medicine, chemistry and a wide range of industries. Microfluidic 
devices can produce monodisperse droplets through a number of 
different methods including jets, T-junctions, cross-flowing, co-
flowing and flow focusing devices. However, both mechanisms 
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require an efficient mixing between the polymer and non solvent 
solutions. In the case of nucleation and growth process, which is the 
process likely to be encountered with microfluidic systems, the faster 
the mixing, the smaller are the NPs. 
Compared with conventional nanoprecipitation batch methods, 
advantages of microfluidic system lay in their excellent ability to 
manipulate nanoliter flows. Microfluidic systems such as micromixers 
can drastically reduce the mixing path of solvent and non-solvent 
down to few tens of micrometers, resulting in a very fast mixing 
achieved by diffusion within few milliseconds down to 
microseconds18. Thus, due to this fast and efficient mixing, different 
physicochemical properties of NPs can be obtained by controlling the 
ratio of flow rates of the non-solvent to the solvent solution or by 
changing the configuration of the micromixer. It usually results in the 
production of smaller particles compared to conventional methods29. 
In addition, microfluidic systems are usually operated in continuous 
flow which supports the potential of NPs production at large scale. 
Another advantage of continuous production is the possibility to 
maintain over time the same quality of the product, a much important 
feature for the pharmaceutical industry. Furthermore, the laminar flow 
ensures predictable and reproducible mixing conditions across fluidic 
interfaces30.  
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I.1.3 Hydrodynamic Flow Focusing in Microfluidics  
The hydrodynamic flow focusing (HFF) is another method to reduce 
the diffusion path and so it is an efficient strategy to enhance the 
mixing31, but has virtually no limitation. Microfluidic devices based 
on HFF widely used to prepare NPs by nanoprecipitation19,30. In the 
HFF, a middle sample solution (injected from the middle inlet) ﬂows 
within the sheath of outer ﬂuids (injected from the side inlets), which 
constrain laterally the inner sample ﬂow to achieve a smaller stream 
and thinner lamination width28. The extent of the width decrease of the 
focused stream depends on the volumetric ﬂow rate ratio between the 
sample ﬂow and sheath ﬂows. The greater the ﬂow rate difference, the 
greater the degree of width reduction. Mixing time is inversely 
proportional to the square of the diffusion path length (in this case 
represented by the focused stream width), therefore, decreasing the 
stream width results in faster mixing28. This effect results in a better 
control of the NPs characteristics like smaller size and narrow size 
distribution. Note that the flow focusing extent can be controlled by 
the ratio of the flow rates of the main inlet flow to the side flows.  
The HFF mixing principle was first introduced by Knight et al. in 
199818 and then adapted in 200819 for the production of amphiphilic 
PLGA-b-poly(ethylene glycol) (PEG) NPs, for which acetonitrile 
served as the polymer solvent. When PLGA was added to the final 
PLGA-PEG polymer, the microfluidic system showed a better control 
on the NPs size compared to the batch process. Indeed, for the HFF 
technology, the size increased from 24 nm to only 34 nm when the 
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PLGA weight content was increased from 0 to 20 wt %, whereas for 
the batch method, the NPs size increased from 30 to 105 nm. 
Interestingly, when Karnik et al.19 admixed the polymer solution with 
a model drug (docetaxel, Dtxl) to get drug loaded PLGA-PEG NPs, 
drug encapsulation efficiency was increased from 20 to 50 % wt 
compared with the batch method. They also found that the final NPs 
size increased when Dxtl was added to the polymer solution. Thus, 
authors investigated the water/acetonitrile ratio (so-called cloud point) 
at which polymer precipitated by gradually adding water to a solution 
of the polymer with or without Dtxl in acetonitrile. Polymer alone was 
observed to precipitate for a water/acetonitrile ratio of 25% v/v, the 
presence of Dtxl shifted this value up to 45% v/v. It indicates that Dtxl 
starts precipitating after the polymer. Hence, a rapid mixing may yield 
to slightly lower drug encapsulation efficiencies as some drug may be 
‘locked out’ of the NPs that have already been formed before the drug 
starts to precipitate. Capretto et al.30 proposed a Y-type HFF setup that 
was used to prepare β-carotene loaded Pluronic F127 copolymer NPs 
by nanoprecipitation using tetrahydrofurane (THF) solution and water 
as solvent and non-solvent, respectively. When only Pluronic F127 
was used, a mean NPs diameter of 130 nm was obtained. When β-
carotene was used alone, it was found that β-carotene precipitated 
immediately due to its higher hydrophobicity. As a result, aggregation 
of big particles completely blocked microchannel. When both β-
carotene and copolymer composed the solvent solution, obtained NPs 
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showed a much smaller size, of around 70 nm. Thus, it is clearly 
demonstrated that the composition of polymer solution has a 
significant influence on final NPs size as well as the superiority of the 
microfluidic approach compared to its batch counterpart, in terms of 
potential to control the NPs size. Palocci et al.32 proposed a novel HFF 
microfluidic device by assembling commercial stainless steel micro-
capillary tubes with cross junctions. Dexamethasone was used to get 
drug-loaded PLGA NPs (35–350 nm). Encapsulation efficiency was 
found to reach values up to 93%, whereas by the batch method, 
encapsulation efficiency reached a ceiling value of only 60%. To 
increase the throughput production of HFF micromixers, Kang et al.33 
designed a three-layered poly(dimethyl siloxane) micromixer 
comprising 100 parallel flow focusing microchannels. The parallel 
flow focusing micromixer was then adopted to prepare NPs, similarly 
using PLGA-PEG amphiphilic polymer. The results indicated the 
device was quite robust in producing reproducible highly 
monodisperse NPs regardless the molecular weight of both 
copolymers and their weight content compared to the batch method. 
Lim et al.34 reported the same structure to synthesise NPs. According 
to the results of Kang et al.33, monodisperse NPs obtained from high 
molecular weight polymers were difficult to prepare by a batch 
method due to uncontrollable mixing process resulting in NPs 
aggregation. Thus, in order to use higher molecular weight polymers 
and to increase the polymer weight content in solvent solution as well 
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as to avoid unexpected clogging, a 3D flow focusing geometry was 
developed by Rhee et al.35,36 This 3D HFF micromixer was 
successfully used for the production of NPs from PLGA95K-PEG5K 
having a high molecular weight and introduced at weight content up 
to 5% w/v in acetonitrile. Sun et al.37 proposed another 3D HFF 
micromixer based on the original concept of ‘origami chip’ and 
applied this new device to the production of doxorubicin-loaded 
PLGA NPs. The resulting NPs sizes obtained with the flat system (i.e. 
2D device) were compared to those produced with the double spiral 
and arc systems. While the minimum size obtained with the former 
was 100 nm, in the same condition of flow rates, the last two systems 
produced much more monodisperse NPs sizes around 70 nm which 
was attributed to the significant reduction in mixing time (from 29 s 
down to 15 s) as simulated by computational fluid dynamics (CFD). 
Encapsulation efficiency of doxorubicin had reached 50 wt%. Souza 
Bicudo et al.38 described a process for the production of Hyaluronic 
Acid (HA) crosslinked nanoparticles by nanoprecipitation at the 
interface of organic solvent/water phases. HA nanoparticles were 
crosslinked with adipic dihydrazide (ADH) and chloride carbodiimide 
(EDCL) and presented sizes ranging from 140 to 460 nm, depending 
on operational conditions.  
I.1.4 Aim of the Chapter 1 
In this chapter, we first have introduced theoretical considerations 
about the advantages of nanoprecipitation through mixing strategies 
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in microfluidics, which play a key role in the generation of high-
quality nanoparticles, compared to batch production processes. Later, 
we have highlighted several representative microfluidic systems for 
controlled synthesis of nanoparticles with particular attention to 
Hydrodynamic Focusing approaches.  
In this perspective, we present our work based on the design of a 
microfluidic platform to synthesize Hyaluronic Acid Nanoparticles 
(HANPs) under 50 nm. Herein, we demonstrate that rapid and tunable 
hydrodynamic flow focusing in microﬂuidics can be used to obtain 
HANPs with the deﬁned size of about 50 nm and lower polydispersity. 
The proposed Microfluidic approach allows a continuous and 
controlled production of nanoparticles, overcoming the limits of 
common batch processes, and guaranteeing an instantaneous 
formulation and absence of purification step. Furthermore, our 
approach is also able to manipulate and modify the nanoparticle 
characteristics by fine-tuning the processing parameters such as flow 
rates or polymer concentration39. 
I.2 Case Study 
I.2.1 Experimental Section 
I.2.1.1 Materials 
Sodium Hyaluronate ( Mw = 42 kDa)  was purchased from Bohus 
Biotech (Sweden). Acetone (CHROMASOLV, for HPLC, ≥ 99.8%; 
molecular formula CH3COCH3; Mw = 58.08), Ethanol (ACS reagent, 
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≥ 99.5%  (200 proof), absolute; molecular formula CH3CH2OH ; 
Mw = 46.07) were purchased by Sigma-Aldrich Co. The water, used 
for synthesis and characterization, was purified by distillation, 
deionization, and reserve osmosis (Milli-Q Plus).  
I.2.1.2 Microfluidic set-up for flow focusing (FF) approach 
A quartz microfluidic device “X- Junction Chip, 190 µm”, purchased 
from Dolomite Centre Ltd, was used to perform all the experiments. 
The device has a flow focusing geometry with a 90° angle between the 
inlets to enhance the diffusion process (Figure I-1a and b).  
 
 
Figure I-1. Microfluidic Device. a) “Droplet Junction Chip 190 µm” with two 
configurations T- and X- junction, which can be used in combination. b) Droplet 
Junction Chip is compatible with Chip Interface H for fluidic connections. 
The experimental set-up was summarized in (Figure I-2). The device 
was connected to 2.5-5 mL glass syringes (Microsyringes ILS 
Innovative Labor System) with FEP tubing (1/16’’x 0.25 mm) 
controlled by the syringe pumps (Low Pressure Syringe pumps, 
Nemesys system). Three-way isolation ETFE valves, connecting glass 
Chapter I 
33 
 
syringe with the microfluidic device, make the automatic fill-in of the 
syringes feasible, thus allowing a continuous dispensing of reagents. 
The linkage between FEP tubes and microdevice is carried out through 
a specially designed connection with PTFE connectors. The flow 
focusing behaviour on the microchannel was observed using an 
Optical Fluorescence Microscope (Olympus IX71) with a 4 or 10 x 
scanning objective. 
 
Figure I-2. Experimental set-up. The microdevice is connected to glass syringe 
controlled by Nemesys system. The flow focusing behaviour is observed using an 
Optical Fluorescence Microscope. 
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I.2.1.3 Production of Hyaluronic Acid Nanoparticles (HANPs) 
by nanoprecipitation in microfluidics 
Different flow rates were tested, and the influence of the Flow Rate 
Ratio FR2, defined as the ratio of Volume Flow Rate Solvent and 
Volume Flow Rate Non-Solvent, was determined. For the feasibility 
study, a 5 mL aqueous solution containing HA concentrations ranging 
from 0.01 to 0.1% wt/v was used to explore the effects of the 
nanoprecipitation by flow focusing exclusively due to the 
concentration of the polymer. The initial solution was kept under 
continuous stirring for at least 4 hr and then injected through the 
middle channel. The flow rate of the middle channel was changed 
from 5 to 100 µL/min. Acetone or Ethanol, used as non-solvent and 
injected through the side channels, were laterally injected to induce 
nanoprecipitation by a non-solvent extraction. The flow rates of the 
side channels were ranged from 50 µL/min to 300 µL/min, increasing 
each step of 10 µL/min. Precipitated nanoparticles were collected in a 
Petri glass containing about 25 mL of non-solvent and kept under 
continuous stirring. Each experiment was repeated at least 10 times. 
I.2.1.4 HANPs purification and recovery 
Purification was performed by a solvent gradient dialysis (Spectra Por 
Cellulose Membrane 6 – Mw cut-off MWCO 50.000) or by 
ultracentrifugation. A typical procedure consisted of loading collected 
samples into the dialysis tube and keeping the solution under 
continuous stirring at 130 rpm. Water was slowly added to the solution 
creating a concentration gradient and avoiding aggregation and 
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diffusion phenomena across the membrane. The recovery was 
performed at 15° C, at 80000 rpm for 45 min (ultracentrifugation). 
I.2.1.5 HANPs size characterization 
Following the purification of HANPs, Dynamic light scattering (DLS) 
was used to determine nanoparticle size and surface charge (Zeta sizer, 
Zeta Potential Malvern). DLS measures the light scattered from a laser 
that passes through a colloidal solution and by analyzing the 
modulation of the scattered light intensity as a function of time, the 
hydrodynamic size of particles and particle agglomerates can be 
determined. Larger particles will diffuse slower than smaller particles 
and the DLS instrument measures the time dependence of the scattered 
light to generate a correlation function that can be mathematically 
linked to a particle size. DLS is a valuable tool for determining and 
measuring the agglomeration state of nanoparticles as a function of 
time or suspending solution. The wavelength of the laser is 630 nm 
and the scattering angle used is 173°. The cuvettes used are the 12mm 
square glass couvettes for 90° sizing (PCS8501). An ideal sample 
submission for DLS analysis has a volume of 1-2 mL. 
In DLS analysis, the z-Average value represented the mean value of 
the hydrodynamic diameter of the particle, while the polydispersity 
index measured the width of the particle size distribution.  
The formula for Polydispersity is: 
𝑃𝑑𝐼 = (
𝜎
𝑑
)
2
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where the polydispersity (PdI) = the square of the standard 
deviation/mean diameter. If the polydispersity index is > 0.1, if the 
cumulants fit error is > 0.001, or if the Result quality is Poor, then the 
data is more suspect and further analysis should be done to determine 
if valid data has been generated.  
Nanoparticles Tracking Analysis measurements were performed with 
a NanoSight (NanoSight, Malvern), equipped with a sample chamber 
with a 640-nm laser and a Viton fluoroelastomer O-ring. The samples 
were injected in the sample chamber with a sterile syringe until the 
liquid reached the tip of the nozzle. All measurements were performed 
at room temperature. The samples were measured for 40s with manual 
shutter and gain adjustments. Three measurements of the same sample 
were performed for all samples. 
I.2.1.6 Scanning Electron Microscopy  
After these treatments, a hundred microliters of purified samples were 
deposited on a polycarbonate Isopore Membrane Filter (0.015, 0.05, 
0.1 and 0.2 µm) by ultrafiltration vacuum system. The precipitated or 
deposited particles were coated with gold-palladium, and their 
morphology was observed by ULTRA PLUS Field Emission 
Scanning Electron Microscope (FE-SEM Carl Zeiss, Germany) with 
an accelerating voltage of 10-20 kV and using a lens detector. Samples 
for SEM applications need extremely thin, grain-free, uniform 
coatings to eliminate charging and to improve contrast on low density 
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materials. The device used was 208HR High Resolution Sputter 
Coated (Cressington). 
I.2.2 Results and Discussion 
I.2.2.1 Diffusive mixing time in Hydrodynamic Flow Focusing 
approach 
The mixing time τmix is a key parameter for the formation of NPs 
through nanoprecipitation, which directly affects the size 
characteristics of the NPs produced40. By adjusting the width of the 
focused stream (wf) the mixing process can be controlled, providing a 
direct means for the control of particle characteristics, as demonstrated 
previously41. Indeed, it is the diffusion of the solvent and non solvent 
molecules in and out the focused stream that cause the diffusive 
mixing, and in turn the solvent jump, which drives the 
nanoprecipitation process41. Hydrodynamic focusing reduces the 
width of the focused stream (wf) and consequently the distance over 
which the molecules diffuse, which represents the diffusion length for 
liquids to mix31,42. 
As reported by Capretto28, according to the mass conservation 
principle, the volume of sample liquid that passes through the middle 
channel Q2 must match the volume of the focused stream Qf: 
Q2 = v2w2h = vfwfh = Qf 
wf =
Q2
vfh
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wf  and w2  represent the width of the focused stream and middle 
channel, respectively. Q2 and Qf are the volumetric flow rates of the 
middle channel and focused stream, respectively. h is the height of the 
channels, and v2  and vf  are the average velocity of the flow in the 
middle channel and of the focused stream, respectively. 
This equation provides a simple guideline for predicting the focused 
stream width. However, it does not reﬂect the effect of other factors 
such as device structure, channel surface, and ﬂuidic property, which 
could affect the focusing process. In this respect, Lee et al.43 proposed 
a similar model in which the effect of the density of the different ﬂuids 
is taken into account, where wf can be represented by: 
wf =
𝑄𝐼
𝑄𝐼 + 𝑄𝐸
∙ (wb +
𝜋
2
ℎ) ∙ 𝑎 
where 𝑄𝐼 and 𝑄𝐸 are the flow rates of the middle stream and the total 
side streams respectively; 𝑤𝑏 and ℎ are the bottom width and heigh, 
respectively of the main channel; a is a factor dependent on channel 
geometries and the viscosity. 
Consequently, the theoretical mixing time (τmix) was basically 
calculated as19: 
𝜏𝑚𝑖𝑥 ≈
𝑤𝑓
2
4𝐷
≈
(𝑤𝑏 +
𝜋
2 ℎ)
2
∙ 𝑎2
4𝐷 (1 +
1
𝑅)
2  
Where 𝐷 is the Diffusion coefficient of the solvent and 𝑅 is the ratio 
of the flow rate of the focused stream to the total flow rate of the sheat 
flow. 
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In our microfluidic experiment, at standard process conditions, wf is 
resulting in an average 𝜏𝑚𝑖𝑥 of 46 ms therefore allowing the creation 
of homogeneous starting conditions for nanoprecipitation in which the 
role of mixing was not convoluted with the kinetics of aggregation. 
I.2.2.2 Synthesis of Hyaluronic Acid Nanoparticles (HANPs) by 
Hydrodynamic Flow Focusing 
Controlled nanoprecipitation of NPs relies on minimizing the mixing 
time to ensure a homogeneous environment during nucleation and 
growth of the NPs44. This is realized by a fast solvent shifting, from 
organic to non-solvent, which provides a high level of supersaturation 
for all species, leading to nucleation and diffusion-limited aggregation 
of precipitates45. An effective way to obtain controllable, fast and 
predictable mixing is the use of a microfluidic device architecture that 
allows the creation of a hydrodynamic focusing flow pattern. 
In the flow-focused nanoprecipitation30,42,46, the continuous phase, 
flowing through two side channels, meets the dispersed phase in the 
main channel, where the dispersed phase becomes compressed, and 
the solvents mutually diffuse promoting the precipitation of the solute 
and, therefore, the production of nanoparticle morphologies. 
Figure I-3 shows a schematic of the microfluidic device used to 
synthesized Hyaluronic Acid (HA) NPs by nanoprecipitation of a 
hydrogel solution induced through a flow focusing approach.  
HA dissolved into the aqueous solution flowing from the middle 
channel, mixed with non solvent flowing from the two side channels, 
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by achieving a stable hydrodynamic flow focusing along the main 
channel. 
HA nanoparticles were formed at the interface between the organic 
phase and water in a laminar flow. As water diffuses into the non 
solvent phase, a supersaturated HA solution was formed at the 
interface between the phase, leading to HA nanoprecipitation. 
 
 
Figure I-3. Nanoprecipitation of HANPs. Schematic representation of the 
microfluidic device consisting of three inlets creating a hydrodynamic ﬂow focusing 
with a middle stream of water and two side streams of non solvent. The width of the 
focused central stream (wf) can be varied by altering the volumetric ﬂow rates of the 
three inlets. 
I.2.2.3 Influence of the non solvent on the HANPs 
characteristics 
In order to better control the Nanoprecipitation process in our 
microfluidic device, the influence of the organic solvent (non solvent) 
has been studied. In fact, to improve the mixing process, all 
experiments were conducted using Acetone and Ethanol as non 
solvent. 
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Results show that the viscosity effects are crucial at the micrometer 
scale, and the different types of organic solvents also affected the flow 
field inside the microchannel.  
Acetone presents the lower viscosity value (0.35 mPa s), thus its flow 
resistance is lower. The lower viscosity facilitates water transfer to the 
organic phase, leading to narrower streams. On the other hand, in the 
experiments with Ethanol the polydispersity is higher compared with 
Acetone. In fact, Ethanol extracts the water more slowly and thus it 
destabilizes the entire hydrodynamic focusing.  
Finally, Acetone is preferred because it has a greater affinity with 
water and then a more rapid extraction, so Nucleation is favored to the 
Growth, obtaining smaller and monodisperse NPs. The affinity 
between water and the organic solvents can be analyzed by the 
Interaction (X) and Hansen Solubility ∆δ parameters38 as reported in 
Souza Bicudo et al.38. 
The affinity leads to a higher nanoprecipitation rate and consequently 
to smaller nanoparticles. 
I.2.2.4 Influence of Flow Rate Ratio and polymer 
concentration and on HANPs characteristics 
Flow rate conditions play a key role and Flow conditions of greater 
interest are selected analyzing the values of z- Average and of PDI 
obtained by Dynamic Light Scattering (DLS). We compared the 
effects of varying the flow rates on the mean diameter and the 
polydispersity of the HANPs.  
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Different flow rates are tested and results are presented in terms of the 
already defined Flow Rate Ratio FR2. Nanoparticle size varies from 
35 nm to 500 nm, on the dependence of FR2 ranging from 0.2 to 0.6 
(as showed in Table I-1).  
In DLS measurement, the z-Average value represents the mean value 
of the hydrodynamic diameter of the particle, while the polydispersity 
index measures the width of the particle size distribution related to the 
standard deviation σ.  
 
Table I-1. Dynamic Light Scattering Results at different FR2 in terms of z-Average and 
Standard Deviation 
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Indeed, through the increase of the Non-Solvent Flow Rate and, 
therefore, the reduction of FR2, a more stable and narrow 
hydrodynamic focusing is achieved (Figure I-4a).  
Our attention is focused on “easier to process” and high yield process 
parameters where the fast extraction of the solvent promotes 
nucleation to the detriment of growth leading to the production of 
almost monodisperse nanoparticles. Results are confirmed by low 
standard deviation values (Table I-1). 
Moreover, the presence of precipitate in the mixing channel and the 
width of hydrodynamic focusing are considered. As already reported 
by Capretto et al., the mixing time strongly influences the formation 
of the nanoparticles by providing a high level of supersaturation for 
all species, when a stable hydrodynamic flow focusing is achieved 
along the main channel. In our system, a higher FR2 increases the 
width of the middle stream, requiring a longer time to perform the 
mixing by diffusion and the non-solvent extraction by means of the 
nearby streams. This effect results in a larger amount of solvent in the 
final mixture possibly causing core swelling, hence the formation of 
large NPs (Figure I-4). Therefore, the selected optimal conditions 
provide fine focusing and absence of a precipitate in the mixing 
channel even for several hours (Figure I-4a). 
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Figure I-4. Optical Fluorescence Microscope images of Flow focusing at several FR2: 
a) 0.3; b) 0.4; c) 0.8; d) 1.5 and FE-SEM images, respectively. 
Furthermore, surface properties analysis of the HANPs is conducted 
to assess the promising delivery functions. HANPs have a negative 
surface charge of -50 mV (± 4.5 mV) which can be attributed to the 
presence of carboxylic end group of the polymer on the nanoparticle 
surface, proposing their availability to future decorations of the 
nanoparticles.  
We also examined the effect of polymer composition on 
nanoprecipitation by adding different amounts of HA.  
The increased size of the NPs at higher initial polymer concentration 
could be explained as an effect of viscosity increasing and diffusivity 
decreasing. This observation can be explained by taking into 
consideration various phenomena associated with the supersaturation 
level and fluidic conditions.  
A higher polymer concentration corresponds to a higher 
supersaturation level and faster nucleation and growth kinetics, 
therefore, stabilization occurs when growing NPs reach a larger size. 
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In addition, the more significant number of nuclei formed at higher 
concentrations could lead to particle aggregation before the 
stabilization takes place, thus forming larger NPs. 
Furthermore, it has also been suggested that the increased viscosity of 
the organic phase at higher species concentrations might hinder the 
diffusion of solvent and non-solvent, requiring a longer mixing time 
and hence affecting the NP size and size distribution. Thus, 
Hyaluronic Acid concentration (CHA) also affects the 
nanoprecipitation, and most of our experiments are conducted at a 
constant CHA, 0.05% wt/v, allowing a longer stability of the system.  
Quasi-monodisperse nanoparticles are obtained even for all FR2 lower 
than 0.4 (Table 1). However, the value of FR2 of 0.3 (obtained at 30 
µL/min -solvent flow rate – and at 100 µL/min – non solvent flow rate) 
and CHA of 0.05% wt/v is considered as an optimal condition (Figure 
I-5a and b). This choose is explained by the prolonged stability of the 
hydrodynamic flow focusing, the absence of massive precipitation and 
a higher yield in terms of nanoparticle collection and monodispersity.  
These preferred optimal values are selected as “standard conditions” 
and are used for the following evaluation steps. Field Emission 
Scanning Electron Microscopy (FE-SEM) images of the collected 
morphologies at size vs FR2 and size vs CHA are reported in Figure 
I-5c, d, and e. 
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Figure I-5. Feasibility Study. a) Nanoparticles Size versus different Flow Rate Ratio 
FR2 at constant Solvent Flow Rate: 30 µL/min (- ■ -); 20 µL/min (- ● -); 40 µL/min (- ♦ 
-) for Hyaluronic Acid concentration CHA of 0.05% wt/v. b) Nanoparticles Size versus 
CHA (0.01% wt/v; 0.05% wt/v; 0.1% wt/v), at FR2 of 0.3, obtained at Solvent Flow Rate 
30 µL/min (- ■ -); 20 µL/min (- ● -); 40 µL/min (- ♦ -). Field Emission Scanning Electron 
Microscopy (FE-SEM) images of Nanoparticles at FR2 of c) 0.4; d) 1.5; e) 0.3. 
To assess aggregation phenomena and stability, cHANPs have been 
tested by Nanoparticles Tracking Analysis (NTA) to evaluate if they 
are more suitable for onward development. NTA is a powerful 
characterization technique that complements DLS and is particularly 
valuable for analyzing polydisperse nanosized particles and their 
concentration. NTA measurements are performed with a NanoSight 
(NanoSight, Malvern), equipped with a sample chamber with a 640-
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nm laser and a Viton fluoroelastomer O-ring. The samples are injected 
in the sample chamber with a sterile syringe until the liquid reached 
the tip of the nozzle. All measurements are performed at room 
temperature. The samples are measured for 40s with manual shutter 
and gain adjustments. Three measurements of the same sample are 
performed for all samples. The mean size and SD values obtained by 
the NTA software correspond to the arithmetic values calculated with 
the size of the nanoparticles analyzed by the software. 
 
Figure I-6. Nanoparticles Tracking Analysis. Size distribution of cHANPs obtained 
through Nanoparticles Tracking Analysis. (a), (b) Concentration (particles/mL) versus 
size; (c) intensity (arbitrary unit) versus size; (d) summarized results. 
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I.2.2.5 Comparison between the traditional and microfluidic 
nanoprecipitation 
Comparison between the traditional and microfluidic 
nanoprecipitation regarding nucleation and growth by diffusion is 
qualitative reported in Figure I-7a and Figure I-7b . In the traditional 
nanoprecipitation, the mixing time drives the formation of 
nanoparticles of a certain size (Figure I-7a).  
In the flow-focused nanoprecipitation, when a stable and thin 
hydrodynamic flow focusing is achieved along the main channel, the 
mixing time can be extremely reduced, and a fast extraction occurs at 
the nozzle section by providing a high level of mixing for all species 
(Figure I-7b).  
In our microfluidic system, a high molecular weight polymer solution 
is added to the middle channel and focused by the non-solvent lateral 
flows. In these conditions, a rapid increase in the concentration of free 
polymer chains into the solution takes place, inducing a “burst 
nucleation” which makes other free polymer chains in solution 
unavailable. Indeed, during this “effective nucleation”, an increase in 
the rate of nucleation into the main channel produces a strong dilution 
of the polymer chains that limits the diffusion of the chains through 
the solution; consequently, reducing the growth by diffusion (Figure 
I-7b). 
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Figure I-7. Comparison between nanoprecipitation in bulk and in microfluidics. 
Interpretation of the nucleation and growth phenomena a) in a traditional batch 
system; b) in a microfluidic device. Panel a) shows the well-known thermodynamics 
related to the batch processes reported in the table for different polymers-solvent-
non solvent systems. Panel b) represents the interpretation of the thermodynamics 
when nanoprecipitation occurs in a microfluidic device and a stable focused stream 
produces monodisperse nanoparticle by an effective nucleation. 
I.2.2.6 Application of the proposed approach to additional 
materials  
The exceptional strength of the proposed work, compared to the other 
investigations related to the formation of nanostructures, is also the 
ability to generalize our approach to other biomaterials. Our definition 
of the FR2 and of the range of concentration enable to let unvaried the 
experimental process parameters even for other polymers such as 
polysaccharides, which are soluble in water or hydrophilic, selected 
from the group consisting of dextran, chitosan, 
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carboxymethylcellulose, glycosaminoglycans, including hyaluronic 
acid, derivatives and mixtures. 
Results show that our microfluidic approach can be applied to various 
other polymers maintaining unchanged process parameters in terms of 
optimal FR2 and range concentration to obtain easily several 
polysaccharide nanoparticles in a one step manner  
I.3 Conclusions 
The microfluidic synthesis is an emerging approach for the 
development of controllable nanoparticles for therapy and imaging. 
Because of the fast mixing and precise fluid control in microchannels, 
the monodisperse nanoparticles of complex structures can be 
continuously generated in a one-step manner.  
Herein we demonstrate that microfluidics is a useful technology for 
nanoprecipitation synthesis of smaller and more homogeneous 
HANPs as compared to bulk synthesis. Microfluidics enables control 
over the rate of mixing, and in conjunction with controlling precursor 
composition, it may be used to tune nanoparticle size, homogeneity, 
and eventually drug loading and release. 
Our work suggests that microfluidic synthesis of nanoparticles by 
controlled nanoprecipitation may enable better control over the 
physicochemical properties of nanoparticles and may prove to be 
useful in the emerging field of nanomedicine. A microfluidic-based 
approach has been used to produce a monodisperse collection of HA 
nanoparticles under 50 nm through a controlled Nanoprecipation in a 
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microfluidic flow focusing approach. Our findings are interesting to 
investigate how the microfluidic environment determines the NPs size 
and stabilization, to facilitate further application of this rapidly 
growing technique. The influence of the process parameters, such as 
non solvent, HA concentration, Flow rate Ratio (FR2) were examined 
on the controllability of NPs size and on the kinetics and mechanism 
of the nanoprecipitation process. It has been shown that when HA 
concentration increases the average particle diameter increased and 
the size distribution became wider. Typically, the microfluidics 
enables a fast mixing in the microchannels promoting the formation of 
nanomaterials at laminar flow condition. In our system, we have 
individuated a threshold value FR2 of 0.3 below which it is possible to 
obtain more monodisperse and stable nanoparticles as low as 50 nm 
than the ones produced by similar bulk and microfluidic approaches. 
Furthermore, this threshold value is valid for high molecular weight 
polymers and at several polymer concentrations and different 
solvent/non-solvent couples. Our approach has the potential 
advantage of being able to generate a wider range of slot sizes of 
hydrogel structure while maintaining monodispersity compared to the 
similar bulk system. Furthermore, the flexibility of the process enable 
the tuning of the nanoparticles’ size for a specific disease through 
changes of the hydrodynamic boundary conditions. The knowledge of 
this parameter will aid the proper selection of stabilizer type, 
concentration, and process parameters to obtain stable NP batches. 
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Moreover, the presented results extend the knowledge of the role that 
microfluidic reactors exert in controlling and tuning NP 
characteristics. 
Nevertheless, optimization of a NP formulation depends on the 
specific properties and requirements of the systems, our results and the 
defined parameters and range of parameters represent a valid tool to 
approach the problem of nanoprecipitation in microfluidic. 
Furthermore, these results with Hyaluronic Acid NPs could be 
potentially translated into a variety of similar polymer combinations, 
and be useful in the emerging fields of microfluidic formation of 
organic NPs and nanomedicine.  
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II. CHAPTER II - A Microfluidic Platform to control the 
interference of Gd-DTPA in the design of crosslinked 
Hyaluronic Acid Nanoparticles (cHANPs) for MRI 
application  
 
Graphical Abstract II-1. A Microfluidic flow focusing approach to design Gd-loaded 
cHANPs to be used in MRI field. 
Abstract 
A microfluidic flow focusing approach is proposed to synthesize crosslinked 
Hyaluronic Acid NanoParticles (cHANPs) down to 50 nm to be used in 
Magnetic Resonance Imaging (MRI). By fine tuning of the process 
parameters, microfluidic strategies based on hydrophilic-lipophilic balance 
(HLB) of the surfactants and pH conditions are reported to overcome 
interference in the precipitation derived from the presence of Gd-DTPA. 
Results are discussed regarding the role of the contrast agents on the 
nucleation and growth phenomena, and the competition between 
nanoprecipitation behavior and crosslinking reaction to optimize the 
entrapment of Gd-DTPA within cHANPs.  
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II.1 Background 
II.1.1 Introduction  
Microfluidic techniques allow preparing micro and nanoparticles 
having a specific narrow size distribution and further enable to 
perform high encapsulation efficiency and strong crosslinking 
reaction with ease1,2. In effect, among the several advantages that 
microdimension of microfluidic tools provides there are also the 
ability to use rapidly products libraries of different materials by 
changing composition and flow rates; and the production of particles 
having coefficient of variation is less than 5% and high encapsulation 
efficiency; furthermore, parallelization on microfluidic chips allows 
high throughput and multiple analysis and reaction at a time. In this 
perspective, Karnik et al.3 synthesized biodegradable PLGA–PEG 
polymeric nanoparticles through a hydrodynamic flow focusing by 
nanoprecipitation where particle size and drug loading can be varied 
by flow rates, polymer composition and concentration. A nano-
suspension of hydrocortisone was prepared using a microfluidic 
nanoprecipitation approach4. An axisymmetric flow focusing 
microchip was utilized to synthesize crosslinked alginate 
microparticles and nanoparticles using aqueous alginate droplets as 
templates, followed by the shrinkage of the drops due to the water 
diffusion to the continuous phase5. These authors go forward 2 years 
later6,7 with a similar flow focusing microfluidic device controlling the 
nanoprecipitation, showing that the co-encapsulation of hydrophilic 
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and hydrophobic anticancer drugs with high encapsulation efficiency, 
platinum prodrug, and docetaxel, respectively. They also indicate that 
modifying the surface of the resulting nanoparticles, by grafting A10 
aptamer on the carboxylic function, gives rise to a specific targeting 
of prostate cancer cells up to the modification of the nuclear DNA by 
cisplatin. Very recent  studies on such technology reported potential 
in vivo applications with hybrid/ PLGA nanoparticles designed as 
therapeutic and imaging agents8. Nanoparticle core encapsulated 
cytotoxic agent (doxorubicin) and lipid shell containing the anti-
angiogenic drug. Contrasting properties were obtained using gold 
nanocrystals entrapped in the core as well as a dye (Cy7) grafted onto 
the surface. The authors showed the sustained release of the two drugs, 
with a longer time for the doxorubicin (encapsulated in the core), as 
well as in vivo the passive accumulation of the nanoparticles in the 
tumor. Detection was achieved through fluorescent modality, although 
the gold concentration was too low to allow a signal detection in CT. 
In another detailed microfluidic study, Capretto et al.9 presented the 
formation of block copolymer stabilized NPs (hybrid NPs), by 
examining the effects of operational ﬂuidic conditions and the feed 
concentration of polymers and actives on the size characteristics and 
the polymer coverage of the organic actives. Pluronic F127 was used 
as a model block copolymer while highly hydrophobic β-carotene was 
used as a model drug. Results demonstrated the existence of 
competitive reactions leading to the formation of two types of 
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nanoparticles, i.e., either with or without loading β-carotene in the 
core–shell structure. Other microfluidic-based nanoprecipitation 
processes are reported using another biocompatible and biodegradable 
polymer that is chitosan, but this time playing on the aqueous 
solubility of the polymer as a function of the pH. Chitosan presents a 
pKa around 6.2 at room temperature, and thus, once solubilized at low 
pH, the mixing with a basic solution through microfluidic channels 
may induce the polymer nanoprecipitation. This idea was reported in 
recent articles10,11, using hydrophobically modified chitosan, that is, 
by grafting palmitic acid on primary amines of chitosan with 
activation of acid by N-hydroxysuccinimide esters. The produced 
nanoparticles were ranging in size between 50 and 300 nm, and served 
to precisely encapsulate and release active hydrophobic principle 
(paclitaxel) over 1 week.  
Nanoprecipitation processes in such devices open new advantages and 
new benefits regarding size control and also drug encapsulation 
control and improvement. 
Starting from the observation of the Chapter 1, through microfluidics, 
we aim to achieve a fine-tuning of the mixing process among all 
species, and  consequently, a tight control of their nanoprecipitation 
behaviour, of the crosslinking reaction, and of the encapsulation 
efficiency of a Magnetic Resonance Imaging (MRI) Contrast Agents 
(CAs), Gd-DTPA.  
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To date, Gd-based CAs are the most used in the clinical MRI with over 
10 million contrast enhanced MRI scans every year, because of their 
relatively high stability and inertness in the body even if they still lack 
in tissue specificity and exhibit low relaxivity12. Several strategies 
have been investigated to develop better contrast agents using 
nanotechnology. However, the exploitation of the microfluidic 
approaches to support the design of nanostructures entrapping 
clinically approved CAs for MRI is still missing. 
Regarding the crosslinking strategy to adopt for Hyaluronic Acid 
Nanoparticles, several mechanisms have been reported in the 
literature13. The effectiveness of four different reagents, 
glutaraldehyde (GTA), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC), poly(ethylene glycol) diglycidyl ether (EX 810), 
and divinyl sulfone (DVS) as crosslinkers for cast hyaluronic acid 
(HA) ﬁlms has been studied by Collins et al.13. The functional groups, 
which are mainly responsible for crosslinking of HA molecules are the 
hydroxyl and carboxyl groups. Hydroxyl groups may be crosslinked 
via an ether linkage and carboxyl groups via an ester linkage. If 
desired, the HA may be chemically modiﬁed prior to crosslinking to 
form other chemically reactive groups. Thus, for example, HA may be 
treated with acid or base such that it will undergo at least partial 
deacetalization, resulting in the presence of free amino groups. GTA-
crosslinked ﬁlms were found to be of low stability compared with 
those treated with EDC, EX 810, and DVS, due to in part residual acid 
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catalyst and also to molecular weight. Swelling studies showed that 
both the molecular weight of the ﬁlms and the crosslinker type 
inﬂuenced the crosslink density of the ﬁlms. DVS was found to be 
fastest reacting crosslinker14-16. The degree of swelling of DVS 
crosslinked gels can be controlled through swelling medium salt 
content and pH and this may be of value for drug release purposes. 
The EDC crosslinker system made gels of medium stability and to 
some degree stability is determined by the HA molecular weight14. 
However, the only one literature study that uses microfluidic approach 
to crosslink hyaluronic acid (HA) nanoparticles is represented by 
Souza Bicudo et al.17. They described a process to produce HA 
crosslinked nanoparticles by nanoprecipitation at the interface of 
organic solvent/water phases. HA nanoparticles were crosslinked with 
adipic dihydrazide (ADH) and chloride carbodiimide (EDCL) and 
presented sizes ranging from 140 to 460 nm, depending on operational 
conditions. Taking into consideration the observation about the 
stability and the high-speed reaction, we have selected DVS as the 
crosslinking agent for HA. Furthermore, even if DVS is highly 
reactive and toxic, the biocompatibility of the HA-DVS hydrogel has 
extensively been confirmed by histological analysis18. 
II.1.2 Aim of Chapter 2 
In this Chapter 2, we match a flow focused nanoprecipitation to an 
efficient crosslinking reaction based on Divinyl Sulfone (DVS) to 
entrap the relevant clinical Gd-DTPA in crosslinked Hyaluronic Acid 
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Nanoparticles (cHANPs) able to potentially increase its relaxometric 
properties without the chemical modification of the chelate. By fine 
tuning all process parameters, specific microfluidic strategies are 
developed based on the hydrophilic-lipophilic balance (HLB) of the 
surfactants and pH conditions, to overcome the interference of Gd-
DTPA in the polymer precipitation phenomena. Interferences of the 
contrast agent in the flow focusing approach are reported for the first 
time, and different strategies are proposed to improve the 
encapsulation efficiency from 10% to 89% of the metal compound, at 
specific conditions. The developed strategies, allowing a fine tuning 
of the formulations, can be easily applied to other materials involved 
in nanomedicine field. The proposed approach has the objective to 
introduce microfluidic strategies to modulate the nanoprecipitation 
playing on the hydrophilic-lipophilic properties of the surfactants or 
the pH solution conditions to optimize relaxometric performances19. 
II.2 Case Study 
II.2.1 Experimental Section 
II.2.1.1 Materials 
Materials used for cHANPs preparation were the same presented in 
Chapter 1. Sodium Hyaluronate (Mw = 42 kDa) was purchased from 
Bohus Biotech (Sweden). Hyaluronate Thiol (HA-SH), MW 50 kDa, 
and mPEG-Vinylsulfone (PEG-VS), MW 2kDa, were purchased from 
Creative PEGWorks. Diethylenetriaminepentaacetic acid 
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gadolinium(III) dihydrogen salt hydrate Gd-DTPA (Mw = 547.57 g/
mol) ; Span80; Tween21; Tween85, Divinyl Sulfone (or Vinyl 
Sulfone) contains <650 ppm hydroquinone as inhibitor; purity 97%; 
density 1.117 g/ml at 25°C (lit.); molecular formula C4H6O2S; Mw =
118.15 mp ), Sodium Hydroxide NaOH (ACS reagent,  ≥ 97.0% , 
Mw = 40.00), Gadolinium Chloride Solution GdCl3(Mw = 263.61), 
Sodium Chloride NaCl (ACS reagent,  ≥ 99.0% , Mw = 58.44) , 
ATTO633 652 g/mol were purchased by Sigma-Aldrich Co. 
Polyethylene glycole (PEG) – Fluorescein isothiocyanate (FITC) 
( Mw = 1 kDa) is purchased from Nanocs; HRP-conjugated 
Streptavidin, EDC (1-Ethyl-3-(3 dimethylaminopropyl)-
carbodiimide) and N-hydroxysuccinimide (NHS) were purchased 
from Sigma Aldrich Co. The water, used for synthesis and 
characterization, was purified by distillation, deionization, and reserve 
osmosis (Milli-Q Plus). 
II.2.1.2 Study of Gd-DTPA interference on the nanoprecipitation  
The influence of the Gadolinium on nanoprecipitation was also 
evaluated. The entrapping of GdCl3 or Gd–DTPA was exploited at 
several weight ratios HA/Gd ranging from 1:0.05 to 1:10, adding the 
metal complex to the HA aqueous solution. Loading capability and 
encapsulation efficiency were calculated by Induced Coupled Plasma 
(ICP-MS) - NexION 350. Nanoparticles were suspended in a solution 
of deionized (DI) water at a concentration of 150.000 particles/mL. 
All data were collected and processed using the Syngistix Nano 
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Application Module. Gd was measured at m/z 157 using a 100 µs 
dwell time with no settling time. 
II.2.1.3 Preparation of crosslinked Hyaluronic Acid 
Nanoparticles (cHANPs) 
As already presented in the Introduction, literature studies report that 
the chemical reaction between HA and DVS is performed at high pH 
values (0.2 M NaOH, 0.1 M NaCl, pH> 13)14,20,21. In our microfluidic 
system, a study on the reagents was conducted to create, at the nozzle 
section, sulfonyl bis-ethyl linkages between the hydroxyl groups of 
the polymer chains forming nanoparticles. Several experiments are 
carried out to study the effect of NaCl and NaOH to promote the 
reaction and to reduce growth's step suddenly after the nucleation 
phase. The crosslinking agent was injected alternatively into the 
middle channel or in the side channels at different concentrations, 
ranging from 0 to 20% v/v and from 0 to 8% v/v, respectively. In some 
strategies, the device is heated at 35°C through a heat chamber. In our 
system, the occurrence of the solvent extraction produces the dilution 
of water into the mainstream, slightly increasing the reaction time. For 
these reasons, to promote the crosslinking reaction, purification and 
dialysis in water of the collected nanoparticles are performed after 4 
hr that nanoparticles have been kept under continuous stirring.  
II.2.1.4 Fourier transform Infrared spectroscopy (FT-IR) 
Fourier transform infrared spectra (FT-IR)20,21 were collected from 
Nicolett 6700 FT-IR spectrometer (Thermo Scientific). All the IR 
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spectra of the specimen were collected at 0.09 cm-1 resolution with 2 
min interval. The characteristic peaks for DVS, which exhibit 
absorptions at 1310 cm-1 (S=O asymmetric stretching vibrations), 
1130 cm-1 (S=O symmetric stretching vibrations) and 794 cm-1 (S−C 
stretching vibrations) and through the ether bond at 1255 cm-1 
(C−O−C stretching vibrations). 
Furthermore, thiolated HA, mPEG-Vinylsulfone and PEGylated 
cHANPs were analyzed to confirm if the reaction has taken place. 
Spectra were recorded and analyzed for signal assignation. 
II.2.1.5 Effect of the surfactant concentrations and pH conditions 
on the system parameters 
All experimental conditions were tested by adding NaOH and NaCl to 
the HA solution at the concentrations ranging from 0.1 M to 0.3 M and 
0.02 and 0.2 M, respectively. 
Alternately, three surfactants were tested at different reagent 
concentrations for all experimented flow rates. Tween 85 (ranging 
from 0.5% v/v to 1% v/v), Tween 21 (ranging from 0.5% v/v to 3% 
v/v) and Span 80 (ranging from 0.5% v/v to 1.5% v/v) were mixed to 
the non-solvent or to the aqueous solution. Experiments were 
conducted without the addition of DVS. 
II.2.1.6 Stability and swelling behaviour of the cHANPs 
Because of the clinical relevance of Gd-DTPA and, on the contrary, 
the high cytotoxicity of the GdCl3, stability studies were optimized 
only on Gd-DTPA. The Gd-DTPA loaded cHANPs were mixed with 
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150 μL of Phosphate Buffered Saline (PBS). The nanoparticles were 
kept under shaking at 150 rpm at 37°C. The solution was divided into 
two equal parts and observed at 12, 24, 48, 96 and 172 hr post 
incubation. ICP-MS was used to assess a one-half of the solution for 
the total concentration of Gd3+ ions loaded within the nanoparticles. 
The other half of the solution was filtered using 0.45 µm filter, and the 
filtrate was analyzed for Gd3+ ions. 
II.2.1.7 Loading capability and Encapsulation efficiency of Gd-
DTPA in cHANPs 
The lyophilization of cHANPs was performed using a freeze-dryer 
Christ, 1-4LSC. Briefly, a freezing step was conducted for 3 hr at 80 
°C. A cooling profile of 1 °C/min was applied, sublimation at a shelf 
temperature of 6 °C and pressure of 0.85 mbar for at least 24 hr22. 
Finally, a secondary drying at 25 °C and 0.03 mbar was performed for 
5-6 hr. Trehalose or sucrose ranging from 1-3% wt/v was added as 
cryoprotector if necessary. Dried particles were also observed by Field 
Emission-SEM. The quantification of drug loading and the 
encapsulation efficiency was determined by weighing a certain 
amount of particles, typically 1 mg, into each of three 1.5 mL 
ultracentrifuge tubes. Dry particles were collected at the bottom of the 
tube by performing a quick spin-down (80.000 rpm – 45 minutes – 
15°C). Two methods were utilized to solubilize the compound 
contained in the particles: dissolving the particles in a solvent or 
swelling the particles to allow the release of the compound into 
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solution by shaking at 37°C for 1hr. The equations used to determine 
the loading capability 𝑳𝑪 and the encapsulation efficiency 𝑬𝑬 are23:  
% 𝑳𝑪 = 𝑪𝒊𝑽𝒊 𝒎𝒏𝒑𝒔⁄  
% 𝑬𝑬 = (𝑪𝒊𝑽𝒊 𝒎𝒏𝒑𝒔⁄ ) (𝒎𝑮𝒅 (𝒎𝑮𝒅 + 𝒎𝑯𝑨)⁄ )⁄  
II.2.1.8 Preparation and characterization of PEGylated cHANPs 
Carbodiimide chemistry is used for conjugation of PEG to hyaluronic 
acid nanoparticles. Carboxyl groups on the surface of the NPs are 
activated by re-suspending the NPs in PBS and reacting with EDC and 
NHS. MES buffer is used because it has no amine or carboxyl groups 
that could compete in the reaction. NPs are then ultracentrifuged to 
remove excess EDC/NHS and the water-soluble isourea by product. 
Activated NPs are re-suspended in PBS buffer and reacted with NH2-
PEG-FITC. NPs are again centrifuged and washed with PBS buffer to 
remove unbound PEG. Qualitative characterization of PEGylated 
cHANPs is carried out by Stimulated Emission Depletion (STED), 
while the PEG chains, attached to the HA backbone, is qualitatively 
estimated by the bicinchoninic acid (BCA) assay24, which results to 
be extremely precise and sensitive being able to detect the amount of 
protein of 0.5 µg/mL. The bicinchoninic acid under alkaline 
conditions is an extremely sensitive reagent, stable and specific for the 
Cu+, and form with it a compound of the intensity of purple colour 
that it is proportional to the amount of protein. The variation of the 
intensity is determined by absorbance measurements in a 
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spectrophotometer at 562 nm. As expected, 150 µL of the nanoparticle 
suspension were reacted with an equal amount of the working reagent 
solution and the mixture was incubated at 37 ° C for 2 hr. The results 
were compared with a BSA calibration curve and the concentration 
value was then extrapolated by a straight line of calibration obtained 
using bovine serum albumin samples of known concentration (0 - 40 
µg/ml). All measurements were performed in triplicate. 
II.2.1.9 Quantification of fluorophore concentration 
The concentration of the fluorophore encapsulated within the cHANPs 
was measured by Spectrofluorimetry (EnSpire Multimode Plate 
Reader PerkinElmer). Different concentrations of the cHANPs 
suspension were investigated and compared with a calibration line. 
Each measurement was made in triplicate.  
II.2.2 Results and Discussion 
II.2.2.1 Successful conditions to produce cHANPs for MRI 
through a Microfluidic Flow-Focusing platform 
As presented in Chapter 1, in the flow focused nanoprecipitation9,25,26, 
the non solvent phase, flowing through two side channels, focuses the 
solvent phase in the main channel inducing the mutual diffusion of all 
solvents and promoting the precipitation of the solute and, therefore, 
the production of HANPs. The value of FR2 of 0.3 (obtained at 30 
µL/min -solvent flow rate – and 100 µL/min – non-solvent flow rates) 
and CHA of 0.05% wt/v are considered as “standard process 
conditions” for all the experiments. 
Control of the interference of Gd-DTPA in the design of cHANPs for MRI 
70 
 
II.2.2.2 Interference of Gd-based Contrast Agents on the 
nanoprecipitation and strategies to control the flow 
focusing pattern 
We next investigate the role of Gd-based contrast agents, GdCl3 and 
Gd-DTPA, on the nanoprecipitation. The effect of the metal 
compounds is observed, and a comparison is made regarding the 
stability of the flow-focusing in the presence of these two CAs; 
furthermore, their influence on the morphology is also reported.  
Figure II-1 reports a change in nanoparticle size obtained, at the 
standard conditions, by varying the concentration of CAs (CCAs), Gd-
DTPA and GdCl3, alternately. 
 
Figure II-1. Influence of Gadolinium based compounds. Nanoparticles size versus 
different CCAs: (Gd-DTPA (- ■ -); GdCl3 (- ● -)); at standard conditions showing how 
the stability of the hydrodynamic flow-focusing is compromised when Gd-DTPA is 
added to the solvent phase. No interference is observed in presence of GdCl3 at 
different concentration. 
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A strong influence of Gd-DTPA on the focused stream and, therefore, 
on the precipitation is observed, which induces a significant increase 
in the nanoparticle's size and their uncontrolled shape. Further 
investigations are required to address this behaviour towards the 
control of the hydrogel nanoparticles. The stability of the 
hydrodynamic flow focusing results altered when Gd-DTPA is added 
to the solutions (Figure II-2 a and b) and, consequently, the 
morphology of the nanoparticles is compromised (Figure II-2 c and d). 
 
Figure II-2. Influence of Gd-DTPA on the nanoprecipitation. Instability of the 
Hydrodynamic Flow-Focusing when Gd-DTPA is added to the solvent phase. a) at the 
beginning and b) at the end of the experiment. FE-SEM images of larger and 
aggregated morphologies obtained at the concentration of Gd-DTPA of c) 0.1% wt/v, 
d) 0.05% wt/v. 
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Therefore, the formulation of rational strategies is needed to control 
the nanoprecipitation in the presence of Gd-DTPA. In details, the 
addition of the Gd-DTPA results in larger and high polydisperse 
nanoparticles. To control this interference and to restore optimized 
process parameters, we explore two different strategies: the tuning of 
pH conditions and the addition of hydro or lipophilic surfactants. In 
the first case, pH conditions are accurately tuned in the HA solution 
by varying NaOH concentration and keeping constant NaCl to avoid 
massive precipitation. Typically, a change in NaCl results in an 
increase of the crosslinking degree of the hydrogel nanoparticles. 
However, Figure II-3a shows how a further increase of NaCl 
concentration results in a massive and uncontrolled precipitation. The 
optimal value of NaCl concentration to obtain nanoparticle 
morphologies is 0.05 M; indeed, at higher concentrations, it is only 
possible to observe fiber-like morphologies mixed to nanoparticles 
(Figure II-3b). 
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Figure II-3. Influence of NaCl on nanoparticles morphologies. a) Nanoparticles size 
versus NaCl concentration by varying CHA (0.01 % wt/v (- ▲ -); 0.05 % wt/v (- ● -); 0.1 
% wt/v (- ■ -); b) FE-SEM image of morphologies at 0.1M NaCl concentration showing 
fiber-like morphologies.  
To restore the previous morphology, a narrow range of pH values, 
from 11.5 to 12.5, is found to be appropriate to control the interference 
between Gd-DTPA and HA matrix. Indeed, the variation of pH in the 
middle channel, when Gd-DTPA is also added, strongly influences the  
flow-focusing pattern by reducing the flow perturbations within the 
microfluidic device. Nanoparticles of around 40 nm in diameter are 
obtained for this range of pH. Furthermore, the significant success of 
this strategy can not only be found in the reduced size of the 
nanoparticles but also into the considerable increase of the Gd-DTPA 
concentration in the HA solution from 0.005 to 0.1% wt/v.  
Figure II-4a clearly shows the effect of pH on the nanoparticle size 
due to the improved stability of the flow-focusing. This first strategy 
confirms that the addition of alkali changes the conformation of the 
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molecule through the breaking of hydrogen bonds, therefore 
influencing the interference with the Gd-DTPA, and the polymer 
molecules begin to untangle from each other, aligning in the direction 
of flow and resulting in a drastic reduction in viscosity. This optimal 
pH range reduces the viscosity of the medium and anomalous 
precipitations and promotes the degree of crosslinking of the NPs, as 
reported in the next paragraphs. The second proposed strategy is 
exploited by adding surfactants to the side channels to support the 
streams during the focusing action and to modulate the 
nanoprecipitation. The optimization of the flow-focusing pattern is 
found to be strongly dependent on the hydrophobicity and 
hydrophilicity of the surfactants. Indeed, the good hydrophilicity of 
the Tween 21 (HLB =13.3) highly interferes with the extraction of the 
water solvent by increasing instability of the focusing and, 
consequently, inducing agglomeration or polydispersity of the 
observed sample. Contrarily, when the less hydrophilic Tween85 
(HLB=11) is added to the non-solvent, the flow-focusing appears very 
stable, compared to the previous one, because the lower compatibility 
of the Tween85 with the water solvent reduces the formation of 
heterogeneities at the interface. However, for both surfactants, a slight 
increase of the nanoparticle size is observed (Figure II-4b). Following 
the previous results, a more hydrophobic surfactant is tested. Span80 
(HLB=4.3) is highly insoluble in water but presents good solvation in 
alcohol. Indeed, when Span80 is added to the non-solvent, the stability 
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of the focusing strongly increases in comparison to the other 
surfactants. This significant result shows that it is possible to reduce 
the interferences at the solvent-non-solvent interface using an 
appropriate surfactant that can simply modulate the affinity between 
solvent and non-solvents, regaining the control of the flow focusing 
pattern and, consequently, the morphology of the nanoparticles 
(Figure II-4c and d).  
For completeness of results, a few tests are also performed by adding 
the water-soluble surfactants to the middle channel, but the formation 
of nanostructured morphologies is not observed.  
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Figure II-4. Strategies to control the interference of Gd-DTPA on Flow-Focusing. Size 
of nanoparticles at CHA 0.05% wt/v and at Gd-DTPA 0.1% wt/v reported for several 
a) pH values, b) concentration of surfactants; FE-SEM images of nanoparticles 
obtained at standard conditions: c) tilted image at 15° after the optimization of the 
pH value, d) not tilted image in presence of the hydrophilic surfactant Tween21 at 
0.5% v/v. Data are collected without performing the crosslinking reaction and 
nanoparticles size is observed in Ethanol. 
These strategies are also conducted at different pH values, confirming 
the preferred range of pH even in the presence of surfactants. 
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Table II-1. Optimization of loading capability and crosslinking reaction. Process 
conditions of the investigated strategies to control the interference of Gd-DTPA in 
the nanoprecipitation mechanism: concentration of surfactants and tuning of pH 
condition together with the concentration of DVS added to the middle channel and 
to the side channel 
II.2.2.3 Crosslinking and Swelling behaviour of cHANPs 
Therefore, crosslinking strategies are needed to control the 
nanoprecipitation and stability of crosslinked HANPs (cHANPs) in 
the presence of Gd-DTPA. In this perspective, Divinyl Sulfone (DVS) 
has been selected among different highly reactive crosslinking agents 
for HA. Indeed, even if our DVS is highly reactive and toxic, the 
biocompatibility of the HA-DVS, i.e. sulfonyl bis-ethyl linkages 
between the hydroxyl groups of the polymer chains Figure II-5, has 
extensively been confirmed by histological analysis18, making our 
cHANPs appropriate for the potential clinical application. 
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Figure II-5. Crosslinking reaction of HA hydroxyl groups with divinyl sulfone (DVS). 
Furthemore, to confirm the success of the crosslinking reaction also 
IR analysis are performed. Figure II-6a and b show IR spectra of dried 
HA and of a dried solution composed by HA and DVS at pH 12. The 
chemical modiﬁcations of HA are identiﬁed in IR spectra of the 
cHANPs (Figure II-6c) by the characteristic peaks for DVS appearing 
between 1384 and 1280 cm-1, which were attributed to the sulfone 
group (vSO2=1350, 1310 cm-1). 
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Figure II-6. IR spectrum, plotted as transmission, of a) dried HA powder b) dried 
solution composed by HA and DVS and c) and d) cHANPs 
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In the presence of Gd-DTPA, while nanoprecipitation occurs, two 
different crosslinking strategies are exploited to perform a 
simultaneous reaction: the injection of DVS into the middle channel 
or the side channels (Figure II-7a and b). These rational strategies are 
discussed in term of concentration and role played by pH and HLB of 
selected surfactants (i.e. Span 80, Tween 21 and 85), respectively used 
to avoid swelling and support the streams during the focusing action 
and modulating the nanoprecipitation. 
 
Figure II-7. Schematic illustration of the crosslinking strategies. Qualitative 
illustration within our microfluidic device of the two different crosslinking strategies: 
a) when DVS is added into the middle channel; b) when DVS is added into the side 
channels. 
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For the first strategy, a strict control of the temperature is necessary to 
avoid the onset of the crosslinking reaction in the HA aqueous solution 
before precipitation happens (Figure II-7a). During the injection, the 
polymer solution within the syringe is kept constant at 5°C while the 
microfluidic device is heated at 35°C, through a heat chamber, to 
promote the reaction at the nozzle section, where the mixing takes 
place. In this approach, nanoparticles of about 70 nm are produced at 
DVS concentrations of 0.6-0.8% v/v at standard conditions and CSpan80 
0.5% v/v (Figure II-8a time point at zero seconds). Smaller 
nanoparticles are obtained of about 40 nm (Figure II-8b time point at 
zero seconds), at the standard conditions and pH equal to 12.3, by 
adding DVS to the side channels (Figure II-7b) even if an excess 
amount of agent, up to 4 % v/v, is necessary to avoid their swelling in 
water (Figure II-8b). Several experiments are also performed by 
adding DVS and surfactants to the side channels, but in this last case, 
both the morphologies and the crosslinking reaction result 
compromised. Both our chosen crosslinking approaches have the 
advantage to be highly tunable through process parameters and 
temperature. In our system, the occurrence of the solvent extraction 
produces the dilution of water into the mainstream, slightly increasing 
the reaction time. For these reasons, to promote the crosslinking 
reaction, purification and dialysis in water of the collected 
nanoparticles are performed after 4 hr of continuous stirring. 
However, the competition between crosslinking reaction and water 
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extraction affects mainly the second formulation, where an additional 
barrier to the reaction is represented by DVS diffusion from the side 
flow to the main one.  
Additionally, the effect of the crosslinking degree is evaluated by the 
swelling behaviour under physiological conditions for both strategies: 
when DVS is injected through middle or side channels. In the first 
approach, a lower amount of crosslinker is used to reduce the swelling 
behaviour even after several hours. Indeed, stable nanoparticles are 
obtained for CDVS ranging from 0.8 to 1.2% v/v. The increase of CDVS 
at more than 1.2% v/v, however, promotes an instability of the flow or 
compromises the crosslinking reaction and, consequently, the swelling 
(Figure II-8a and c). Compared to the first approach, for the other one, 
a higher amount of agent is added to avoid a rapid swelling behaviour 
of nanoparticles in water. In particular, for CDVS ranging from 4 to 
4.5% v/v, the swelling behaviour of the cHANPs is not observed even 
after several days. Higher or lower concentrations of DVS lead to the 
formation of swelling particles or flow instability (Figure II-8b and d). 
Once again, the comparison between the two proposed strategies 
highlights considerable differences in the nanoparticle behaviour. 
Indeed, the smaller size and the absence of swelling behaviour 
obtained in the first strategy can be related to a faster and efficient 
crosslinking reaction due to more favourable reaction conditions in the 
aqueous environment, an ideal pH and temperature able to promote a 
faster crosslinking among the polymer chains. Additional data at 
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higher concentration of DVS, resulting in agglomeration and 
undefined morphologies or absence of nanoparticle formation, are not 
reported. 
 
 
Figure II-8. Study of the Swelling behavior. Swelling behavior regarding 
nanoparticles size observed at several time points for different CDVS when a) DVS is 
added in the middle channel, at standard process conditions, CSpan80 of 0.5% v/v and 
35°C; and b) DVS is added in the side channels, at pH equal to 12.3. FE-SEM images 
of cHANPs in water at the time zero when c) 0.8% v/v of DVS is added in the middle 
channel; d) 4 % v/v of DVS is added in the side channels. 
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II.2.2.4 Loading Capability, Encapsulation Efficiency and 
Surface properties of Gd-loaded cHANPs 
The proposed strategies also have the capability to increase or control 
the encapsulation efficiency (EE) in the cHANPs, to prevent the waste 
of expensive compounds and sustain their dosage over an extended 
treatment period. Results show that a DVS concentration added to the 
middle or the side phase has a significant impact on the entrapment 
efficiency of cHANPs. In details, for DVS in the middle channel, it is 
observed that an increase in DVS concentration (from 0.6 to 1% v/v) 
results in a rise of cHANPs encapsulation efficiency from 27 to 89% 
and a loading capability from 22 to 59%. On the contrary, a worse 
control is observed by increasing the concentration of DVS in the non-
solvent phase, where a slight increase in cHANPs encapsulation 
efficiency and loading capability is obtained from 39 to 53% and from 
26 to 35%, respectively, for selected DVS values of 4 and 4.5% v/v. 
Loading capability is only reported for stable nanoparticles in water 
and, it is also compared with loading capability resulting by the 
encapsulation of a highly toxic and non-chelate Gadolinium, GdCl3 at 
equal conditions, proving that values reached are of about 90% (see 
the specific paragraph in the Experimental Section). The importance 
of a high encapsulation efficiency has been already emphasized since 
a large nanoparticles recovery is required for reducing manufacturing 
costs while size and morphology are important for quality control and 
biodistribution of injectable products. Furthermore, surface properties 
analysis of the empty cHANPs or cHANPs containing Gd-DTPA is 
Chapter II 
85 
 
conducted to assess the promising delivery functions of the cHANPs. 
Gd-free cHANPs have a negative surface charge of -50 mV (± 4.5 mV) 
which can be attributed to the presence of carboxylic end groups of 
the polymer on the nanoparticle surface, proposing their availability 
to future decorations of the nanoparticles. Zeta Potential 
measurements show a significant increase to -36.4 mV (± 3.01) linked 
to the encapsulation of Gd-DTPA27.  
II.2.2.5 General observation about the interference of Gd-based 
CAs on Nucleation and Growth in Microfluidics 
A comparison between the traditional28 and microfluidic 
nanoprecipitation has been already presented in Chapter 1, now we 
have shown how this comparison has been carried out to take 
advantage from the Gd-DTPA interference and to design some 
rational strategies that could systematically ensure the entrapment of 
Gd-DTPA and the control of its loading. A qualitative evaluation 
regarding nucleation and growth by diffusion is reported in Figure 
II-9a. In the flow-focused nanoprecipitation, when a stable and thin 
hydrodynamic flow focusing is achieved along the main channel, the 
mixing time can be extremely reduced, and a fast extraction occurs at 
the nozzle section by providing a high level of mixing for all species 
Figure II-9a. However, the stability and the width of the hydrodynamic 
flow focusing are altered when even small concentrations of Gd-
DTPA are added to the solutions (Figure II-9b), compromising 
morphology, size and loading capability of the nanoparticles. Indeed, 
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the Gadolinium complex acts probably as a salt compound, increasing 
the hydrogel strength significantly. A possible explanation can be that 
the electrostatic repulsion resulting from the charged groups on 
polymer chains is suppressed by the accumulation of counterions due 
to the metal complex29. Furthermore, starting from the considerations 
reported by Gouin et al.30 about the interaction between DTPA and 
HA, we hypothesize that Gd-chelate modifies the affinity of the 
polymer solution shifting the supersaturation to a low degree and leads 
to a slow heterogeneous nucleation followed by the growth of 
produced nuclei into large or aggregated particles. These specific 
interactions induce flow perturbation, causing an uncontrolled size 
variation and formation of aggregated morphologies (Figure II-9b). As 
showed, several rational strategies, based on pH of the solution and 
HLB of the surfactants, have been proposed to exploit the effects on 
the relaxivity of the presence of Gd-DTPA during the 
nanoprecipitation. A further outcome of the formulated strategies is 
the increase in the loading capability of Gadolinium based contrast 
agent that can be attributed to the repulsion between surfactant and 
water phase. Indeed, the retaining of the Gd-CAs is supported by the 
hydrophobic nature of the Span80 that increases the interface viscosity 
and prevents Gd-DTPA diffusion towards the external antisolvent 
phases. This behaviour is also explained by the higher molecular 
weight of the CAs, whose extraction, in these conditions, is less 
favoured compared to the small water molecules. This finding is of 
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crucial importance because the use of a surfactant is very easy to 
enforce compared to other alternatives, such as the utilization of a co-
solvent, reduced concentration or addition of reacting components that 
could interfere with the reaction yield and contaminate samples. Later, 
the macrocyclic molecules have been firmly entrapped within the 
hydrogel matrix, using a crosslinking reaction simultaneously 
occurring with the nanoprecipitation. Investigations related to the 
addition of the DVS in the middle channels or into the side channels 
have furnished to the hydrogel nanoparticles some peculiar properties 
responsible for the modulation of the release behaviour and swelling 
properties.  
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Figure II-9. Interference of the CA on the Nanoprecipitation mechanism. The 
schemes report the interpretation of the nucleation and growth phenomena in a 
microfluidic device. Panel a) represents the interpretation of the thermodynamics 
when nanoprecipitation occurs and a stable focused stream produces monodisperse 
nanoparticle by an effective nucleation. Panel b) represents changes of the 
nanoprecipitation phases, when Gd-DTPA is added to the solvent, and instability of 
the flow-focusing produces aggregated and polydisperse nanoparticles from a slow 
heterogeneous nucleation. 
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ICP-MS results demonstrated that using our flexible platform it is 
possible to take advantages from the strong interference detected by 
the presence of Gd-DTPA producing Gd-entrapped nanoparticles with 
enhanced loading.  
The proposed approaches aim to overcome some drawbacks of the 
traditional procedures for the production of nanoparticles such as high 
polydispersity, expensive and time-consuming purification/recovery 
steps31. Furthermore, results present the effective strategy to dose all 
species and to control properly the entrapment of CAs within the 
hydrogel nanostructures that potentially influences MRI performances 
in terms of signal intensity and tissue specificity.  
II.2.2.6 Simultaneous encapsulation of other agents  
After the optimization of the Gd-DTPA entrapment within cHANPs, 
to confirm the versatility of our designed microfluidic platform, we 
have performed a successful simultaneous encapsulation of 
fluorophores, such as ATTO 633, ATTO 488, with Gd-DTPA for 
multimodal imaging. 
The addition of a fluorophore to the middle channel, at “standard 
process conditions”, in quantities of at least 1 nmol /100 mL, does not 
influence the nanoprecipitation and crosslinking reaction, and, 
consequently, the flow focusing behaviour.  
Field Emission Scanning Electron Microscopy (FE-SEM) 
characterization confirm the stability of the Nanoparticle’ size, while 
as showed in Figure II-10. STED image of cHANPs with ATTO633 
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and Gd-DTPA entrapped. STED image proves the encapsulation of 
the fluorophore. 
 
Figure II-10. STED image of cHANPs with ATTO633 and Gd-DTPA entrapped. 
II.2.2.7 PEGylation of cHANPs 
Owing to its high binding affinity for CD44, which is abundant in the 
tumor tissue, HA has been extensively investigated for the 
development of tumor-targeted imaging agents and drug delivery 
systems32. However, it is worthy of note that the targetability of HA is 
compromised by its binding to other receptors in normal organs, such 
as the LYVE-1 receptor on cells located in the lymphatics and the 
HARE receptor on liver sinusoidal endothelial cells33. Therefore, it 
can be expected that modulation of the binding affinity of HA to the 
receptors may affect in vivo biodistribution and, eventually, 
targetability by a combination of active and passive targeting 
mechanisms. In this study, we aim to control delivery properties of 
cHANPs by PEGylation. Therefore, cHANPS of about 40 nm 
diameter are bioconjugated with PEG-FITC (1KDa). Previously zeta 
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potential results demonstrated that they are negatively charged 
surfaces (-40 mV), attributed to the presence of deprotonated carboxyl 
groups of HA. As expected, the zeta potential of the nanoparticles was 
slightly decreased by PEGylation (-15 mV), causing consumption of 
carboxylic acids at the backbone of HA. PEGylation is also useful to 
assess the surface stability of the nanoparticles during the chemical 
decoration and the ability to retain the loaded Gd compound. SEM, 
TEM and STED images of cHANPs after PEGylation reaction are 
reported in Figure II-11a, b, and c.  
 
Figure II-11. PEGylation of cHANPs. FE-SEM a) TEM b) and STED images c) of cHANPs 
after conjugation reaction with PEG1000-FITC.  
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II.3 Another case study: preliminary results 
II.3.1 Synthesis of PEGylated crosslinked nanoparticles by 
nanoprecipitation in microfluidics in a one-step 
manner 
While in the above reported paragraph the PEGylation has been 
performed and optimized after the synthesis and the purification of 
Gd-loaded nanoparticles. In this session, we intend to demonstrate the 
versatility of our designed microfluidic platform by synthesizing 
PEGylated cHANPs (PEG-cHANPs) in microfluidics through a co-
nanoprecipitation process of HA –SH and PEG-VS at the same 
condition just used to produce cHANPs but avoiding the batch 
pegylation reaction of our nanoparticles. 
For the feasibility study, an aqueous solution containing thiolated HA 
(HA-SH) concentrations ranging from 0.01 to 0.1 % wt/v was tested. 
The initial solution was kept under continuous stirring for at least 4 hr 
and then mixed with PEG-vinylsulfone (PEG-VS) (ranging from 0.9 
to 2.25 % v/v) at neutral pH and at 4°C to avoid the crosslinking 
reaction before nanoprecipitation occurs within the microfluidic 
device. Then, HA-SH and PEG-VS solution was injected through the 
middle channel. The flow rate of the middle channel was kept constant 
at 30 μL/min. Acetone, used as non-solvent and injected through the 
side channels, was laterally injected to induce nanoprecipitation by a 
flow focusing approach. The flow rates of the side channels were 
unchanged at 110 μL/min. Precipitated nanoparticles were collected 
in a Petri glass containing about 25 mL of non-solvent and kept under 
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continuous stirring. In the literature studies, hydrogels between HA-
SH and PEG-VS were obtained through a Michael addition in PBS at 
37 °C. The molar ratio of thiol groups to vinylsulfone groups was kept 
at 1.234,35. In our microfluidic platform, a study on the reagents was 
conducted to create, at the nozzle section, the nucleophilic addition of 
a carbanion (HA-SH) to unsaturated carbonyl compound (PEG-VS). 
Several experiments were carried out to promote the reaction and to 
reduce suddenly growth’s step after the nucleation phase. Each 
successful experiment was repeated at least 10 times. 
In this perspective, we have obtained HA-PEG hydrogels 
nanoparticles (of about 70 nm) using as aqueous solution 0.05 % wt/v 
thiolated HA (HA-SH) and 1.35 % v/v PEG-vinylsulfone (PEG-VS) 
to explore the effects of the nanoprecipitation on the flow focusing 
behaviour exclusively due to the presence of another polymer with not 
negligible molecular wight (PEG-VS = 2 KDa). Lower concentrations 
of PEG-VS lead to the formation of swelling particles while higher 
concentrations provoke uncontrolled precipitation of PEG-VS and 
flow instability. 
In our microfluidic device, at the nozzle section, the nucleophilic 
addition of a carbanion (HA-SH) to unsaturated carbonyl compound 
(PEG-VS) is performed (Figure II-12a). 
Transmission Electron Microscopy (TEM) and Field Emission 
Scanning Electron Microscopy (FE-SEM) images of the collected 
morphologies are showed in Figure II-12b and c, respectively. We can 
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observe that collected nanoparticles maintain their shape even after 48 
hours in water due to a strong crosslinking reaction performed together 
with nanoprecipitation, encapsulation of Gd-DTPA and PEGylation of 
cHANPs. TEM image (Figure II-12b) shows a different electron 
density between the core and the shell, that can give a previous 
indication of the presence of an outer covering coating different from 
the cHANPs before the PEGylation. Results show that our 
microfluidic approach is able to maintain unchanged process 
parameters and further the concentration ratios between the various 
components in order to obtain monodisperse PEGylated crosslinked 
HA-PEG-VS nanoparticles in a one step manner. 
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Figure II-12. Morphology of HA-PEG-VS Nanoparticles. a) Schematic illustration of 
the Michael Addition reaction mechanism of thiolated HA with PEG-VS. b) TEM and 
c) FE-SEM images of the PEGylated cHANPs in water after 48 hours.  
II.3.2 Fourier Transform Infrared (FT-IR) 
FT-IR analysis is performed to confirm the effectiveness of the 
reaction. Comparative FTIR spectra of HA-SH, PEG-VS and 
PEGylated cHANPs are showed in Figure II-13. The analysis shows 
that the PEGylated cHANPs do not exhibit the double bond C=C, 
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observed for PEG-VS at 750 cm-1, due to the Michael Addition 
reaction between the double bond of the PEG-VS and thiol group of 
HA. Furthermore, the success of the reaction is also guaranteed by the 
presence of the peak at 600 cm-1 that indicates the C-S bond stretching. 
Nevertheless, results on PEGylated cHANPs also present the peak at 
1245 cm-1 associated with C-SH vibration related to the residual not 
reacted thiols of the precursor HA-SH.  
 
Figure II-13. FT-IR AnalysisComparison of FT-IR spectra of a) PEGylated cHANPs; b) 
HA-SH and c) PEG-VS  precursors. 
FT-IR analysis finally reports that microfluidic platform to produce 
PEGylated cHANPs can accurately control the tuning of the 
crosslinking reaction to improve relaxometric properties and stability 
of the system. 
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II.4 Conclusions 
Crosslinked Hyaluronic Acid Nanoparticles (cHANPs) to be applied 
in MRI field have been developed and loaded with a clinically relevant 
Gd-CA, Gd-DTPA. For the first time, an interference of the Gd-DTPA 
in nanoprecipitation mechanism is reported which has added some 
significant advances in the basic knowledge of the interactions 
between Gd chelates and hydrogel matrix. We have demonstrated that, 
through our microfluidic strategies, it is possible to take advantages 
from the observed interference between HA and Gd-DTPA promoting 
a high entrapment of the Gd-DTPA within the cHANPs without 
chemically modifying the approved Gd-metal chelate. The designed 
strategies have allowed a fine control of the nanoparticle properties, 
such as the monodisperse average size of 40 nm, surface charge and 
the loading capability of 59%. A controlled degradation and release 
behaviour up to 96 hr under physiological conditions, high 
encapsulation efficiency of the hydrophilic metal chelate up to 89% 
are also reported. Furthermore, the surface charge analysis reports the 
presence of carboxylic groups that can be readily functionalized with 
targeting moieties, increasing potentially chemical functionalities to 
impact on tissue specificity and integrating additional imaging and 
therapeutic capabilities. 
Our straightforward and scalable strategies are proposed as a 
microfluidic platform to develop hydrogel nanoparticles entrapping 
clinically approved agents for potential application in diagnostics and 
therapy.
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III. CHAPTER III - Gd-DTPA loaded cHANPs for enhanced 
in vitro and in vivo MRI analysis 
 
Abstract 
Strategies to enhance relaxometric 
properties of clinically approved 
Magnetic Resonance Imaging 
(MRI) Gadolinium-based Contrast 
Agents (Gd-based CAs) without 
the chemical modification of the 
chelates have proved to be the 
most effective to impact suddenly 
on the diagnostic field. Here, a 
microfluidic platform is used to 
synthesize crosslinked Hyaluronic 
Acid NanoParticles (cHANPs) in 
which a clinically relevant MRI-
CAs, Gd-DTPA is entrapped. The 
proposed crosslinked formulations 
allow the control of the relaxometric properties of CAs, thus providing a 
boosting of the relaxation rate T1, since a T1 of 1562 is achieved with a 10 
μM of Gd-loaded cHANPs while a 
similar value is reached with 100 
μM of the clinical relevant Gd-
DTPA in solution. Results led us to 
identify this approach as an 
adjustable scenario to design intravascularly-injectable hydrogel 
nanoparticles entrapping Gd-DTPA thus overcoming general drawbacks of 
clinically approved CAs suffering from poor relaxivity and nephrotoxicity 
effects. The significant enhancement of signal intensity is observed in vitro 
and confirmed in vivo after PEGylation and peptide reactions. 
  
Graphical Abstract III-1. Boosting of the 
relaxation time of the Gd-DTPA loaded 
cHANPs compared to Gd-DTPA “free” in 
water. 
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III.1 Background 
III.1.1 Introduction  
The Magnetic Resonance Imaging (MRI) represents the first-line 
diagnostic imaging modality for numerous indications. It provides 
high-resolution anatomic images of all body organs, including soft 
tissues and can be used for visualizing functions of cardiac, brain, and 
central nervous system, as well as detecting tumor. It is a clinically 
well-established, non-invasive technique that leverages the magnetic 
properties of water protons present in the body to produce three-
dimensional whole body anatomical and functional images1,2. 
High magnetic fields (1.5 T and above) are clinically favoured because 
of their higher signal-to-noise ratio, capability for MR spectroscopy3 
and other forms of functional MRI, such as high-speed imaging and 
high-resolution imaging. MRI signal intensity is related to the 
relaxation rate of in vivo water protons and can be enhanced by the 
administration of a contrast agent (CA) prior to scanning.  
These CAs utilize paramagnetic metal ions to enhance the contrast in 
an MR image by positively influencing the relaxation rates of water 
protons in the immediate surroundings of the tissue in which they 
localize. The ability of CAs to effectively enhance image contrast 
depends on their relaxivity (longitudinal r1; transversal r2;) and the 
level of accumulation at the target site4.  
Among different CAs, Gadolinium-based ones, used in up to 30% of 
clinical MRI scans5, consist of poly(amino carboxylate) complexes of 
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Gd ions, where Gd ions cytotoxicity is sequestered via chelation with 
ligands such as diethylenetriaminepentaacetic acid (DTPA) and 
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)6-8. However, 
despite its certain role, Gadolinium-based CAs, like most of other 
clinically relevant CAs, suffer from poor sensitivity6 and rapid renal 
clearance, requiring long scan times, thus severely limiting the time 
window for MRI. In addition, they present low tissue specificity, 
leading to concerns in linking the use of these CAs with nephrogenic 
systemic fibrosis (NSF)9 and progressive accumulation in various 
central nervous system (CNS) structures following repeated 
gadolinium administration10.  
To date, several efforts have increased tissue specificity, thus reducing 
nephrotoxicity, by designing architectures that entrap or conjugate 
CAs11-20. Recently, approaches using batch conventional synthesis 
were shown to successfully boost relaxivity by entrapping Gd-based 
CAs into biocompatible matrices, without chemically modifying the 
clinically approved Gd-chelates21-23. Decuzzi et al.4 optimized the 
performance of MRI nanoconstructs by confining Gd-DTPA within 
porous structures of silicon microparticles (about 1-2 µm) produced 
by microfabrication. They examined the consequences of geometrical 
confinement of CAs within the nanopores, achieving a 2-3 times 
enhancement in r1 without chemical modification of the chelate; 
however, a considerable increase of the relaxometric properties was 
observed only when nanotubes or fullerenes were also incorporated 
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into the silicon structure. Courant et al. enhanced relaxivity by 
encapsulating Gd-chelates (Gd-DOTA) into hydrophilic and 
biocompatible polymer nanoparticles (about 250 nm) obtained by the 
ionotropic gelation between Chitosan (CH) and Hyaluronic Acid 
(HA)24. 
Therefore, it is essential to highlight the need to build up a 
biocompatible system with higher relaxivity able to protect the chelate 
around Gd ions from transmetallation phenomena and control the 
accumulation and the clearance of the Gd-based CAs in a specific 
organ. Recently, in this perspective, we have exploited the impact of 
crosslinked and un-crosslinked biopolymer matrices on relaxometric 
properties of CAs where the contribution to the enhancement of CAs 
is highlighted and attributed to the reduced mobility of water within 
the hydrogel25. However, systems with nanometric and monodisperse 
size under 100 nm are likely to improve delivery functions26 to the 
tissues, stability of the metal chelates, and also provide enhanced 
relaxometric properties of the Gadolinium-based CAs.  
Over the past decade, microfluidics has enabled the production of a 
variety of enhanced nanoparticles for applications in therapy and 
diagnostics27-37 38,39. However, although great efforts have been made 
to apply microfluidic technologies to the production of nanoparticles, 
the exploitation of microfluidic approaches to support the design of 
nanostructures to improve relaxometric properties of clinically 
approved CAs for MRI has not been developed.  
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It is well known that the size, shape and size distribution of core 
nanoparticles affect the contrast resolution of MRI. Therefore, in the 
application of nanoparticle based MRI contrast agents, it is highly 
desirable to have uniform size of core material, which is one of the 
most important parameters. To address these demands, a microfluidic 
platform has been already presented as an ideal method to tightly 
control the final particle properties, i.e. size, polydispersity, 
entrapping of CAs etc., due to the process’s ability to accurately 
control process parameters and thus enables efficient, continuous and 
tunable mixing40-46. 
III.1.2 Aim of Chapter 3 
In this Chapter, in vitro and in vivo MRI analysis of the Gd-loaded 
cHANPs obtained through the already discussed microfluidic platform 
are performed. We have presented that it is possible to achieve a fine-
tuning of the mixing among all species and the control of their 
nanoprecipitation behaviour and crosslinking reaction. Now we 
demostrate how the mixing also control the relaxometric properties of 
the contrast agents entrapping within the cHANPs. For both 
production strategies proposed to design Gd-loaded cHANPs, a 
considerable improvement in relaxation rate is found for DVS 
concentration at 4% v/v in the side channels and at 0.8% v/v in the 
middle channel. In particular, a T1 of 1562 ms is achieved with 10 μM 
of Gd-loaded cHANPs suspension, while 100 μM of Gd-DTPA free in 
solution is required to achieve a comparable T1 (about 1724 ms). 
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Indeed, the relaxation time reported for cHANPs is achieved with a 
concentration about 10 times lower than that of the free Gd-DTPA. 
This observation is crucial to lead potentially to a significant reduction 
of administration dosage on clinical usage of T1 contrast agents and to 
gain advantages in the imaging modalities based on nanotechnologies. 
Also preliminary in vivo results clearly show the improvement of the 
MRI and confirm the stability of cHANPs. Gd-loaded cHANPs could 
potentially provide tissue specificity and reduce nephrotoxicity and, at 
the same time, they have the capability to retain Gd-based contrast 
agents to boost the MR signal without the chemical modification of 
the chelates. Later, we have performed and optimized a reaction of 
PEGylation and a decoration with peptide to aim a specific target. 
III.2 Case Study 
III.2.1 Experimental Section 
III.2.1.1 Materials 
Materials used for Gd-loaded cHANPs preparation were the same 
presented in Chapter I and II.  
Materials used for the conjugation reaction: EDC (N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide, MW=191.70), NHS 
(N-Hydroxysuccinimide, MW=115.09) and Streptavidin (1mg/ml) 
were purchased from Sigma Aldrich Co. Cy7- PEG1KDa-NH2, and 
Fitc- PEG1KDa-NH2 were purchased from Nanocs Inc. Peptide 
pA20-36 (MW=1922, 1 mg/ml) was purchased from CASLO ApS.  
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The protein quantification assay, QuantiProTM BCA assay kit and the 
WST-1 assay were purchased from Sigma Aldrich Co. Plasma from 
human P953 was purchased from Sigma Aldrich Co. 
III.2.1.2 In vitro cytotoxicity 
A adenocarcinomic human alveolar basal epithelial cells (A549) was 
used. The cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 10% fetal calf serum and L-glutamine (2.9 
mg/ml) at 37 °C in water-saturated air supplemented with 5% CO2. 
For the cytotoxicity measurements, the cells were plated in 96-well 
plates for 24 hr before the addition of the nanoparticles. Fresh medium 
containing an increasing concentration of nanoparticles was added to 
each well and the cells were incubated for 24 h. At the end of the 
incubation time, the cytotoxicity of the nanoparticles was tested using 
an WST-1 assay (SIGMA-ALDRICH, MI). Briefly, phosphate-
buffered saline (PBS) containing WST-1 was added to each well and 
the cells were incubated for 30 min, 1 hr, 2 hr, 4 hr, 12 hr and 24 hr. 
Spectral absorption of the samples were measured at 450 nm with 
ELISA Reader (Biotek, Winooski, VT). The number of live cells is 
proportional to the amount of formazan produced.  
III.2.1.3 In vitro MRI 
Unloaded and Gd-loaded cHANPs at different concentrations were 
tested by in vitro MRI and results were compared with Magnevist, Gd-
DTPA in water as a control. After vigorously stirring, changes in 
relaxation time (T1 and T2) were evaluated at two different magnetic 
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fields, 1.5 T and 3 T in a Clinical Magnetic Resonance (Philips 
Achieva 1.5T and 3T ) using Sense Head 8 coil and by Minispec 
Bench Top Relaxometer at 1.5 T (Bruker corporation) by adding 300 
μL of the sample to a specific tube35. For T1 measurement by the 
clinical instruments, the inversion recovery sequence was used with 
the following parameters: repetition time TR= 2500 ms; echo time 
TE=12 ms; inversion time TI=50, 100, 200, 400, 800, 1100, 1800 ms; 
FOV= 180x146 mm; slice thickness=4 mm, acquisition 
matrix=360x292. Only modulus images were recorded and were 
loaded on MR map. T1 maps can be generated from sets of inversion 
recovery images (multiple series, each containing one image) with 
varying inversion time (TI), After sorting the images by their 
corresponding TI, a 3-parameter curve fitting using a Levenberg-
Marquardt algorithm is performed for each pixel position where signal 
intensity of any of the corresponding source pixels is above the user-
defined noise level. Therefore, MR_map performs several cycles of 
additional curve fittings on the whole data set, where each time the 
signs of the signal in an increasing number of leading images are 
switched to negative, starting with the image with the lowest TI and 
finishing with the last image where TI <0.67 × limit T1 (ms). Finally, 
the combination of signs yielding the best (= lowest) Chi value during 
the curve fitting process was selected and its curve fitting results were 
used to reconstruct the map. Finally, relaxivity r1 was calculated using 
weighted linear regression (R1=1/T1 s-1 relaxation rate plotted against 
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Gd concentration, mM, and r1, mM-1 s-1, is the slope of the fitted 
curve). Estimation of measurement uncertainty was evaluated using 
weighted linear regression. Furthermore, the relaxation time 
distribution was obtained by CONTIN Algorithm. The relaxation 
spectrum was normalized with respect to the CONTIN processing 
parameters. The integral of a peak corresponds therefore to the 
contribution of the species exhibiting this peculiar relaxation to the 
relaxation time spectrum47. 
III.2.1.4 Sorption of Gd-DTPA 
Later, Gd-DTPA was also adsorbed to empty cHANPs by placing 
cHANPs in Gd-DTPA solution. Briefly, a solution of Gd-DTPA 180 
μM was dissolved in the same volume of cHANPs solution and the 
suspension was placed on wheel for 48 hr in order to get maximum 
sorption of Gd-DTPA on NPs mainly through diffusion. Since the 
concentration of Gd-DTPA was higher outside the NPs than inside the 
NPs, Gd-DTPA diffuses from external solution to the cHANPs 
polymer matrix. Then, the sample was dialyzed against water in 
dialysis membrane bag of 50000 MCWO for 12 hr. The concentration 
of Gd-DTPA from the external medium of dialysis bag, treated by 
evaporator, was calculated by T1 value measured at 37°C on Bruker 
Minispec mq60 instrument using standard inversion-recovery pulse 
sequence. Later the content of gadolinium adsorbed on NPs was 
calculated by subtracting the amount of gadolinium in the external 
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medium from the total amount of Gd-DTPA which had been added in 
the system.  
III.2.1.5 In vitro stability in plasma 
The in vitro stability of the test compounds was studied in human 
plasma. The plasma was reconstructed following the protocol reported 
from Sigma Aldrich Co. After, the plasma was activated at 37 °C in a 
shaking water bath for 20 min. 100 µL of cHANPs was mixed with 
100 µL of PBS. The assays were performed in a shaking water bath at 
37°C and conducted in triplicate. Samples (50 µL) were taken at 0, 15, 
30, 45, 60, 90 min. The samples were subjected to vortex mixing for 
1 min and then centrifugation at 4°C for 15 min at 14,000 rpm. The 
clear supernatants were analyzed by HPLC. The in vitro plasma half-
life (t1/2) was calculated using the expression t1/2=0.693/b, where b is 
the slope found in the linear fit of the natural logarithm of the fraction 
remaining of the parent compound vs. incubation time. 
III.2.1.6 Quantification of carboxyl groups on the surface of 
cHANPs 
Back titration method was performed to directly quantify carboxylic 
groups on the surface of cHANPs. In brief, 10 mL of cHANPs (0.1 
mg/mL) was dispersed in 20 mL of 0.01 M NaOH solution, stirred for 
30 min and then pH annotated. A standard solution of 0.01 mM HCl, 
was used as the titrant. After each addition of titrant the solution was 
stirred magnetically for 1 min and the pH was recorded. From the 
difference of NaOH and HCl concentration at equivalent point, the 
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molar concentration of carboxylic sites was calculated. The titration 
was repeated on a second NP sample to check for reproducibility. 
III.2.1.7 Direct conjugation with PEG-NH2-Dye 
The formation of an amide bond between the COOH groups on the 
nanoparticle surface and the -NH2 end groups of the PEG labeled with 
fluorophore was adopted as a strategy of attack to carry out the 
reaction of direct PEGylation. Especially for each reaction, PEG1KDa 
amino and labeled with different fluorophores (Cy7-PEG1KDa-NH2, 
FITC-PEG1KDa-NH2) were used. The activation of the carboxylated 
surface of the cHANPs was occurred after contact for 10 minutes with 
500 µL of the starting sample to a solution of EDC (230 µL at 70 mM) 
and NHS (230 µL at 21 mM). Thereafter, 2mM of NH2-PEG1KDa-
Dye was added, allowing to react in the dark for 4 hours and in a slight 
rotation. The excess reagents were removed by ultracentrifugation 
(30.000 rpm, 15°C, 10 min) or spin-x corning system (4000 rpm, 
20°C, 10 min) and the pellet was suspended in a phosphate buffer (pH 
6.8). The amount of reagents was stabilized basing on the 
quantification, carried out by titration of the carboxyl groups available 
on the surface of the cHANPs.  
III.2.1.8 Indirect conjugation streptavidin-biotin-peptide 
The streptavidin-biotin bond was adopted as a strategy of attack to 
make the conjugation of the peptide to the nanoparticle surface. For 
this purpose, the peptide pA20-36 (EYVNCDNLVGNCVIRG, MW 
1922 Da), due to the presence of a C-ter of biotin molecule position, 
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has been previously conjugated to streptavidinate nanoparticles. 
Therefore, the surface of the nanoparticle, first, has been activated 
with EDC (0.0155 µmol/mL) and NHS (0.13 µmol/mL) for 10 
minutes, then the streptavidin (0.006 µmol/mL) was added and 
allowed to react overnight in a slight stirring. After removal of the 
excess reagents by different methods of purification, the peptide (0.02 
µmol/mL) to be conjugated was added to the resulting pellet 
suspended in PBS. The reaction was left for 4 hours under stirring, and 
finally a further purification was carried out to remove the excess 
peptide. The collected material was resuspended in PBS.  
III.2.1.9 Direct conjugation with peptide 
500 µL of cHANPs were reacted with EDC and NHS. Since the 
EDC/NHS excesses were in equilibrium with the aqueous 
environment and provide no interference with the next step reaction, 
they have not been removed. After 15 minutes, the peptide (0.020 
µmol/mL), previously deactivated with TEA, was added directly to 
the reaction. Reactions were kept in agitation by a rotating shaker. 
After 4 hours, the excess peptide was removed by various purification 
methods. 
III.2.1.10 Quantification of PEG concentration 
The amount of PEG conjugated to cHANPs was determined by 
spectrofluorimetric (ENSPIRE Multimode Plate Reader 
PerkinElmer). All measurements were performed in triplicate. The 
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calibration line was set in the range of 0-80 nmol/mL (Ex/Em 480-
550). 
III.2.1.11 BCA assay 
BCA assay, which results to be extremely precise and sensitive being 
able to detect the amount of protein of 0.5 g/mL, was used to measure 
the concentration of the peptide on the surface of the cHANPs. It is 
based on the principle that under alkaline conditions the copper Cu2+ 
ions form a complex with peptide bonds of proteins and are reduced 
to Cu +. The bicinchoninic acid, under alkaline conditions, is a highly 
sensitive reagent, stable and specific for the Cu +, and form with it a 
compound of purple colour and its intensity is proportional to the 
amount of protein present. The intensity variation is determined by 
absorbance measurements in a spectrophotometer at 562 nm. As 
expected, 150 µL of the cHANPs suspension were reacted with equal 
amount of working reagent solution and the mixture was incubated at 
37°C for 2 h. The results were compared with a BSA calibration curve 
and the concentration value was then extrapolated by a straight line of 
calibration built using bovine serum albumin samples of known 
concentration (0 - 40 mg/mL). All measurements were performed in 
triplicate. 
III.2.1.12 In vivo MRI 
Unloaded cHANPs have been preliminary tested in vivo to evaluate 
the acute and chronic toxicity on C57-bulb mice model. In details, the 
chronic toxicity tests have been assessed by injecting 200 µL of 
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unloaded and loaded cHANPs intravenously at 1 hr, 24 hr, 48 hr and 
after 40 days. Experiments have been repeated in triplicate.  
Later, for T1 measurement, the in vivo experiments for loaded 
cHANPs were conducted by PET/MRI 3T Siemens instrumentation 
with a dose of 150 µL applying an Inversion Recovery (IR) sequence 
(VOF= 100x75 mm; slice thickness=1.2 mm without GAP, contiguous 
slice, acquisition matrix=192x144; Averages: 6; Turbo spin-echo; 
Sequence duration: 10 minutes -36 seconds; Signal to Noise Ratio: 1; 
Spatial Resolution: 0.5 x 0.5; TR: 550; TE: 11). A basal acquisition 
has been conducted for all subjects before the injection protocol. 
The biodistribution analysis have been made at different time points: 
45 minutes, 3 hr, 6hr, 8 hr, and for 24hr. Experiments have been 
repeated in triplicate. After the MRI scans, the blood and tissue 
samples were collected at predetermined sampling points. 
Quantitative analysis has been made by digesting and homogenizing 
the organ with nitric acid at 100°C for at least 3 hr. Later, the samples 
are diluted and the liquid analyzed by ICP-MS with the same protocol 
described in the paragraph II.2.1.2. 
All studies were performed with mice under general anesthesia, 
obtained with an intraperitoneal injection of tribromoethanol solution 
at a final concentration of 12.5 mg/mL and administered at a dose of 
about 250 mg/kg. Once anesthetized, mice were prepared for venous 
cannulation by bathing the whole tail in tap water warmed at 39 °C to 
obtain proper vasodilation. A lab-made catheter, consisting of a 30 G 
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needle mounted on a polyethylene tube, was delicately advanced in 
one of the lateral caudal veins, until blood could be seen in the tube. 
Hence, two-three drops of surgical glue were spilled on the needle /tail 
interface area and let dry. The tube was flushed with 20 µL of a 
heparinized solution and the tip of the tube was closed to avoid further 
bleeding. The mice were then positioned on magnetic compatible 
bedding within a head coil and the baseline acquisition was performed. 
Hereafter, 150 µL of the contrast agent solution was slowly injected, 
following any eventual reaction of the mouse or any change in the 
respiratory pattern. Acquisition were performed every 10 minutes till 
one hour post injection, and then after 3, 6, 8 and 24 hr. Two solutions 
were studied: Gd-loaded cHANPs and Gd-DTPA. In each solution, the 
final Gd concentration was the same. 
The DICOM files of each acquisition were stored on an external unit. 
The files were imported in dedicated software for imaging analysis 
(OsiriX© Lite, Pixmeo SARL, Bernex, Switzerland). A circular 
region of interest (ROI) of about 2 mm2 was drawn and then saved, to 
be used in the analysis of all images. The anatomic areas studied were: 
renal cortices and medullas, the urinary bladder, the salivary glands. 
The mean intensity obtained for each organ (IO) was normalized to 
the mean muscle intensity (IM) applying the formula: IOnorm = IO/IM, 
and the result was used to calculate the percentage of contrast 
enhancement (% CE) according to Corbin et al.48 % CE = (Ipost – Ipre) 
/ Ipre * 100.  
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III.2.2 Results and Discussion 
III.2.2.1 In vitro cytotoxicity 
Typically, structural alterations of nanoparticles in aqueous solutions, 
in cell-culture medium, might also affect and change the final results 
of the in vitro toxicological studies. Therefore, cytotoxicity tests are 
essential to assess preliminarily the biocompatibility of the cHANPs. 
Likewise, the surface charge of NPs plays an especially important role 
in cell–NP interactions because cell membranes themselves are 
charged. Understanding the behavior of NPs at the time of 
toxicological assay may play a crucial role in the interpretation of its 
results. Nasti et al. suggest that the cytotoxicity of chitosan/TPP 
nanoparticles is a function of their surface composition/charge 
because the HA-coating reduces the cytotoxicity while the positively 
charged nanoparticles are more rapidly internalized than those of 
opposite charge. The mechanical stability and the enzymatic 
degradation of the nanoparticles is determined by the degree of 
crosslinking of HA structures. As highlighted by studies of Lai, HA 
sheets incorporated different concentrations of DVS in a range 
between 0 and 50 mM had a good cytocompatibility2. For this study, 
the toxicity of loaded cHANPs is tested using a WST-1 assay, which 
is based on the conversion of a water-soluble tetrazolium salt 
(yellowish in color) to water insoluble formazan (purple color) by 
living cells. Scalar concentrations of cHANPs are tested in a range 
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between 10 μg/mL and 100 μg/mL. It is evident that the cHANPs 
showed no detectable cytotoxicity in vitro (Figure III-1). 
The varied NP–cellular localization and interaction might lead to 
various modes of toxicity. Even NPs of the same material can show 
completely different intracellular behavior due to, for example, slight 
differences in surface coating, charge and size. It has been reported 
that especially the NP size determines the efficiency of cellular uptake 
and subsequent intracellular processing. 
The disruption of the NPs inside the cell greatly influences the 
resulting toxic effects. The cytotoxicity could be attributed to the 
chemical composition of the nanostructure, but it should be considered 
that the NPs destabilization results in the release of their content into 
intracellular compartments, which can present synergic cytotoxic 
effects. This cytotoxicity can be desired, in antitumor treatments, or 
undesired during NPs application for diagnostics purposes. 
Furthermore, an excellent cell uptake of the NPs guarantees the 
efficient cell MRI and intracellular drug delivery. 
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Figure III-1. In vitro cytotoxicity. A549 cell viability expressed as a percentage of the 
value obtained with a concentration of cHANPs in a range between 10 μg/mL and 
100 μg/mL for three different time intervals. The error bars represent the standard 
deviations calculated from three independent experiments. 
III.2.2.2 In vitro MRI 
Given the versatility of our cHANPs, it is of particular interest to 
investigate how the selection of the different crosslinking 
reaction’s strategies, presented into the Chapter II, could result in 
advanced and tailorable CAs-loading functionalities. 
In vitro relaxivity is studied for loaded and unloaded cHANPs 
and the results are presented for Gd-DTPA in water at different 
concentrations. For all MR instruments, T1 values measured on 
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Gd-loaded cHANPs show a higher relaxation rate compared to 
the relative “free” contrast agent, confirming that active 
compounds are not only dispersed or encapsulated but even 
wrapped within the hydrogel polymer matrix of cHANPs. It is 
also observed that reaction strategies can not only affect the 
stability and degradation behavior but even the MR functionality.  
The relaxation time values of Gd-DTPA and cHANPs are first 
calculated at 37 °C and 1.5 T (Minispec mq60). A notable change 
in relaxation rate is found for Gd-loaded cHANPs obtained by 
adding DVS in the side channels (CDVS at 4% v/v) and in the 
middle channel (CDVS 0.8% v/v). Comparison between the 
relaxation time distributions of loaded cHANPs, at the same 
concentration of Gd-DTPA in HA solution, is reported in Figure 
III-2 and Table III-1. Results clearly show that the relaxation time 
for Gd-DTPA entrapped within cHANPs is shorter than that of 
the “free” contrast agent. By tuning the process parameters and 
adjusting the crosslinking reaction, a T1 of 1562 ms is achieved 
with 10 μM of Gd-loaded cHANPs suspension, while 100 μM of 
Gd-DTPA free in solution is required to achieve a comparable 
T1. Indeed, the relaxation time reported for cHANPs is achieved 
with a concentration about 10 times lower than that of the free 
Gd-DTPA. The value related to the unloaded cHANPs is also 
reported, proving that the nanoparticles do not contribute 
themselves to the relaxivity. 
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Figure III-2. In vitro relaxation time distribution. Relaxation time distribution 
reported for: Gd-DTPA in water solution at (-▼-) 10 μM, (- ▲ -) 60 μM and (-◄ -) 
100 μM; un-loaded cHANPs (- ■ -); loaded cHANPs at standard conditions obtained 
using (- ● - ) 4% v/v DVS in the side channels, at pH 12.3, reported at 12 μM of Gd-
DTPA, (- ♦ -) 0.8 % v/v DVS and Cspan80 0,5v/v in the middle channel, reported at Gd-
DTPA of 10 μM. 
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Table III-1. Relaxation time analysis. Data obtained performing relaxation time 
measurements are reported showing an increase of 1/T1 values compared to the free 
Gd-DTPA in water. cHANPs obtained by adding DVS (4% v/v) in the side channels and 
DVS (0.8 % v/v) in the middle channel, at standard conditions and pH of 12.3. Each 
relaxation time measurement is repeated at least 10 times and shows a standard 
deviation lower than 10 %. 
Results are also confirmed using a clinical MRI instrumentation 
1.5 T and 3 T. Indeed, loaded-cHANPs, obtained by adding DVS 
in the middle channel (0.8% v/v) and in the side channels (4% 
v/v), show a maximum r1 relaxivity of about 48.97 mM-1s-1 and 
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14.09 mM-1s-1, respectively. Both values are considerably higher 
than the value of 3.9 mM-1 s-1 reported for commercial Magnevist 
(Figure III-3). 
 
Figure III-3. In vitro MRI. Longitudinal relaxation rate (1/T1) versus Gd-DTPA 
concentration for (-▲-) free Gd-DTPA in water and for Gd-DTPA loaded cHANPs 
obtained by injecting DVS (-●-) in the side channels and (-■-) in the middle channel, 
showing a relaxivity of 3.9 mM-1s-1, 14.09 mM-1s-1 and 48.97 mM-1s-1 respectively.  
As well-known49, the relaxivity is defined as the rate of change 
in relaxation times of the water protons per mM concentration of 
metal ions. Larger is the relaxivity of a given CA and larger is 
the induced spin-lattice relaxation time T1 and spin-spin 
relaxation time T2 shortening. In the presence of CAs, T1 and T2 
may be shortened considerably. However, an increase in contrast 
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agent concentration provides an increase in signal intensity due 
to the effect on T1 until a certain optimal concentration is reached 
while further increase in concentration reduces the signal because 
of a broad effect on T2, producing as net result a non-linear 
relation. This peculiar behaviour dictates their use in clinical 
practice, preferring contrast agents that have a relatively greater 
effect on T1 than on T2 and reveals the enormous advantage of 
manipulating clinical relevant contrast agents with enhanced 
MRI sensitivity. The relaxation times of the selected cHANPs 
samples remain unchanged at standard physiological conditions 
for at least 5 days after sample preparation, ensuring no leakage 
of Gd-DTPA from the cHANPs during MRI acquisitions. 
Additionally, a significant difference can also be found in the 
relaxation time distributions reported for both strategies in Figure 
III-4. We notice that it is possible to modulate the T1 by changing 
the DVS concentration within the same strategy. This is 
particularly evident when DVS is added to the middle channel, 
because any variation in DVS concentrations corresponds a 
change in the relaxation rates distribution of the produced 
nanoparticles. 
However, at a value of DVS concentration of 0.8% v/v a narrow 
relaxation time distribution is obtained demonstrating optimal 
equilibrium conditions to boost the MRI signal. 
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Figure III-4. Relaxation time distribution reported for Gd-DTPA loaded cHANPs 
obtained by adding DVS in the middle channel, at Span 80 0.5 % v/v, at Gd-DTPA 0.1 
%wt/v at standard flow conditions. 
For completeness, we have also evaluated the relaxivity of unloaded 
cHANPs compared with free Gd-DTPA in water showing that they do 
not contribute to the enhancement of MRI signal (Figure III-5). 
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Figure III-5. Relaxometric properties of unloaded cHANPs. The relaxation time 
measurements versus Gd-DTPA concentration show that the unloaded cHANPs do 
not contribute to the enhancement of MRI signal. 
III.2.2.3 Sorption of Gd-DTPA 
In this sorption analysis, detailed into the experimental section, the 
release of Gd-DTPA is very fast and there is no enhancement in MRI 
signal at the same concentration of Gd-DTPA in water. Furthermore, 
the adding of Gd-DTPA alters the morphology of formed cHANPs 
(Figure III-6). However, after the sorption, no enhanced relaxivity is 
observed compared to the free Gd-DTPA, but partial release of the 
Gd3+ ions is observed even after 12 h. 
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Figure III-6. FE-SEM images of cHANPs obtained by nanoprecipitation in 
hydrodynamic flow focusing and treated by sorption of Gd-DTPA. 
III.2.2.4 Direct conjugation with PEG-NH2 -dye 
For in vivo applications, to potentially reduce adhesive interactions of 
colloids with intracellular components, the surface of cHANPs has 
been coated with polyethylene glycol (PEG). PEG is a coiled polymer 
of repeating ethylene ether units with dynamic conformations. This 
polymer is non-toxic, non-immunogenic, non-antigenic, highly 
soluble in water and FDA approved. In both drug-delivery and 
imaging applications, the addition of PEG to NPs reduces RES uptake 
and increases circulation time versus uncoated counterparts. Indeed, 
the PEGylation has several advantages: a prolonged residence in body, 
a decreased degradation by metabolic enzymes and a reduction or 
elimination of protein immunogenicity.  
Using back titration, the concentration of carboxylic groups is 
determined by making them to react with an excess volume of base 
solution at a known concentration and then titrating the resulting 
mixture with the standardized acid solution. To optimize PEGylation 
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reaction, we first perform quantitative characterization of carboxyl 
functionalities of cHANPs. Using back titration, we can quantify the 
number of surface functionalities, providing important information 
about the surface physicochemical properties and the eﬀects on the 
quality and reproducibility of the functional nanomaterial. We 
estimate about 15 nmol of carboxylic group/mg of NP.  
As expected, PEGylation produces a chemical decoration of the 
particles inducing a larger nanoparticle size distribution due to the 
PEG-corona. Indeed, the measured size of the cHANPs decorated with 
PEG-FITC (1KDa) is of about 60 nm diameter. Previously zeta 
potential results demonstrated that cHANPs have a negatively charged 
surfaces (-40 mV), attributed to the presence of deprotonated carboxyl 
groups of HA. In details, PEGylation reduces the carboxylic groups 
from 15 ± 2.5 nmol/mL to 7 ± 1.5 nmol/mL, proving that some 
COOH- groups are still not conjugated. It  could be since using 
titration we have also quantified carboxylic groups not exposed on the 
nanoparticle surface, that were not available for the PEGylation 
reaction due to the high molecular weight of the PEG. However, as 
expected, the zeta potential of the nanoparticles was slightly decreased 
by PEGylation (-15 mV), caused by the consumption of carboxylic 
acids at the backbone of HA. PEGylation is also useful to assess the 
surface stability of the nanoparticles during the chemical decoration 
and the ability to retain the loaded Gd compound during the 
bioconjugation. cHANPs subjected to direct PEGylation have 
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maintained their structural integrity despite the presence of a higher 
surface roughness and a slight increment in size. TEM and STED 
images (Figure III-7 and Figure III-8) show the presence of an outer 
covering coating. 
 
Figure III-7. TEM image of cHANPs after direct PEGylation reaction. 
 
 
Figure III-8. Images of cHANPs after functionalization with NH2-PEG1KDa-FITC. 
The same image is reported in a) fluorescence and in b) transmittance light. 
 
We have also measured the pH varation of the cHANPs during the 
reaction, as follow detailed: 
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- pH pre-reaction 5.85 
- pH post EDC 5.80 
- pH post PEG (time 0) 5.43 
- pH-post PEG (time Over night) 7.04 
III.2.2.5 Direct conjugation with peptide pA20-36 
cHANPs subjected to direct conjugation with peptide pA20-36 have 
maintained their stable morphology. Also in this case, it is possible to 
appreciate the presence of confirmed outer coating by TEM analysis 
(Figure III-9). 
 
Figure III-9. TEM image of cHANPs after direct conjugation with peptide pA20-36. 
III.2.2.6 Indirect conjugation with peptide pA20-36 
To increase the amount of conjugated peptite, cHANPs are subjected 
also to indirect conjugation. In this condition, they have not suffered 
from alterations in the morphology, but it is possible to appreciate an 
increase in the size evidenced by the presence of a double coating layer 
consisting of the streptavidin-biotin-peptide complex observable by 
TEM analysis (Figure III-10). 
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Figure III-10. TEM image of cHANPs after indirect conjugation with peptide pA20-
36. 
III.2.2.7 Toxicity study in vivo  
Results of acute and chronic toxicity tests in the short and long period, 
conducted for loaded and unloaded cHANPs, have proven the 
biocompatibility of the proposed nanostructures even after several 
administrations. The animals are breathing regularly and eating 
normally.  
III.2.2.8 In vivo MRI 
For in vivo MRI analysis, a basal acquisition (Standard MRI protocol) 
has been conducted on pre-clinical 9.4 T MRI instrumentation for all 
subjects before the injection protocol as reported in the experimental 
section. 
Figure III-11 and Figure III-12 show the coronal view MRI images of 
a mouse C57bulb injected with Gd-DTPA and Gd-loaded cHANPs. 
Figure III-11a, Figure III-12a represent mice injected with only Gd-
DTPA at 800 µM, while Figure III-11b and Figure III-12b report Gd-
loaded cHANPs at 10 µM at different time intervals. Figures report an 
Chapter III 
131 
 
acquired slice of kidney and bladder respectively. Image Analysis 
related to the injection of Gd-DTPA at 150 µM are not reported 
because the signal is not appreciable. 
 
Figure III-11. In vivo MRI. Qualitative Image Analysis for kidney at different time 
intervals after injection of a) Gd-DTPA at 800 µM; and of b) Gd-DTPA loaded cHANPs 
at 10 µM 
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Figure III-12. In vivo MRI. Qualitative Image Analysis for bladder at different time 
intervals after injection of a) Gd-DTPA at 800 µM; and of b) Gd-DTPA loaded cHANPs 
at 10 µM 
While the experiments are performed, no side effects of the used CAs 
are observed. As showed in Figure III-13, because of the elimination 
of the Gd-DTPA is by renal clearance, the kidney shows a lighter 
image compared to other tissues. After about 4 min from Gd-DTPA 
injection, the kidney appears brightened and the signal intensity 
reaches the maximum of intensity of 62 %, followed by rapid decay. 
After injection for 1 h, the signal intensity of the whole mice body 
tends to the normality. Because of the duration time of acquisition 
used the signal intensity in the heart or liver is not visible. The urinary 
bladder becomes lighter after 6 min from injection, the maximum 
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value of signal intensity (343 %) is recorder after 45 min from Gd-
DTPA administration and remains high to 1 hr, while the whole mice 
body returns to appear normal. 
Also after injection of Gd-loaded cHANPs the signal intensity in the 
kidney immediately increases. The enhanced signal intensity is 
detectable after 3 min, it reaches to the highest (82%) at 48 min and 
remains visible to 1 h after i.v.  
In conclusion, preliminary in vivo results clearly demostrate the 
improvement of the MRI signal and confirm the stability of cHANPs 
ensuring no release of Gd-DTPA during the time course of the 
relaxation measurements (Figure III-13, Figure III-14). 
It is also important to highlight the higher persistence of the MRI 
signal in the case of Gd-loaded cHANPs compared to the free Gd-
DTPA in water Figure III-13 and Figure III-14. 
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Figure III-13. In vivo MRI. Quantitative Image Analysis at different time intervals 
after injection of Gd-DTPA at 150 µM and of Gd-DTPA loaded cHANPs at 10 µM for 
a) kidney and b) bladder. 
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Figure III-14. In vivo MRI. Qualitative Image Analysis 
Same analysis is conducted on a PET/MRI 3 T scanner to evaluate the 
% contrast enhancement (CE) of the images for a scanner used in a 
clinical practice. In details, a multivariate analysis of variance for 
repeated measures (RM-MANOVA) is used to study the selected 
parameters of the treatment group with Gd-loaded cHANPs and Gd-
DTPA. No significant effect of the treatment group could be detected 
for renal medulla (0.96) and salivary glands (P=0.65). The urine % CE 
resulted significantly affected by the interaction of time over group 
(P=0.0008), with the cHANPs having the highest % CE than Gd-
DTPA treated mice. A significant difference between groups was 
detected for the renal cortex (P=0.03) and a significant effect of the 
interaction of time over group (P=0.0007) is recorded, as well, with 
cHANPs showing a higher and increasing % CE from 10 minute to 1 
hour. 
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Figure III-15. Dynamic MRI study in coronal view of a mouse treated with HA NPs. 
The slices selected include the kidneys (upper row) and the urinary bladder (lower 
row). Baseline acquisition (A, E) is followed by intravenous injection of the HA NPs 
suspension, and the mice are scanned at 30 minutes (B, F), one hour (C, G) and 3 
hours (D, H) post injection. The same window level (WL=320) and window width 
(WW=610) were used in all images. 
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Figure III-16. Dynamic MRI study in coronal view of a mouse treated with Gd-DTPA. 
The slices selected include the kidneys (upper row) and the urinary bladder (lower 
row). Baseline acquisition (A, E) is followed by intravenous injection of the Gd-DTPA 
solution, and the mice are scanned at 30 minutes (B, F), one hour (C, G) and 3 hours 
(D, H) post injection. The same window level (WL=320) and window width (WW=610) 
were used in all images. 
III.2.2.9  In vivo biodistribution study 
We have also performed some preliminary study of biodistribution, 
stated as percentage of injected dose per gram of organ (% ID/g), in 
mice at 1 h after intravenous injection of cHANPs. These results are 
still work in progress even if no residuals are detected in the organs 
after 24 hr.  
Mice are sacrificed 8 hours after the injection and the accumulation of 
the metal within the organs is measured by ICP–MS after 
homogenization and digestion as reported in the Experimental Section. 
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Evaluation of the biodistribution and cleareance is currently under 
investigation but the weight of the organs is anyway reported as 
available data for further analysis. Preliminary results show no 
residuals of the metal in the organs (for further details see the 
Appendix V.I.). Tables below show the weights of the organs after 8 
hours. 
Subject Organ Weight (mg) 
Mouse 1 
(T1) 
Liver 909.30 
Kidney 219.25 
Lung 141.41 
Spleen 75.75 
Heart 80.40 
Blood ≈1ml 
Brain 382.20 
 
Subject Organ Weight (mg) 
Mouse 2 
(T2) 
Liver 674.32 
Kidney 256.38 
Lung 151.14 
Spleen 100.23 
Heart 100.03 
Blood ≈1ml 
Brain 412.00 
 
Subject Organ Weight (mg) 
Mouse 3 
(T3) 
Liver 683.61 
Kidney 191.78 
Lung 133.11 
Spleen 47.65 
Heart 67.15 
Blood ≈1ml 
Brain 395.00 
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III.3 Another case study 
III.3.1 In vitro MRI of Gd-loaded PEGylated cHANPs 
Given the versatility of our platform, it is of interest to investigate how 
the selection of the different crosslinking reaction’s strategies, or the 
encapsulation of different agents could result in advanced and 
tailorable CAs-loaded nanoparticles. 
In vitro relaxivity is studied for loaded and unloaded cHANPs and the 
results are compared also with nanoparticles after PEGylation. 
The relaxation time values of Gd-DTPA and cHANPs are first 
calculated at 37 °C and 1.5 T (Minispec mq60). For all MR 
instruments, results clearly show that the relaxation time for Gd-
DTPA entrapped within cHANPs is shorter than that of the “free” 
contrast agent.  
Also in these conditions, after PEGylation for both strategies, we have 
achieved a T1 of 1590 ms which corresponds to 20 μM of Gd-loaded 
cHANPs suspension (measured through ICP-MS), while 100 μM of 
Gd-DTPA free in solution is required to achieve a comparable T1 
(Figure III-17). Indeed, the relaxation time reported for cHANPs is 
achieved with a concentration about 5 times lower than that of the free 
Gd-DTPA.  
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Figure III-17. In vitro relaxation time distribution. Relaxation time distribution 
reported for: Gd-DTPA in water solution at 20 μ M and 100 μ M; PEGylated loaded 
cHANPs at standard conditions obtained using 4% v/v DVS in the side channels, at pH 
12.3, reported at 20 μ M of Gd-DTPA.  
III.4 Conclusions 
cHANPs performances have been assessed in terms of longitudinal 
relaxation rates as a function of the crosslinking degree and loading 
conditions. Additionally, a relaxation rate T1 of 1562 ms is achieved 
with 10 µM of Gd-loaded cHANPs while 100 µM of Gd-DTPA 
solution is required to reach similar T1 (about 1724 ms). 
Results support the concept that the entrapment of the Gd-based CAs 
within the hydrogel structure can enhance relaxivity, thus enable 
potentially low dosage administration. Therefore, the positive contrast 
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effect is preserved, ensuring an improvement of the time window for 
clinical imaging acquisitions due to the reduction of long scan time 
and rapid renal clearance. Proposed cHANPs could improve the 
stability and reduce toxicity related to the Gd-chelate. Furthermore, 
the surface charge analysis reports the presence of carboxylic groups 
that are readily functionalized with targeting moieties, increasing 
potentially chemical functionalities to impact on tissue specificity and 
integrating additional imaging and therapeutic capabilities. 
Preliminary studies about toxicity, in vivo biodistribution and MRI 
acquisition highlight the powerful effect of the produced 
nanostructures for application in clinical imaging 
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IV. CHAPTER IV - Impact of biopolymer matrices on 
relaxometric properties of Contrast Agents: the 
definition of Hydrodenticity 
Abstract 
Properties of water molecules at the interface between MRI CAs and 
macromolecules could have a valuable impact on the CAs’ relaxivity by 
modifying the correlation times of the metal chelate. However, an 
understanding of the physicochemical properties of polymer/CA systems is 
necessary to improve the efficiency of clinically used CAs. In this context, 
we investigate the impact of Hyaluronic Acid (HA) hydrogels on the 
relaxometric properties of Gd-DTPA and we observe that the presence of Gd-
DTPA could alter the polymer conformation and the behaviour of water 
molecules at the HA/Gd-DTPA interface, thus modulating the relaxivity of 
the system. The tunability of hydrogel structures could be exploited to 
improve magnetic properties of metal chelates. Thus, hydrogel structural 
parameters of cHANPs are investigated to control the status of hydrated Gd-
DTPA subjected to the osmotic pressure deriving from elastodynamics of 
swollen gels, establishing an equilibrium able to boost relaxometric 
properties of the Gd-DTPA without the chemical modification of the chelate. 
This capability has been here called Hydrodenticity and defined in terms of 
crosslink density and mesh size, tunable through our microfluidic approach.   
Graphical Abstract IV-1. The new concept of Hydrodenticity 
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IV.1 Background 
IV.1.1 Introduction 
Investigation of water molecules at the interface between relevant 
clinical Contrast Agents (CAs) for Magnetic Resonance Imaging 
(MRI) and macromolecules can be of great interest to increase the 
performances of metal chelates. Indeed, most of the clinically-used 
CAs are characterized by poor effectiveness in the high magnetic 
fields region, which is clinically favored because of its higher signal-
to-noise ratio and high-resolution imaging. MRI CAs also lack of 
tissue specificity and can cause heavy allergic effects, serious 
nephrotoxicity1-3 and intracranial deposition of metal ion after 
repeated intravenous administration4. Despite their wide use, currently 
available CAs exhibit low relaxivity5, which is far below its theoretical 
maximum required to obtain an accurate diagnosis at safe 
administration dosage6. In these perspectives, the possibility to have a 
CA that could work at low concentration but without giving over its 
signal intensity and, therefore, positive contrast effect is of great 
interest, as already said in Chapter 3. The extensive research on nano-
engineered systems and polymer-based nanocomposites7-17 has led to 
significant advances also in the field of MRI13,18-22. In particular, some 
recent studies have shown that nanoconstructs can improve CAs’ 
relaxivity and many efforts have been devoted to the development of 
polymer-based carriers for MRI CAs with particular reference to 
Gadolinium (Gd) chelates, which are the most commonly clinically 
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used agents18,23-28. In this framework, Port et al.29 have reported that 
the rigidiﬁcation of MRI CAs, obtained through covalent or non-
covalent binding to macromolecules, could be favourable to an 
increase in relaxivity of the metal-chelate. Later, Decuzzi et al.5,30 have 
proved that it is possible to modify through the geometrical 
confinement the magnetic properties of MRI CAs by controlling their 
characteristic correlation times without the chemical modification of 
the chelate structure. Furthermore, Courant et al.25 have highlighted 
the capability of combined hydrogels to boost the relaxivity of Gd-
based CAs. In details, hydrogels31-34 show these three-dimensional 
networks, made of hydrophilic polymer chains held together by 
chemical or physical crosslinking, they are glassy in the dry state but 
have the ability to swell in water, forming elastic gels that retain a 
large quantity of fluid in their mesh-like structures35. The presence of 
hydrophilic polymer interfaces and the control of water behaviour in 
hydrogels play a fundamental role in the relaxation enhancement of 
the Gd-based CAs by influencing the characteristic correlation times 
defined by the theory of Solomon and Bloembergen36. As stated by 
this theory,37,38 indeed, high relaxivity can be achieved by a fine and 
accurate control of the characteristic parameters that regulate the 
dipolar interaction between water protons and Gd-based CAs.39 the 
number of water molecules (q) in the Inner Sphere (IS), i.e. those 
present in the coordination sites of the Gd ion, and their residence 
lifetime (τM); the rotational correlation time of the metal complex (τR); 
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the diffusion correlation time (τD) of the water molecules in the Outer 
Sphere (OS), i.e. those diffusing nearby the metal complex. According 
to these parameters and by exploiting the versatile properties of nano- 
and bio-materials, several nanostructured CAs with enhanced 
relaxivity have been investigate.40-45 
Despite several experimental studies addressed in this field, a 
comprehensive knowledge of the mechanisms involved in the 
relaxation enhancement due to the entrapment of CAs in polymer-
based architectures is still missing. In particular, the role played by the 
water at the interface between polymer chains and MRI CAs has not 
been fully investigated and could lead to the availability of tailored 
models that accurately describe these novel complex systems. In this 
perspective, we believe that a more in-depth knowledge about the 
interference between macromolecules and MRI CAs and an 
understanding of their physicochemical properties is necessary to 
impact in the design strategies of the nanostructures and, 
consequently, to overcome the limitations of clinically used MRI CAs, 
particularly linked to the low relaxivity. To this aim, it is crucial to 
study the main phenomena involved in the formation of polymer 
matrices and how their properties can influence the relaxivity of MRI 
CAs is performed. 
IV.1.2 Aim of Chapter 4 
In the Chapter 4, we aim to investigate the impact of hydrogel-CA 
systems on the relaxometric properties of metal chelates to understand 
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better the clear role of the water, which mediates interactions and 
could be responsible for their behaviour in solution. On one hand, the 
magnetic properties of the water protons surrounding the CA are 
fundamental to enhance the CAs’ relaxivity. On the other, the presence 
of water molecules can induce changes in the polymer structure 
through polar interactions, hydrogen bonding and osmotic pressure. 
Among different biopolymer, Hyaluronic Acid (HA)46 is chosen as 
model polymer due to its hydrophilic nature and established 
biocompatibility and biodegradability. Commercially available Gd-
DTPA is selected as the CA due to its widespread use in clinical 
practice 47.  
First experiments are focused on determining the water self-diffusion 
coefficients in polymer and CA solutions through Time-Domain NMR 
relaxometry to observe changes in water mobility in the presence of 
both HA and Gd-DTPA. Self-diffusion measurements have already 
proved especially successful for probing interfacial water structure 
and dynamics near various biological and polymer surfaces48. 
Intramolecular interactions, as well as entropy costs, can alter the 
mobility of solvent molecules within polymer matrices or in confined 
environments, with a slowing effect on the diffusion49-51. Moreover, 
since the relaxation efficiency is mediated by translational and 
rotational diffusion48, a variation of the water diffusion behaviour at 
the interface between polymer chains and MRI CAs could impact on 
the τD of the complex, thereby influencing the relaxometric properties 
The definition of Hydrodenticity 
152 
 
of the metal chelate. Isothermal Titration Calorimetry (ITC) is 
employed after that to investigate thermodynamic interactions 
involved in the mixing of HA with Gd-DTPA52-54. Finally, 
relaxometric properties of HA/Gd-DTPA solutions are investigated by 
means of time-domain NMR relaxometry55. The knowledge of these 
complex systems could be scaled to nanoscale dimensions, inspiring 
the development of a new class of nanostructured MRI CAs with 
highly tunable relaxometric properties. Starting from these 
observations, we have also proved that, by changing structural 
parameters of a hydrogel matrix containing a CA, through our already 
presented Microfluidic Flow Focusing approach, it is possible to affect 
the dipolar coupling between the electronic magnetic moment of the 
metal ion and the nuclear magnetic moment of the water nuclei 
(relaxation rate). This effect results from the complex equilibrium 
established by the elastic stretches of polymer chains, water osmotic 
pressure and hydration degree of Gd-based CAs, that we have called 
Hydrodenticity. 
Hydrodenticity, hence, refers to the status of the hydrated Gd-DTPA 
with the coordination water subjected to osmotic pressure56,57 deriving 
from elastodynamics equilibrium of swollen gels.58-61 We hypothesize 
that the attainment of this equilibrium is reached when the normal 
energetic stability of the meshes is compromised by the presence of 
the Gd-DTPA and evolves to a new spontaneous equilibrium 
involving the formation of nanocompartments, called “Gado-
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Meshes”, in which water is in an abnormal aggregate state that 
influences the relaxivity. The capability to control the organization of 
these nanocompartments within the nanoparticles can be applied to 
define a new class of medical devices useful to improve the properties 
of CAs for MRI. Within the cHANPs, the properties of Hydrodenticity 
can be modulated to obtain desired crosslink density, mesh size, 
hydrophilicity and loading capability, playing on the biodegradable 
behavior and relaxometric properties of the Gd-loaded cHANPs. 
IV.2 Case Study 
IV.2.1 Experimental Section 
IV.2.1.1 Materials 
HA (Bohus Biotech, Sweden) with an average molecular weight of 
42000 Da is used for the polymer matrix because of its 
biocompatibility, biodegradability and swelling properties. 
Commercially available Gd-DTPA (Sigma-Aldrich) with a molecular 
weight of 547.57 Da is used since it is a well-known, low-risk CA. 
Divinyl Sulfone (DVS) (Sigma Aldrich) with a molecular weight of 
118.15 Da is used as crosslinking agent. Milli-Q water is 
systematically used for sample preparation and analysis. 
IV.2.1.2 Sample preparation 
Non-crosslinked hydrogel-CA solutions were prepared by dispersing 
both the HA and the Gd-DTPA powders in distilled deionized water 
and then mixing using magnetic stirrer. Different HA concentrations, 
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ranging from 0.1 to 5 % w/v, was utilized for the experimentation. For 
each fixed concentration of HA, Gd-DTPA concentration was varied 
between 0 and 0.2 mM. 
Crosslinked hydrogel-CA solutions were prepared by adding DVS to 
the above-described solutions to crosslink the polymer network 
chemically. Hydrogels were prepared at different HA: DVS ratios 
(from 1:1 to 1:16).  
IV.2.1.3 Water self-diffusion coefficient 
Diffusion measurements of water molecules were carried out on a 
Bruker Minispec (mq 20) bench-top relaxometer operating at 20 MHz 
for protons (magnetic ﬁeld strength: 0.47 T). A pulsed ﬁeld gradient 
spin echo (PFG-SE) sequence62, with two magnetic ﬁeld gradient 
pulses of length δ and strength g, and with a delay Δ between the 
leading edges of them, was used to measure water self-diffusion 
coefficients. The self-diffusion coefficient, D, was derived by linear 
regression of signal attenuation ratio curve, a semi-logarithmic plot of 
the echo attenuation as a function of the tunable parameter of the 
sequence, k = (γgδ)2 * (Δ - δ/3). 
IV.2.1.4 Isothermal Titration Calorimetry 
Isothermal Titration Calorimetry (ITC) measurements were conducted 
by filling the sample cell (0.7 mL in volume) with an aqueous solution 
of HA at different concentrations (from 0.1 to 0.7 % w/v) and the 50 
μL syringe with an aqueous solution of Gd-DTPA at 1.5 mM. 
Measurements were performed at 25 °C and fixed stirring rate of 200 
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rpm. Fifty injections, each of 1 μL of Gd-DTPA, were delivered in 
intervals of 500 s. Data analysis and processing to provide ITC and 
enthalpy change, ΔH, profiles were carried out using the NanoAnalyze 
(TA instruments) and the Origin Pro 9.1 SRO software (OriginLab 
Corporation, USA). 
IV.2.1.5 Relaxometric measurement 
Relaxation times were measured on a Bruker Minispec (mq 60) bench-
top relaxometer operating at 60 MHz for protons (magnetic ﬁeld 
strength: 1.41 T). The acquisitions were performed at 37°C, and before 
each measurement, the sample was placed into the NMR probe for 
about 15 min for thermal equilibration. Longitudinal relaxation times, 
T1, were determined by both saturation (SR) and inversion recovery 
(IR) pulse sequences, by using the same protocol presented into the 
paragraph III.2.1.4. Data were treated by a least-squares method using 
Origin Pro 9.1 SRO software (OriginLab Corporation, USA).  
IV.2.1.6 Swelling Ratio and Hydrogel parameters  
Swelling Ratio (SR) is calculated as follows: 
𝑆𝑅 = 𝑑𝐻2𝑂 𝑑𝑒𝑡ℎ⁄  
where 𝑑𝑒𝑡ℎ (in nm) 𝑑𝐻2𝑂 (in nm) are the nanoparticle’s diameters in 
Ethanol and in water respectively, measured by Dynamic Light 
Scattering. A simplified version of the the Flory-Rehner equations are 
used in order to compute the hydrogel structure parameters (𝑀𝑐̅̅ ̅̅ : 
molecular weight between crosslinks (g/mol); 𝑣𝑒: effective crosslink 
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density (mol/cm3); ξ: mesh size (nm). See the Appendix V.II for the 
detailed calculations. 
IV.2.2 Results and Discussion 
IV.2.2.1 Diffusion Coefficient 
In our systems, we have observed that water mobility slightly 
changes with increasing network density induced by crosslinking 
reaction (Figure IV-1). Besides, a more significant decrease in the 
water diffusion is observed in the presence of increasing polymer 
concentration rather than increasing CA concentration ( 
Table IV-1). However, the study of the diffusion coefficient as a 
function of the crosslinking degree requires further investigation to 
understand its influence on the relaxometric properties.  
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Figure IV-1. Stejskal Tanner Plot is used for calculating water self-diffusion 
coefficient of: (1) distilled water; (2) 0.25 % w/v HA solution with 5 μL DVS 8 hours 
after the crosslinking reaction; (3) 5 % w/v HA solution with 40 μL DVS 8 hours after 
the crosslinking reaction. 
Table IV-1. Range of water self-diffusion coefficients, D, measured for: (1) distilled 
water; (2) Gd-DTPA solutions at different Gd-DTPA concentrations; (3) 0.25 and 5 % 
w/v HA hydrogel solutions at varying crosslinking degrees, i.e. different DVS 
concentrations. 
HA 
(% w/v) 
DVS 
(μL) 
Gd-DTPA 
(mM) 
Da 
(*10-9 m2s-1) 
0 0 0 3.19 
0 0 0.05 ÷ 1 3.18 ÷ 3.09 
0.25 0 ÷ 25 0 3.05 ÷ 2.90 
5 5 ÷ 40 0 2.88 ÷ 2.83 
a Values of the standard deviation for the measured diffusion coefficients are all 
below 0.4*10-12 m2s-1. 
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Further details on diffusion data are reported in Table IV-2 and Table 
IV-3.  
 
Table IV-2. Water self-diffusion coefficient measured at different Pulse Gradient 
Amplitudes for 0.25 and 5 % w/v HA hydrogel solution at varying crosslinking degrees 
(different DVS concentrations). Diffusion coefficients have been measured 8 and 24 
hours after crosslinking reaction. 
HA 
(% w/v) 
DVS (μL) 
D after 8h 
(*10-9 m2s-1) 
D after 24h 
(*10-9 m2s-1) 
0 0 3.19 ± 0.01 3.19 ± 0.01 
0.25 0 3.05 ± 0.01 3.06 ± 0.02 
0.25 5 3.01 ± 0.02 3.02 ± 0.01 
0.25 10 2.97 ± 0.03 2.98 ± 0.02 
0.25 15 2.95 ± 0.03 2.96 ± 0.02 
0.25 20 2.92 ± 0.02 2.94 ± 0.02 
0.25 25 2.90 ± 0.02 2.92 ± 0.03 
5 10 2.88 ± 0.02 2.87 ± 0.01 
5 20 2.85 ± 0.01 2.85 ± 0.02 
5 30 2.83 ± 0.02 2.85 ± 0.01 
5 40 2.84 ± 0.01 2.84 ± 0.02 
 
 
 
Chapter IV 
159 
 
Table IV-3. Range of water self-diffusion coefficient measured for Gd-DTPA solutions 
at different Gd-DTPA concentrations. 
Gd-DTPA 
(μM) 
D 
(*10-9 m2s-1) 
0 3.19 ± 0.01 
50 3.12 ± 0.02 
100 3.14 ± 0.02 
150 3.09 ± 0.02 
200 3.18 ± 0.01 
500 3.11 ± 0.02 
1000 3.13 ± 0.03 
 
Furthermore, results show that water mobility starts decreasing even 
at very low polymer concentration (0.25 % w/v HA). This dynamic 
can be attributed to the high molecular weight and hydrophilicity of 
the HA, which allows the formation of several hydrogen bonds at the 
surface of the polymer, thereby stabilizing the polymer structure and 
reducing water self-diffusion. At first, because of the diffusion 
measurements, we can observe that thanks to the high hydrophilicity 
of the HA promoting the hydrogen bonds formation at the surface of 
the polymer, water mobility starts decreasing even at very low 
polymer concentrations. 
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IV.2.2.2 Isothermal Titration Calorimetry 
Here, ITC is proposed to calculate the energetic contribution and 
thermodynamic interactions deriving from the mixing of Gd-chelates 
with the polymer solution. 
In our experiment, a simple dilution of Gd-DTPA in water or water in 
HA exhibits only small constant exothermic peaks (Figure IV-2 and 
Figure IV-3).  
 
 
Figure IV-2. Titration curves of Gd-DTPA in water at 25 °C and 200 rpm. 
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Figure IV-3. Titration curves of water into 0.2% w/v HA solutions at 25 °C and 200 
rpm. 
On the contrary, when Gd-DTPA is injected as titrant into the cell 
containing HA solution a change from exothermic to endothermic 
behaviour is clearly observed. This change occurs at an HA/Gd-DTPA 
molar ratio of 0.5 (Figure IV-4), i.e. when the molar concentration of 
Gd-DTPA in solution is twice the HA molar concentration. Starting 
from these observations, we hypothesize that at a certain HA/Gd-
DTPA ratio, the enthalpy variations obtained in the binding 
experiment can be related to changes in the polymer structure, which 
in turn can be associated with the water-mediated interaction between 
the Gd-chelate and the polymer. The presence of Gd-DTPA, which 
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has a high affinity for water molecules, may interfere with the polymer 
solution and induce peculiar arrangements in polymer chains’ 
conformation. 
 
Figure IV-4. Thermograms (heat flow versus time) of Gd-DTPA into aqueous solution 
of HA at 0.6 % w/v. Temperature and stirring rate have been kept constant at 25 °C 
and 200 rpm, respectively, for each sample. 
These experimental observations could be of crucial importance in the 
design of polymer-based MRI CAs. Therefore, we have subsequently 
investigated how the polymer conformation can influence the 
relaxometric properties of the MRI complex in the polymer solution. 
Secondly, ITC results suggest that the presence of Gd-DTPA induce 
considerable thermodynamic variations in the polymer/CA mixing 
process that can be related to changes in polymer conformation. 
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IV.2.2.3 Time-Domain Relaxometry 
Through Time-Domain Relaxometry, relationships between system 
formulation, polymer matrices and relaxivity enhancement are 
provided. Results show how the relaxivity could be varied by 
changing the structural parameters of the hydrogel, namely polymer 
concentration and crosslinking degree (DVS concentration). Figure 
IV-5 a) and b) display the longitudinal relaxation rate, R1, and 
longitudinal relaxation time distribution for Gd-DTPA in distilled 
water and different crosslinked and non-crosslinked HA/Gd-DTPA 
solutions.  
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Figure IV-5. a) Longitudinal relaxation rate as a function of Gd-DTPA concentration 
and b) longitudinal relaxation time distribution for: (1) Gd-DTPA in distilled water; 
(2) Gd-DTPA in 0.3 % w/v HA solution; (3) Gd-DTPA in 0.5 % w/v HA solution; (4) Gd-
DTPA in 0.3 % w/v HA crosslinked with DVS (HA: DVS = 1:8); (5) Gd-DTPA in 0.5 % w/v 
HA crosslinked with DVS (HA:DVS = 1:8). Linear regression is applied to each set of 
data reported in a). 
In detail, Figure IV-5 a) demonstrates the variation of relaxation rates 
against the concentration of Gd-DTPA. As expected, R1 rises linearly 
as Gd-DTPA concentration increases and surprisingly, the relaxivity, 
r1, appears to be tuned mostly by the variation of hydrogel structure 
(polymer concentration and crosslinking degree). Therefore, we found 
out that could be possible to modulate the r1 by changing the DVS 
concentration and to induce corresponding changes in the relaxation 
rates through the hydrogel matrix. Slopes of the regression lines in 
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Figure IV-5 a), indicating each obtained relaxivity r1 value, are 
reported in Table IV-4. Figure IV-5 b) highlights through the 
relaxation time distribution the influence of hydrogel structure on the 
relaxation times as already discussed in Figure IV-5 a). In particular, 
it displays a narrower relaxation time distribution in the presence of 
crosslinking, thereby indicating an enhancement of the MRI signal. As 
shown in Table IV-4, a slight increase in the relaxivity (from 1% to 
6%) on the reference solution (Gd-DTPA in water) is observed for the 
non-crosslinked samples. Besides, for crosslinked hydrogel-CA 
systems, in the presence of a crosslinked network, the relaxivity 
increases to an even greater extent, ranging from 11% up to 25%. 
About this last result, it seems that the crosslinking degree is 
interfering more on the relaxivity of CAs than on the diffusivity of 
water, acting, therefore, more on the rigidification of the CAs than on 
the water mobility. 
Table IV-4. Relaxivity enhancement for the investigated polymer/CA systems. 
HA 
(% w/v) 
DVS 
(% w/v) 
r1 
(mM-1s-1) 
r1 increment 
(%) 
0 0 3.07 ± 0.04 0 
0.3 0 3.18 ± 0.05 3.6 
0.3 2.4 3,81 ± 0.16 24,1 
0.5 0 3,11 ± 0.06 1.3 
0.5 4 3,65 ± 0.23 18,9 
0.7 0 3,26 ± 0.06 6.2 
0.7 5.6 3,41 ± 0.21 11.1 
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However, this aspect is of crucial important and will require further 
investigations and comparison. Percentages of increment in the 
relaxivity are calculated by dividing the difference between the 
relaxivity of the polymer/CA system and the reference (Gd-DTPA in 
water) by that of the reference solution, as follows: 
 
Finally, taking into consideration the computed relaxivity values, we 
can hypothesize that the hydrogel structure, which is strictly 
dependent on the water content and its dynamics within the polymer 
matrix, can significantly impact on the relaxivity of the whole 
polymer/CA system. Table IV-5 shows further details on relaxometric 
data. 
  
Chapter IV 
167 
 
Table IV-5. Relaxation rates (1/T1) and relaxivity values for: (Sample 1) Gd-DTPA in 
water; (Sample 2) Gd-DTPA in 0.3% w/v HA solution; (Sample 3) Gd-DTPA in 0.3% 
w/v HA solution crosslinked with 2.4%  w/v DVS; (Sample 4) Gd-DTPA in 0.5% w/v HA 
solution; (Sample 5) Gd-DTPA in 0.5% w/v HA solution crosslinked with 4%  w/v DVS; 
(Sample 6) Gd-DTPA in 0.7% w/v HA solution; (Sample 7) Gd-DTPA in 0.7% w/v HA 
solution crosslinked with 5.6%  w/v DVS 
Gd-
DTPA 
(mM) 
Sample 
1 
(s-1) 
Sample 
2 
(s-1) 
Sample 
3 
(s-1) 
Sample 
4 
(s-1) 
Sample 
5 
(s-1) 
Sample 
6 
(s-1) 
Sample 
7 
(s-1) 
0.000 
0.265 ± 
0.003 
0.264 ± 
0.001 
0.273 ± 
0.000 
0.273 ± 
0.001 
0.331 ± 
0.001 
0.265 ± 
0.003 
0.301 ± 
0.001 
0.010 
0.299 ± 
0.000 
0.309 ± 
0.000 
0.342 ± 
0.001 
0.315 ± 
0.001 
0.301 ± 
0.001 
0.309 ± 
0.001 
0.313 ± 
0.001 
0.020 
0.330 ± 
0.001 
0.347 ± 
0.001 
0.348 ± 
0.001 
0.339 ± 
0.001 
0.360 ± 
0.001 
0.345 ± 
0.000 
0.342 ± 
0.001 
0.025 - - 
0.351 ± 
0.001 
- - - - 
0.030 
0.361 ± 
0.000 
0.372 ± 
0.001 
0.381 ± 
0.001 
0.384 ± 
0.001 
0.382 ± 
0.001 
0.373 ± 
0.001 
0.403 ± 
0.007 
0.035 
0.379 ± 
0.001 
0.388 ± 
0.001 
- 
0.392 ± 
0.001 
- - - 
0.040 
0.397 ± 
0.002 
0.398 ± 
0.002 
0.449 ± 
0.001 
0.400 ± 
0.005 
0.445 ± 
0.001 
0.398 ± 
0.003 
0.402 ± 
0.006 
0.050 
0.441 ± 
0.003 
0.434 ± 
0.025 
0.436 ± 
0.001 
0.450 ± 
0.001 
0.510 ± 
0.002 
0.445 ± 
0.001 
0.468 ± 
0.001 
0.060 
0.450 ± 
0.001 
0.463 ± 
0.001 
0.510 ± 
0.001 
0.493 ± 
0.001 
0.485 ± 
0.001 
0.452 ± 
0.001 
0.549 ± 
0.003 
0.070 
0.485 ± 
0.001 
0.496 ± 
0.001 
0.512 ± 
0.001 
0.505 ± 
0.001 
- - - 
0.080 
0.528 ± 
0.001 
0.562 ± 
0.003 
0.599 ± 
0.004 
0.503 ± 
0.001 
0.610 ± 
0.015 
0.548 ± 
0.002 
0.547 ± 
0.001 
0.100 - 
0.588 ± 
0.069 
0.702 ± 
0.002 
0.599 ± 
0.004 
0.590 ± 
0.001 
0.594 ± 
0.002 
0.595 ± 
0.007 
0.130 - 
0.685 ± 
0.000 
0.722 ± 
0.002 
0.678 ± 
0.001 
0.701 ± 
0.001 
0.675 ± 
0.002 
0.699 ± 
0.001 
0.150 - 
0.754 ± 
0.001 
0.805 ± 
0.002 
0.757 ± 
0.002 
0.797 ± 
0.001 
0.755 ± 
0.001 
0.786 ± 
0.002 
0.180 - - - - - 
0.845 ± 
0.002 
1.043 ± 
0.003 
0.200 
0.880 ± 
0.002 
0.909 ± 
0.003 
1.075 ± 
0.002 
0.904 ± 
0.008 
1.098 ± 
0.004 
0.971 ± 
0.002 
0.896 ± 
0.004 
0.250 - - - - - 
1.071 ± 
0.003 
1.126 ± 
0.004 
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Relaxivity 
(mM-1s-1) 
3.067 ± 
0.044 
3.185 ± 
0.050 
3.805 ± 
0.164 
3.114 ± 
0.061 
3.655 ± 
0.225 
3.256 ± 
0.064 
3.410 ± 
0.205 
IV.2.2.4 Theoretical interpretation of the enhanced Relaxivity 
Starting from the Solomon–Bloembergen–Morgan (SBM) theory36, 
the physics of CAs is described by a set of physicochemical 
parameters characterizing the fluctuating magnetic dipole created by 
the paramagnetic ion. In detail, according to the SBM model, the metal 
complex can be viewed as having separate coordination spheres63: the 
Inner Sphere (IS), which consists of water molecules directly 
coordinated to the metal ion, and the Outer Sphere (OS), which is a 
less organized structure consisting of bulk water molecules diffusing 
in the near environment of the metal complex. In some cases, a Second 
Sphere (SS) contribution is taken into account, which is related to 
water molecules hydrogen bonded to the metal complex64. Each of the 
coordination mentioned above spheres has its characteristic 
parameters. IS parameters include the number of labile water 
molecules coordinated to the metal ion (q), the residence time of the 
coordinated water molecule (τM), which in turn determines the rate of 
the coordinated water molecule exchanging with the bulk, and the 
rotational correlation time (τR), which is how quickly the contrast 
agent is tumbling in solution. Conversely, OS parameters include the 
translational diffusional time (τD), which represent the diffusion of 
water molecules in the bulk near to the Gd complex. 
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It is already known that molecular motion, size, rigidity and possible 
binding between Gd-chelates and other macromolecules may induce 
changes in relaxivity 2. Furthermore, polymer architecture and 
properties can strongly affect the MRI enhancement20,26,29.  
As previously reported in the SBM theory, characteristic parameters 
of the metal chelate can be physically or chemically tuned and are of 
primary importance in the design of new CAs65. In particular, the Gd-
chelator determines the number of coordinated water molecules (q) 
and the water exchange rate (kex), which is the inverse of the residence 
time τM. Moreover, decreased τD and τR, which can be obtained, for 
instance, through the binding of the metal chelate with large 
macromolecules, generally yield increased relaxation rates at low 
magnetic fields (<1.5 T)3. 
Our findings report that the presence of a polymer network can 
significantly affect the relaxation enhancement since it influences the 
hydration mechanism of the CA, i.e. the number of water molecules 
in either the IS, SS or OS, their diffusion behaviour and exchange rate 
with the water molecule coordinated to the metal ion. 
As schematically represented in Figure IV-6, the obtained results 
suggest that changes in polymer conformation, induced by varying 
polymer/CA molar ratio, could be furtherly exploited to improve the 
relaxivity of the CA. 
Indeed, the altered behaviour of the water molecules at the HA/Gd-
DTPA interface, exhibiting reduced mobility and strong interactions 
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with the highly hydrophilic polymer surface, may have a considerable 
impact on the correlation times, especially τM and τD. In fact, the 
presence of polymer hydrophilic groups can change the access of bulk 
water molecules to the coordinated water molecule and, thus, alter the 
water exchange rate (kex =1/τM). Moreover, polymer chains can 
slightly reduce the mobility of the OS water molecules, with a 
consequent decreasing of τD. A simultaneous reduction of the CA’s 
tumbling rate (τR) can also be hypothesized since the environment 
provided by the presence of the polymer chains as well as of the 
crosslinking degree may induce a slower rotation of the metal chelate. 
 
Figure IV-6. Relaxation enhancement induced by water-mediated HA/Gd-DTPA 
interactions. 
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Here, a study of the interactions involved in polymer- hydrogel-based 
CA solutions has been presented, aiming at understanding the key role 
of the water as a mediating agent that acts at the interface between the 
polymer and the metal chelate and determines both the polymer 
conformation and the relaxation enhancement. The systems have been 
investigated by mixing crosslinked or non-crosslinked HA with Gd-
DTPA at specific polymer/CA molar ratios in aqueous solution 
without introducing chemical modifications of the CA. Water self-
diffusion coefficients, as well as proton longitudinal relaxation curves 
for different HA/Gd-DTPA solutions, have been measured. A 
thermodynamic investigation of the mixing process between HA and 
Gd-DTPA in water has also been conducted. We have observed that, 
in the presence of a crosslinked matrix, it is possible to modulate the 
water content of the system and, therefore, the hydration of the CA, 
by adjusting the crosslinking degree of the hydrogel structure. In these 
conditions, a more stable polymer network can be obtained, promoting 
more efficient water-polymer and water-CA interactions that boost the 
relaxivity to higher values. The crosslinking degree is proposed as an 
advanced tool to modulate the hydrogel network and its properties, 
enabling the tuning of the relaxometric properties. These findings 
could be useful to deepen the knowledge of hydrogel-CA systems and 
to achieve an advanced comprehension of the fundamental 
mechanisms that rule the interaction between MRI CAs and hydrogel 
matrices, and are responsible for the relaxation enhancement. Further 
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characterization studies and computational simulations are necessary 
to insight the water behaviour within polymeric matrices in the 
presence of metal chelates and the potential impact that these 
structures can have on the relaxometric properties of clinically used 
CAs and, therefore, on the performance of MRI diagnosis.  
The knowledge of these complex systems could be scaled to nanoscale 
dimensions, in particular to our case study, inspiring the development 
of a new class of nanostructured MRI CAs with highly tunable 
relaxometric properties.  
IV.2.2.5 Study of hydrogel structural parameters enhancing 
relaxometric properties of Gd-based CAs within cHANPs 
By the above-reported experiments, we have proved that a 
systematic tunability can be achieved by varying the crosslinking 
degree of the hydrogel nanoparticles in the presence of Gd-DTPA 
accurately (Chapter 2 and 3). A narrow or a broad distribution of 
relaxation rates on the DVS concentration is showed with regards 
to changes in the water dynamics, hydrogel conformation and 
slow motion of the CAs. High control of the parameters is mainly 
reached through microfluidic approach66. 
Starting from the observation of a peculiar swelling behavior 
(Figure IV-7) and in vitro relaxometric properties of the cHANPs 
(Figure III-4 in Chapter 3), we propose an explanation of how 
the hydrogel structural parameters can be used to improve the 
relaxometric properties of CAs.67 
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Figure IV-7. Swelling Behavior of cHANPs. (a) Swelling Ratio of crosslinked 
Hyaluronic Acid Nanoparticles (cHANPs) versus DVS concentration after 48 hours in 
water at “standard conditions” by injecting DVS (-■-) in the middle channel at Span80 
0.5% v/v under strict control of temperature and (-●-) in the side channels at pH of 
12.3. (b) FE-SEM images of cHANPs in water by adding DVS in the side channels. (c) 
15° C tilted FE-SEM image of cHANPs in the same conditions of (b). 
According to Flory-Rehner calculations,68 we have determined 
the crosslink density (νe) and mesh size (ξ) of cHANPs in water 
after 48 hr (see Appendix V.II for details about calculations). It 
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has been already reported67 that lower molecular weight ﬁlms 
gave rise to decreased molecular weights between crosslinks as 
well as increased effective crosslink densities and decreased 
mesh size. Even in our results, a general increase of the crosslink 
density by increasing the DVS concentration is also evident for 
both strategies in Figure IV-8a but a different maximum value is 
achieved. Furthermore, as expected, by increasing the crosslink 
density, a reduction in mesh size is also obtained until to a certain 
extent (Figure IV-8b). However, at the most stable conditions 
(0.8 and 4% v/v DVS) i.e. in the absence of swelling for 48 h, we 
observe a difference in the crosslink density for the two strategies 
but not a significant variation in the achieved mesh size. Indeed, 
a mesh size of about 1.5 nm is reached for DVS 4% v/v (side 
channels) and of about 2 nm for DVS 0.8% v/v (middle channel). 
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Figure IV-8. Hydrogel parameters. (a) Crosslink density and (b) Mesh size versus DVS 
concentration for Gd-DTPA loaded cHANPs obtained by injecting DVS (-●-) in the side 
channels and (-■-) in the middle channel. 
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The relationship between the measured structural parameters of 
the hydrogel and changes in CA’s relaxivity is also examined 
Figure IV-9a and b. In our system, even if the mesh sizes 
calculated for both strategies are similar, the highest relaxivity is 
not observed at the maximum crosslink density, hypothesizing 
that an optimal equilibrium among the species should be 
achieved to boost the relaxometric properties. 
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Figure IV-9. Effect of the Hydrodenticity. (a) Bar chart of longitudinal relaxivity (gray 
columns) and mesh size (blue columns) values computed at different crosslink 
densities. (b) Mesh size versus crosslink density (-■-) and corresponding relaxivity 
values (-▲-) along with a graphical representation of cHANPs’ polymer network at 
different mesh size values. 
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IV.2.2.6 Definition of Hydrodenticity as a property referring to the 
Hydrogels/Gd-based CAs interaction 
Results show so far that Hydrodenticity can be proposed as a new 
concept to summarize the complex equilibrium formed by elastic 
stretches of polymer chains, water osmotic pressure and hydration 
degree of Gd-based CAs able to boost the relaxivity. 
Indeed, at the achieved minimum mesh size, crosslink density is 
responsible for the elastodynamic of the hydrogel and is representative 
of the water amount within the polymer meshes, which in turn is 
related to the osmotic pressure. Our results also show that the 
reduction in the elasticity of the matrix with the increase of the 
crosslink density does not correspond to a maximum enhancement of 
the relaxivity. It is probably due to the expelled water from the 
hydrogel network69 that causes a reduction in the osmotic pressure 
within the water compartments of the meshes and a decrease of the 
hydrated status of Gd-DTPA, thus limiting the enhancement of the 
relaxometric properties in the nanostructures. These conditions 
promote the formation of water compartments containing Gd-DTPA 
called “Gado-Meshes”. 
It is also well-known that the crosslink density also acts on the water 
diffusion, which decreases when the crosslink density increases and 
its slowdown in diffusion is more severe at the polymer-water 
interface70,71. Even in the Gd-loaded cHANPs, the water diffusion at 
various crosslink densities is correlated with the water hydrogen 
bonding dynamics, and the variation of diffusion coefficient with 
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crosslink density is related to the variation of water content in different 
crosslink densities. Therefore, by changing further the properties of 
the “Gado-Meshes” through the crosslinking reaction, relaxivity 
increases to an even greater extent due to the Hydrodenticity because 
of the tuning of the crosslink density and, consequently, of the 
aggregated water state and slow moving of the CAs. 
As the Hydrodenticity of CAs within the Gado-Mesh does not involve 
the chemical modification of the CAs, the observed enhancement in 
relaxivity is induced by the synergistic interaction of the aggregated 
water with the hydrogel matrix and Gd-DTPA. Indeed, according to 
the Solomon- Bloembergen-Morgan theory, this effect promotes both 
(§) a further reduction of the water mobility and diffusion, inducing 
an increase of the residence lifetime (τM) and characteristic diffusion 
time (τD) of the inner and outer sphere; and (§§) changes in hydrogel 
structures leading to the formation of nanocompartments enwrapping 
Gd-based CAs, causing a slow motion of the CAs and, therefore, an 
increase of the rotational correlation time (τR) intrinsic of the chelate. 
Furthermore, it is reasonable that the conditions, reached in the Gado-
Mesh, control even the water exchange and, therefore, the relaxivity. 
Indeed, relaxivity can be limited if the water exchange is too slow 
because the relaxation effect is poorly transmitted to the bulk. 
However, relaxivity can also be reduced if the water exchange is too 
fast because the water is not coordinated to the GdCAs long 
enough to be relaxed.72 In the proposed system, at some degree of 
The definition of Hydrodenticity 
180 
 
Hydrodenticity, the hydrated status of Gd complexes, the 
elastodynamic response of HA and the osmotic pressure result 
probably in a much slower rotation. At this point, the importance of 
water exchange becomes significant, but the improved relaxivity of 
Gd-loaded cHANPs confirms that water diffusion is high enough, and 
the process for relaxing the water protons of aggregated water is in 
any case very efficient. We have already demonstrated cHANPs 
themselves do not contribute to the relaxivity of the system (Figure 
III-6). Thus, the increase in the relaxivity of the loaded cHANPs can 
be attributed solely to the formation of the Gado-Mesh and to the 
Hydrodenticity achieved in their organization that influences the 
relaxivity through the characteristic correlation times above 
mentioned. 
Modulation of the Hydrodenticity through the: (i) elastic stretching 
of the polymer meshes (ii) osmotic pressure and (iii) hydrated 
state of Gd-DTPA contributes to the changes of the Inner and 
Outer-Sphere of the CAs. Therefore, through the hydrogel 
structural parameters, we can produce a library of functional 
nanostructures on the needs of a particular pathology, field and 
material properties. 
Results could lead to the identification of a personalized 
diagnostic window (Figure IV-10) that can define the range of 
optimal properties between the hydrogel matrix and the CAs, 
being more efficient in treating a particular disease, avoiding 
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toxic effects and increasing the performance of the MRI 
acquisitions. 
 
Figure IV-10. Hydrodenticity to enhance relaxivity. Schematic illustration of an 
improved diagnostic window in which it is possible to obtain a medical device for 
clinical use in the MRI field able to overcome the limitations related to the use of 
commercial CAs such as low relaxivity, limited acquisition time and reduced tissue 
specificity. 
IV.3 Conclusions 
Here, a study of the interactions involved in polymer-hydrogel-based 
CA solutions has been presented, aiming at understanding the key role 
of the water as a mediating agent that acts at the interface between the 
polymer and the metal chelate and determines both the polymer 
conformation and the relaxation enhancement. We are able to 
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individuate by a calorimetric study the energetic contribution in the 
bulk derived by the interference between the components HA/Water 
and CAs and how this contribution can modify the hydrogel structure. 
After, we have highlighted how the water dynamics in a hydrogel 
matrix can interfere with the relaxation properties of the Gd-based 
CAs. Based also on these findings on hydrogel matrices, the new 
concept of Hydrodenticity is here defined for the first time to intend 
the peculiar environment within the nanostructures composed by the 
ternary system, hydrogel/water/CAs able to improve the relaxometric 
properties of CAs. Parameters related to the hydrodenticity are 
individuated and explained, supported by the literature and a 
theoretical explanation is fully provided by the consolidated Flory-
Rhener theory.  
The microfluidic approach is only used as a tool to prove that 
Hydrodenticity can be modulated to obtain desired crosslink density, 
mesh size, hydrophilicity and loading capability, playing on the 
biodegradable behavior and relaxometric properties of the Gd-loaded 
nanostructures. Results are experimentally proving and modeling the 
relation between the structural parameters of the cHANPs and their 
improved relaxometric properties. This effect results from the 
complex equilibrium established by the elastic stretches of polymer 
chains, water osmotic pressure and hydration degree of GdCAs, that 
we have called Hydrodenticity. 
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Through the definition of this new concept, we aim to contribute to 
the advances in the solution of the both physical and biological limits 
regarding the clinical use of CAs, demonstrating that it is possible to 
increase their relaxivity by tuning the structural parameters of 
hydrogel nanoparticles, and, at the same time, improving potentially 
the tissue specificity, stability of the chelates, imaging diagnostic 
window and reducing the administration dosage. Indeed, starting from 
the observation of the swelling ratio, we show that by tuning the 
hydrogel matrix containing a CA it is possible to affect the dipolar 
coupling between the electronic magnetic moment of the metal ion and 
the nuclear magnetic moment of the water nuclei (relaxation rate).
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Main Conclusions and Perspectives 
A microfluidic-based process has been proposed to design a new class 
of Magnetic Resonance Imaging (MRI) Contrast Agents (CAs) in 
form of intravascularly-injectable and biocompatible hydrogel 
nanostructures able to impact on the relaxometric properties of MRI 
CAs for potential application in diagnosis and therapy.  
In the first part of the thesis, the tunability of the hydrogel 
nanostructures, able to entrap rationally a clinically-relevant Gd-based 
CA, Gd-DTPA, through a microfluidic flow focusing method, is 
exploited and monodisperse crosslinked Hyaluronic Acid 
Nanoparticles (cHANPs) under 50 nm are produced by a controlled 
nanoprecipitation, overcoming the limits of common batch processes, 
and guaranteeing an instantaneous formulation and absence of 
purification step.  
The proposed microfluidic method allows a strict control of the 
physicochemical properties of the nanoparticles and the entrapping of 
the Gd-DTPA, achieving a low polydispersity of nanoparticles and a 
high encapsulation efficiency of the metal compound within the 
nanoparticles. Our findings are interesting to investigate how the 
microfluidic environment determines the NPs size and 
stabilization, to facilitate also the further application of this 
rapidly growing technique. 
Furthermore, a crosslinking reaction is studied and performed, 
simultaneously to the nanoprecipitation, to improve the stability of the 
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polymer matrix, increase loading capability and reduce swelling 
effects. Interferences of the CA in the flow focusing behaviour are 
reported for the first time, and different strategies are proposed to 
optimize the entrapment of the metal compound. In addition, the 
encapsulation efficiency of the metal inside the nanoparticles could be 
adaptable according to needs, and a perfect formulation of the 
involved species is obtained.  
In the second part of the thesis, the relaxometric performances are 
assessed in terms of longitudinal relaxivity r1 as a function of the 
crosslinking degree and loading conditions. In in vitro and in vivo 
analysis, the r1 relaxivity of the Gd-loaded cHANPs is shown to 
increase up to 12 times at specific formulations, without the chemical 
modification of the relevant clinical chelate. This observation is 
crucial to lead potentially to a significant reduction of the 
administration dosage on clinical usage of the CAs and to gain 
advantages in the imaging modalities based on nanotechnologies. 
Indeed, the nanoparticles are widely used for the improvement of 
imaging techniques and the adjustable features reported for our system 
can potentially reduce limitation linked to a fast clearance from the 
bloodstream and low detection due to the dependence on the 
concentration. In fact, Gd-loaded cHANPs ensure an improvement of 
the time window for clinical imaging acquisitions due to the reduction 
of long scan time and rapid renal clearance. Finally, readily 
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functionalized, proposed cHANPs could improve tissue specificity to 
reach a specific organ or tissue.  
It is important to highlight that further benefits of our study are the use 
of completely biocompatible and FDA approved products, the ease of 
the synthesis and the scalability of the proposed process.  
In the last part of the thesis, also a theoretical explanation of how the 
hydrogel structural parameters can impact on the relaxometric 
properties of MRI CAs is studied and the key role of the water, which 
acts at the interface between polymer chains and metal-chelates 
determining both the relaxation enhancement and the polymer 
conformation, is investigated. In this scenario, I could observe that by 
changing structural parameters of a hydrogel matrix containing a CA, 
through a Microfluidic Flow Focusing approach, it is possible to affect 
the dipolar coupling between the electronic magnetic moment of the 
metal ion and the nuclear magnetic moment of the water nuclei 
(relaxation rate). This effect could result from a complex equilibrium 
established by the elastic stretches of polymer chains, water osmotic 
pressure and hydration degree of GdCAs. I have proved how the 
presence of Gd-DTPA can modify the specific interactions between 
water and intramolecular hydrogen bonds, inducing a change in 
polymer conformation, and how, at the same time, the attainment of 
the aggregated status of the water can improve the relaxometric 
properties of the Gd chelates, as called Hydrodenticity. 
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In conclusion, I suppose that the proposed approach for characterizing 
polymer-based CAs could be applied to study the mechanisms 
involved in several combinations of different types of polymers and 
metal ions. In fact, our work bridges different disciplines across 
Material Science, Physics and Engineering and could provide a 
coherent framework for studying and realizing polymer structures and 
devices with potential applications in medical diagnostics and therapy. 
For this reason, I strongly believe that it is likely to be of great interest 
to the vision of scientists who are involved in the study, the modeling 
or the development of novel biomaterials and CAs. These findings 
could be useful to deepen the knowledge of hydrogel-CA systems and 
to achieve an advanced comprehension of the fundamental 
mechanisms that rule the interaction between MRI CAs and hydrogel 
matrices, and are responsible for the relaxation enhancement. Our 
findings could contribute significantly to the prompt introduction of 
new advances in the MRI medical devices and could be apply into 
personalized medicine for each patient, overcoming drawbacks of the 
commonly used CAs, as well as in the comprehension of the dynamics 
and properties characterizing magnetic polymer-based materials. In 
these perspectives, through the tunability of the hydrogel structural 
parameters, future outlook are addressed to the ability to build a library 
of functional nanostructures on the needs of a particular pathology, 
field and material properties. Results could lead to the identification 
of a personalized diagnostic window that can define the range of 
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optimal properties between the hydrogel matrix and the CAs, being 
more efficient in treating a particular disease, avoiding toxic effects 
and increasing the performance of the MRI acquisitions. Next steps 
are also addressed to optimize in vivo study for a specific pathology 
and to perform an active targeting of cHANPs to reach a particular 
tissue. Furthermore, our efficient, straightforward and scalable 
developed microfluidic strategies are easy to move to the 
encapsulation of several drugs for a multimodal imaging or also for 
application in diagnostics and therapy, simultaneously.
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V. Appendix 
V.1 ICP-MS Results 
 
Tables below report the detailed results obtained at ICP-MS 
instrument regarding the three analyzed mice.  
 
Sample 
ID 
Gd 158 
(ppb) 
g/L 
Dil. 
ratio 
tq 
Gd-
DTPA 
(MW.) 
Molarity 
(M) 
µM 
Standard 1 0,100 0,0000001 100 0,00001 547,57 
1,82625E-
08 
0,018262505 
  RSD 5,5%             
Standard 2 0,499 4,99287E-07 100 4,99287E-05 547,57 
9,11823E-
08 
0,091182302 
  RSD 9,9%             
Standard 3 0,997 9,9693E-07 100 9,9693E-05 547,57 
1,82064E-
07 
0,182064363 
  RSD 0,6%             
Standard 4 5,006 5,00647E-06 100 0,000500647 547,57 
9,14307E-
07 
0,914306847 
  RSD 1,0%             
Standard 5 10,141 1,01414E-05 100 0,001014143 547,57 
1,85208E-
06 
1,852079173 
  RSD 1,0%             
Standard 6 99,858 9,98581E-05 100 0,009985811 547,57 
1,82366E-
05 
18,23659205 
  RSD 1,1%             
Standard 7 499,614 0,000499614 100 0,04996139 547,57 
9,1242E-
05 
91,24201489 
  RSD 3,3%             
Calibration 
Curves 
  
            
T1 liver  0,567 5,66999E-07 100 5,66999E-05 547,57 
1,03548E-
07 
0,103548263 
  RSD 1,5%             
T1 liver 1 0,562 5,61731E-07 100 5,61731E-05 547,57 
1,02586E-
07 
0,102586086 
  RSD 2,4%             
T1 liver 2 0,185 1,84868E-07 100 1,84868E-05 547,57 
3,37616E-
08 
0,033761588 
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  RSD 2,0%             
T1 liver 3 0,051 5,09233E-08 100 5,09233E-06 547,57 
9,29986E-
09 
0,009299863 
  RSD 1,4%             
T1 
kydneys 1 
0,045 4,51889E-08 100 4,51889E-06 547,57 
8,25262E-
09 
0,008252618 
  RSD 0,6%             
T1 kidneys 
2 
0,046 4,60571E-08 100 4,60571E-06 547,57 
8,41119E-
09 
0,008411188 
  RSD 0,8%             
T1 
kydneys 3 
0,048 4,78368E-08 100 4,78368E-06 547,57 
8,7362E-
09 
0,008736195 
  RSD 1,5%             
T1 brain 1 0,027 2,6936E-08 100 2,6936E-06 547,57 
4,91919E-
09 
0,004919188 
  RSD 4,4%             
T1 brain 2 0,027 2,67781E-08 100 2,67781E-06 547,57 
4,89035E-
09 
0,004890351 
  RSD 6,3%             
T1 brain 3 0,029 2,87905E-08 100 2,87905E-06 547,57 
5,25787E-
09 
0,005257867 
  RSD 1,2%             
T1 lungs 1 0,040 4,00208E-08 100 4,00208E-06 547,57 
7,3088E-
09 
0,007308798 
  RSD 0,3%             
T1 lungs 2 0,043 4,33447E-08 100 4,33447E-06 547,57 
7,91582E-
09 
0,007915819 
  RSD 2,6%             
T1 lungs 3 0,043 4,33039E-08 100 4,33039E-06 547,57 
7,90837E-
09 
0,007908372 
  RSD 0,8%             
T1 heart 1 0,163 1,63223E-07 100 1,63223E-05 547,57 
2,98086E-
08 
0,029808608 
  RSD 0,9%             
T1 heart 2 0,153 1,53475E-07 100 1,53475E-05 547,57 
2,80283E-
08 
0,02802832 
  RSD 1,4%             
T1 heart 3 0,153 1,52707E-07 100 1,52707E-05 547,57 
2,78882E-
08 
0,027888173 
  RSD 2,0%             
T1 spleen 
1 
0,064 6,3958E-08 100 6,3958E-06 547,57 
1,16803E-
08 
0,01168033 
  RSD 0,7%             
T1 spleen 
2 
0,081 8,13354E-08 100 8,13354E-06 547,57 
1,48539E-
08 
0,01485388 
  RSD 1,0%             
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T1 spleen 
3 
0,089 8,92857E-08 100 8,92857E-06 547,57 
1,63058E-
08 
0,016305806 
  RSD 1,6%             
T2 lungs 1 0,028 2,84027E-08 100 2,84027E-06 547,57 
5,18705E-
09 
0,00518705 
  RSD 1,9%             
T2 lungs 2 0,070 7,01198E-08 100 7,01198E-06 547,57 
1,28056E-
08 
0,01280564 
  RSD 0,4%             
T2 lungs 3 0,035 3,4673E-08 100 3,4673E-06 547,57 
6,33216E-
09 
0,006332155 
  RSD 4,9%             
T2 heart 1 0,021 2,11902E-08 100 2,11902E-06 547,57 
3,86985E-
09 
0,003869854 
  RSD 3,9%             
T2 heart 2 0,026 2,61761E-08 100 2,61761E-06 547,57 
4,78041E-
09 
0,004780411 
  RSD 2,1%             
T2 heart 3 0,025 2,53678E-08 100 2,53678E-06 547,57 
4,6328E-
09 
0,0046328 
  RSD 1,7%             
T2 
kydneys 1 
0,033 3,34313E-08 100 3,34313E-06 547,57 
6,1054E-
09 
0,006105396 
  RSD 5,0%             
T2 
kydneys 2 
0,038 3,7724E-08 100 3,7724E-06 547,57 
6,88934E-
09 
0,006889342 
  RSD 4,6%             
T2 
kydneys 3 
0,038 3,82603E-08 100 3,82603E-06 547,57 
6,98729E-
09 
0,006987287 
  RSD 7,5%             
T2 spleen 
1 
0,058 5,75705E-08 100 5,75705E-06 547,57 
1,05138E-
08 
0,010513813 
  RSD 1,7%             
T2 spleen 
2 
0,067 6,65695E-08 100 6,65695E-06 547,57 
1,21573E-
08 
0,012157251 
  RSD 3,0%             
T2 spleen 
3 
0,062 6,24191E-08 100 6,24191E-06 547,57 
1,13993E-
08 
0,011399287 
  RSD 1,1%             
T2 brain 1 0,020 1,96202E-08 100 1,96202E-06 547,57 
3,58314E-
09 
0,003583138 
  RSD 1,9%             
T2 brain 2 0,021 2,05003E-08 100 2,05003E-06 547,57 
3,74386E-
09 
0,003743861 
  RSD 1,0%             
T2 brain 3 0,031 3,13312E-08 100 3,13312E-06 547,57 
5,72186E-
09 
0,00572186 
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  RSD 1,4%             
T2 liver 1 0,077 7,67027E-08 100 7,67027E-06 547,57 
1,40078E-
08 
0,014007836 
  RSD 5,3%             
T2 liver 2 0,088 8,84826E-08 100 8,84826E-06 547,57 
1,61591E-
08 
0,016159136 
  RSD 2,1%             
T2 liver 3 0,089 8,88013E-08 100 8,88013E-06 547,57 
1,62173E-
08 
0,016217344 
  RSD 1,0%             
T3 heart 1 0,023 2,2778E-08 100 2,2778E-06 547,57 
4,15983E-
09 
0,004159828 
  RSD 2,3%             
T3 heart 2 0,026 2,55011E-08 100 2,55011E-06 547,57 
4,65715E-
09 
0,004657148 
  RSD 3,1%             
T3 heart 3 0,040 3,99796E-08 100 3,99796E-06 547,57 
7,30127E-
09 
0,00730127 
  RSD 7,2%             
T3 lungs 1 0,025 2,50653E-08 100 2,50653E-06 547,57 
4,57755E-
09 
0,004577548 
  RSD 2,0%             
T3 lungs 2 0,026 2,59208E-08 100 2,59208E-06 547,57 
4,7338E-
09 
0,004733796 
  RSD 1,4%             
T3 lungs 3 0,023 2,32789E-08 100 2,32789E-06 547,57 
4,2513E-
09 
0,004251304 
  RSD 1,2%             
T3 
kydneys 1 
0,046 4,61644E-08 100 4,61644E-06 547,57 
8,43078E-
09 
0,008430775 
  RSD 2,1%             
T3 
kydneys 2 
0,049 4,91646E-08 100 4,91646E-06 547,57 
8,97869E-
09 
0,008978694 
  RSD 4,1%             
T3 
kydneys 3 
0,046 4,62307E-08 100 4,62307E-06 547,57 
8,44288E-
09 
0,008442877 
  RSD 4,9%             
T3 spleen 
1 
0,137 1,37454E-07 100 1,37454E-05 547,57 
2,51026E-
08 
0,025102568 
  RSD 4,3%             
T3 spleen 
2 
0,140 1,39908E-07 100 1,39908E-05 547,57 
2,55507E-
08 
0,02555068 
  RSD 1,2%             
T3 spleen 
3 
0,141 1,41037E-07 100 1,41037E-05 547,57 
2,57568E-
08 
0,025756827 
  RSD 2,2%             
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T3 brain 1 0,022 2,1835E-08 100 2,1835E-06 547,57 
3,98762E-
09 
0,003987624 
  RSD 2,9%             
T3 brain 2 0,023 2,30956E-08 100 2,30956E-06 547,57 
4,21783E-
09 
0,004217833 
  RSD 1,1%             
T3 brain 3 0,023 2,32796E-08 100 2,32796E-06 547,57 
4,25143E-
09 
0,004251433 
  RSD 1,6%             
T3 liver 1 0,124 1,24019E-07 100 1,24019E-05 547,57 
2,2649E-
08 
0,022649 
  RSD 2,0%             
T3 liver 2 0,126 1,25577E-07 100 1,25577E-05 547,57 
2,29335E-
08 
0,022933511 
  RSD 3,0%             
T3 liver3 0,127 1,27082E-07 100 1,27082E-05 547,57 
2,32084E-
08 
0,023208377 
  RSD 3,7%             
T1 blood 1 1,947878188 1,94788E-06 100 0,000194788 547,57 
3,55731E-
07 
0,355731356 
  RSD 13,3%             
T1 blood 2 0,655 6,54747E-07 100 6,54747E-05 547,57 
1,19573E-
07 
0,119573256 
  RSD 3,7%             
T1 blood 3 0,642 6,4184E-07 100 6,4184E-05 547,57 
1,17216E-
07 
0,117216082 
  RSD 1,4%             
T2 blood 1 0,365 3,64506E-07 100 3,64506E-05 547,57 
6,65679E-
08 
0,06656793 
  RSD 0,2%             
T2 blood 2 0,248 2,48365E-07 100 2,48365E-05 547,57 
4,53578E-
08 
0,045357757 
  RSD 2,6%             
T2 blood 3 0,377 3,77385E-07 100 3,77385E-05 547,57 6,892E-08 0,068919953 
  RSD 0,5%             
T3 blood 1 0,316 3,15648E-07 100 3,15648E-05 547,57 
5,76453E-
08 
0,057645291 
  RSD 0,7%             
T3 blood 2 0,343 3,43006E-07 100 3,43006E-05 547,57 
6,26415E-
08 
0,062641512 
  RSD 1,2%             
T3 blood 3 0,375 3,75271E-07 100 3,75271E-05 547,57 
6,85339E-
08 
0,068533943 
  RSD 0,9%             
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V.2 Calculations of the hydrogel network parameters  
As previously described, studies on the swelling behavior of the 
nanoparticles are conducted in water at room temperature and the 
obtained results, in terms of swelling ratio, are used to estimate the 
following hydrogel structural parameters of the cHANPs: 
 𝑀𝑐̅̅ ̅̅ : molecular weight between crosslinks (g/mol); 
 𝑣𝑒: effective crosslink density (mol/cm
3); 
 ξ: mesh size (nm). 
In order to compute the above mentioned parameters, a simplified 
version of the Flory-Rehner equations are used. 
Firstly, the average molecular weight between crosslinks (𝑀𝑐̅̅ ̅̅ ) are 
computed using the following equation: 
 𝑄𝑣
5/3 =  
𝑣 ̅ 𝑀𝑐̅̅ ̅̅
V1
 (
1
2
−  𝜒)               (2) 
where Qv is the volumetric swelling ratio, 𝑣 ̅is specific volume of 
polymer (0.814 cm3/g for HA)1, V1 is molar volume of solvent (18 
mol/cm3 for water)2, χ is polymer-solvent interaction parameter (0.473 
for HA) 3. The volumetric swelling ratio, Qv, is estimated based on the 
approximate diameter ratio, determined experimentally by comparing 
the diameters of the swelled cHANPs with the cHANPs’ diameters in 
Ethanol, i.e. before the hydration of the nanoparticles in water. 
Differently from the previous works2-4, in which the volumetric 
swelling ratio is estimated from the mass swelling ratio by dividing 
the sample mass after swelling by the dry sample mass, no dehydration 
of the nanoparticles is performed in order to keep unchanged the 
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structure and the shape of the Gd-DTPA loaded cHANPs. Therefore, 
the nanoparticles’ diameter measured in Ethanol is used as the 
reference value to compute the volumetric swelling ratio. This allows 
us to avoid the alteration of the Gado-Mesh network and the release of 
the entrapped Gd-DTPA caused by the dehydration process, making 
us able to properly investigate the relationship between the cHANPS’ 
hydrogel structure and the relaxivity values, which strictly rely on the 
encapsulation of the contrast agent and on the hydrogel parameters. 
After 𝑀𝑐̅̅ ̅̅  is estimated, the effective crosslink density, ve, is determined 
from the following equation: 
𝑣𝑒 =  
𝜌𝑝
𝑀𝑐̅̅ ̅̅
               (3) 
where ρp is the density of polymer (1.229 g/cm3 for HA)4. 
The water swollen hydrogels mesh size, ξ, is calculated by the 
following equation: 
𝜉 =  𝑄𝑣
1/3 √𝑟?̅?
2                  (4) 
where √𝑟?̅?
2 is the root-mean square distance between crosslinks, 
specifically reported for HA by Collins et al. 3 as follows: 
√(
𝑟?̅?
2
2𝑛
)  ≅  2.4 (𝑛𝑚)               (5) 
where n is the number of monomer units for HA. For HA with a 
molecular weight (Mn) of ~ 4*105, n is ~100, which gives the 
following estimation of √𝑟?̅?
2: 
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√𝑟𝑜2̅̅ ̅̅ = 0.035 √𝑀𝑛               (6) 
Finally, the mesh size can be calculated by combining equations (4) 
and (6) as follows: 
𝜉 = 0.035 √𝑀𝑐̅̅ ̅̅  𝑄𝑣
1/3               (7) 
Estimated values of all swelling study parameters, Qv, 𝑀𝑐̅̅ ̅̅ , ve and ξ 
should be considered as approximate values on account of certain 
assumptions considered in Flory-Rehner calculations and for our 
specific systems. However, these values can be used for making 
comparisons between various network features of different hydrogel 
nanoparticles. 
The following tables report all the computed values for swelled 
cHANPs after 48 hr. 
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Table 6. cHANPs network parameters. Hydrogel network parameters of cHANPs 
after 48 h of swelling, obtained by adding DVS a) in the middle channel and b) in the 
side channels. 
a)               
  
Volumetric 
swelling ratio 
Molecular mass 
between two 
crosslinked points 
[*10
3
 g/mol] 
Effective 
crosslink 
density 
[*10
-5
 
mol/cm
3
] 
Mesh size 
[nm] 
DVS [% 
v/v] 
Q
V
 M̅
C
 ν
e
 Ξ 
  mean SD mean SD mean SD mean SD 
0.00 9.00 0 31.9 0 3.85 0 13.00 0 
1.00 10.23 2.87 39.5 18.5 3.11 1.46 15.09 4.94 
2.00 4.63 1.06 10.5 4.04 11.7 4.47 5.99 1.61 
2.50 4.63 1.04 10.5 3.93 11.7 4.35 5.99 1.56 
3.00 4.34 0.99 9.47 3.60 13.0 4.94 5.56 1.48 
4.00 1.49 0.43 1.58 0.760 77.6 37.2 1.59 0.53 
4.50 1.51 0.34 1.64 0.619 75.1 28.4 1.63 0.43 
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b)               
  
Volumetric 
swelling ratio 
Molecular mass 
between two 
crosslinked points 
[*10
3
 g/mol] 
Effective 
crosslink 
density 
[*10
-5
 
mol/cm
3
] 
Mesh size 
[nm] 
DVS [% 
v/v] 
Q
V
 M̅
C
 ν
e
 Ξ 
  mean SD mean SD mean SD mean SD 
0.00 9.00 0 31.9 0 3.85 0 13.00 0 
0.40 6.00 1.69 16.2 7.60 7.57 3.55 8.10 2.66 
0.60 4.00 0.91 8.26 3.14 14.9 5.67 5.05 1.35 
0.80 2.03 0.46 2.66 1.00 46.2 17.4 2.29 0.60 
1.00 2.03 0.49 2.66 1.07 46.2 18.5 2.29 0.64 
1.20 2.20 0.53 3.05 1.21 40.3 16.1 2.51 0.70 
1.60 25.71 7.36 183 87.5 0.670 0.319 44.25 14.77 
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List of Abbreviations 
 
MRI Magnetic Resonance Imaging 
PET Positron Emission Tomography 
CAs Contrast Agents 
Gd Gadolinium 
Gd-DTPA Gd – diethylenetriaminepentacetate 
GdCl3 gadolinium chloride 
SPIO superparamagnetic iron oxide 
FDA Food and Drug Administration 
NPs Nanoparticles 
HA Hyaluronic Acid 
DVS Divinyl Sulfone 
HANPs Hyaluronic Acid Nanoparticles 
cHANPs crosslinked Hyaluronic Acid Nanoparticles 
HFF Hydrodynamic Flow Focusing  
PEG poly(ethylene glycol) 
DLS Dynamic Light Scattering 
PDI Polydispersity 
FE – SEM Field Emission - Scanning Electron Microscopy 
TEM Transmission Electron Microscopy 
STED Stimulated Emission Depletion  
FR2 Flow Rate Ratio 
CHA Hyaluronic Acid concentration  
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CCA Contrast Agent concentration  
CDVS DVS concentration  
wt/v weight/volume 
v/v volume/volume 
ICP-MS Induced Coupled Plasma mass spectrometry  
HLB Hydrophilic-lipophilic balance 
PBS Phosphate-buffered saline  
HPLC  High-performance liquid chromatography 
HA-SH  Hyaluronate Thiol 
PEG-VS poly(ethylene glycol) – vinyl sufone 
EDC  1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
NHS  N-hydroxysuccinimide
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- “Modulation of hydrogel nanostructures confining Gd-DTPA 
by a microfluidic flow focusing approach to improve MRI 
signal” Poster session at European Materials Research 
Society EMRS Lille, France. 2-6 May, 2016 
 
Communications to Congress/Conferences 
211 
 
- “Design of nanostructures to improve properties of 
paramagnetic contrast agents” Poster session at 3rd 
International Conference on Nanotechnology in Medicine. 
Manchester, UK. 23-25 November, 2015 
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agents”. Interface Focus 20160061, doi: 
http://dx.doi.org/10.1098/rsfs.2016.0061(2016).  
 
- Russo, M, Bevilacqua, P., Netti, P., Torino, E. 
Autocommentary to “A Microfluidic Platform to design 
crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for 
enhanced MRI”. Molecular Imaging. 2017  
 
- Russo, M., Ponsiglione, A., Forte, E., Netti, P. & Torino, E. 
“Hydrodenticity to enhance relaxivity of Gd-DTPA within 
crosslinked Hyaluronic Acid Nanoparticles (cHANPs).” 
Under Revision (2017). 
 
- Russo, M., Netti, P. & Torino, E. " PEGylated crosslinked 
Hyaluronic Acid nanoparticles (cHANPs) designed through a 
microfluidic platform for nanomedicine ". Under revision 
(2017). 
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- Russo, M, Netti, P., Torino. “A Microfluidic Platform to 
design hydrogel nanoparticles for MRI”. JOVE Video 
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Project Activities 
 
This Research activity has been partially developed in the framework 
of the projects:  
 
- "BERSAGLI - Bersagli, sonde e segnali in terapia 
diagnostica" financed by POR Campania 2007/2013 
Obiettivo Operativo 2.1 - BANDO PER LA 
REALIZZAZIONE DELLA RETE DELLE 
BIOTECNOLOGIE IN CAMPANIA (2014- 2016). 
- "CeSMeMo - PONa3_00173”. Project contributed to the 
development of biomedical products, in particular of novel 
nanosystems for diagnostics and therapy. (June 2014 – 
December 2016
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Collaborations 
 
- IRCCS SDN Gianturco Street, 113 -80143-Naples.  
In vivo MRI analysis are performed in the Diagnostic Center, SDN, 
Diagnostics and Nuclear Research Institute, that it is an integrated 
group of specialist clinics in the diagnostic laboratory and imaging. 
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Other Activities 
 
This microfluidic technology, developed during the Ph.D. 
course, has been patented (Patent PT150265) and presented as a 
business idea entitled “KYME”, leading to several awards. 
- Award at StartCup Campania with the project “KYME”, 
Regione Campania, Naples. (October 2016) 
 
 
KYME: First classified in Bio&Nano category 
 
KYME is a spin-off project of the “Center for Advanced 
Biomaterials for Healthcare” of Istituto Italiano di Tecnologia 
(IIT) of Naples in collaboration with the University of Naples 
“Federico II”.   
The project aims to produce injectable medical devices for 
Magnetic Resonance Imaging (MRI). Using nanotechnology, 
KYME aims to improve clinically used Contrast Agents (CAs) 
and to ensure a more effective early diagnosis, thus 
contributing to the improvement of diagnostic Imaging. 
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Public Links to media reporting about KYME:  
http://openinnovation.startupitalia.eu/55278-20170311-
bioupper-kyme-esami-meno-tossici-piu-dettagliati 
 
http://mobile.ilsole24ore.com/solemobile/main/art/impresa
-e-territori/2017-02-27/digitale-campania-rincorre-
223212.shtml?uuid=AESyJSe 
 
http://www.ilmattino.it/innovazione/biotecnologie/biouppe
r_team_campano_kyme_migliori_idee_business_nanotecno
logia_diagnostica_medica-2279797.html 
 
http://www.rainews.it/dl/rainews/TGR/basic/PublishingBlo
ck-d2203e2e-1690-4898-839d-f712cdab8eb1.html 
 
http://ildenaro.it/imprese-e-mercati/168-imprese-e-
mercati/79240/kyme-il-team-campano-tra-i-10-progetti-in-
finale-a-bioupper 
 
https://biomedical.closeupengineering.it/startup-kyme-
crea-contrasto-per-rmn/8881/ 
 
http://ingegneriabiomedica.org/news/diagnostica/start-
cup-campania-2016-la-diagnostica-medica-trova-nuova-
luce-grazie-kyme/ 
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- Partecipation to Premio Nazionale Innovazione PNI. 
(November 2016) 
http://www.pni2016.unimore.it/ 
 
 
- Attendance at Bioupper Startup Accelerator, Milan.  
o First selection (21 June – 16 October 2016) 
o Training Week (12-17 December 2016) 
o Acceleration Program (26 January – 6 April 2017) 
o Award Ceremony (12 April 2017) 
http://www.bioupper.com/news/selezionati-10-progetti-
accedono-finale.shtml 
 
- Elevator pitch to event “Unione Centenario Industriali”. 
(February 2017). 
